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and  DiA  (red)  incorporated  into  the  SM  fraction.  Following  2  hours  incubation,  cells  were  
labeled  with  NucStain  (blue)  and  imaged  by  confocal  microscopy.  Pearson  co-­localization  
coefficient  =  0.75  ±  0.01.  (c)  Cells  were  incubated  with  5A-­SM-­DiD  (red)  for  1,  1.5,  and  2  
hours,  fixed,  stained  for  LAMP1  (green)  and  filipin  (blue),  and  imaged  by  confocal  
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microscopy.  Representative  images  from  2  hours  post  treatment.  Pearson  co-­localization  
coefficient  quantified  below.  (d)  Cells  were  pre-­treated  for  24  hours  with  acetylated  LDL  
containing  [3H]cholesteryl  linoleate  to  specifically  deliver  cargo  to  the  lysosomal  
compartment.  Following  24  hour  equilibration,  cells  were  treated  for  24  hour  with  0.75  mg/ml  
5A  peptide  or  5A-­SM.  Radioactivity  in  media  and  cell  fractions  was  determined  by  liquid  
scintillation  counting  and  values  were  normalized  to  vehicle  treated  group.  Data  are  mean  ±  
s.e.m.  from  three  independent  experiments.  n.s.,  not  significant,  *p≤.05,  **p≤.01,  ****p≤.0001  
by  (a)  One-­way  ANOVA  with  Tukey  posthoc  test  relative  to  Veh  or  5A  (F=10.74,  df=2);;  (c)  
Two-­way  ANOVA  with  Bonferroni  posthoc  test(F,  df=  23.63,  2).  (d)  student’s  t-­test  t=13.09,  
df=4.  Scale  bar  =  (a)  12  µm,  (b)  20  µm,  (c)  10  µm.  ..............................................................  56	  
Figure  2-­7  5A-­SM  does  not  co-­localize  with  EEA1  at  two  hours  post  treatment.  NPC1  
I1061T  fibroblasts  were  treated  with  0.75  mg/ml  5A-­SM-­DiD  (red)  for  two  hours.  Cells  were  
fixed  and  stained  for  EEA1  (green)  and  nuclei  (blue).  Representative  images  from  2  hours  
post  treatment.  Scale  bar  =  50  µm.  ......................................................................................  58	  
Figure  2-­8  5A-­SM  mobilizes  cholesterol  in  vivo  and  ameliorates  disease  phenotypes.  (a)  
Serum  cholesterol  from  seven  week  old  Npc1  I1061T  homozygous  mice  pre-­  and  2  hr  post-­
treatment  with  100  mg/kg  5A-­SM,  i.p.  (b)  Pre-­  (dashed  line)  and  2  hr  post-­treatment  (solid  
line)  serum  was  fractionated  by  HPLC  and  cholesterol  was  quantified  by  cholesterol  oxidase  
assay.  VLDL,  LDL,  and  HDL  fractions  are  indicated  by  arrows.  (c,  d)  Seven  week  old  wild  
type  (WT)  and  Npc1  I1061T  homozygous  (NPC)  mice  were  injected  i.p.  with  vehicle  (Veh)  or  
100  mg/kg  5A-­SM.  48  hrs  later  (c)  liver  HMGCS  transcript  levels  and  (d)  total  serum  bilirubin  
were  analyzed.  (e)  WT  and  Npc1  I1061T  mice  were  injected  i.p.  with  vehicle  (Veh)  or  100  
mg/kg  5A-­SM  three  times  per  week  from  7-­11  weeks  of  age.  The  change  in  weight  of  each  
mouse  from  week  7  (t=0)  to  week  11  (t=4)  was  quantified.  (f)  Seven  week  old  WT  and  NPC  
mice  were  injected  with  Veh  or  100  mg/kg  5A-­SM  three  times  per  week  for  two  weeks.  At  
nine  weeks  of  age  livers  were  stained  for  macrophages  using  F4/80  (green)  and  DNA  
Hoechst  (blue).  Macrophage  area  is  quantified  at  right.  Scale  bar  =  50  µm.  Violin  plot  shows  
median  (dashed  line),  25%  and  75%  (dotted  lines),  and  probability  density  (thickness).  (g)  
Brain  slices  from  8  week  old  Npc1  I1061T  mice  were  incubated  with  vehicle  (Veh)  or  5  
mg/ml  5A-­SM  for  four  days  and  filipin  levels  in  Purkinje  neuron  soma  were  quantified  (see  
also  Additional  file  1:  Fig.  S4b).  (h)  Six  to  seven  week  old  WT  and  Npc1  I1061T  mice  
received  intraventricular  injections  with  vehicle  (Veh)  or  5A-­SM-­DiD.  N:  WT=4,  NPC  Veh=5,  
NPC  5A-­SM=4  mice.  One-­week  later  cholesterol  levels  in  Purkinje  neuron  soma  (green)  
were  analyzed  by  filipin  (blue)  staining.    Dashed  lines  indicate  Purkinje  neuron  soma  (also  
see  Additional  file  1:  Fig.  S6a).  Scale  bar  =  50  µm.  Data  quantified  at  right.  Data  are  mean  ±  
s.e.m.  from  (a,  b,  c)  three;;  (d)  genotype  and  treatment:  number  of  mice,  WT+Veh=5,  WT  +  
5A-­SM=3,  NPC+Veh=4,  NPC+5A-­SM=7;;  (e)  genotype  and  treatment:  number  of  mice  at  9  
wks  &  11  wks,  WT+Veh:  13  &  8,  WT  +  5A-­SM:  9  &  8,  NPC+Veh:  6,  NPC+5A-­SM:  12  &  10  
mice,  (f)  genotype  and  treatment:  number  of  mice,  cells,  WT+Veh:  4,  301,  NPC+Veh:  4,  514,  
NPC+5A-­SM:  3,  373  (g)  WT=93,  NPC  Veh=143,  NPC+5A-­SM=  116  cells.  *p≤.05,  **p≤.01,  
***p≤.001,  ****p≤.0001.  (a,  c)  Student’s  t-­test  (t=(a)  6.375,  (c)  5.23);;  (d,  f,  g,  h)  One-­way  
ANOVA  with  Tukey  posthoc  test  (F,  df=(d)  13.28,  3;;  (f)  368.1,  2  (g)  38.89,  2;;  (h)  108.3,  2),  
(e)  Two-­way  ANOVA  with  Bonferonni  posthoc  test  (F,  df=  7.12,  2).  ....................................  59	  
Figure  2-­9  Effects  of  5A-­SM  treatment.  (a)  Mice  were  treated  i.p.  with  vehicle  (Veh)  or  100  
mg/kg  5A-­SM  three  times  per  week  from  7  days  to  13  weeks  of  age.  Motor  function  was  
tested  every  other  week  from  7-­13  weeks  of  age  by  balance  beam.  Data  are  mean  ±  s.e.m.  
from  WT+Veh  (n=6-­10),  WT  +  5A-­SM  (n=5-­6),  NPC+Veh  (n=3-­5),  NPC+5A-­SM  (n=4)  mice.  
Two-­way  ANOVA  with  Bonferonni  posthoc  test  (F,  df=  (52.46,  3).  n.s.,  not  significant,  
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*p≤.0.05,  **p≤.01,  ***p≤.001,  ****p≤.0001.  (b)  Brain  slices  from  8  week  old  Npc1  WT  or  
I1061T  (NPC)  mice  were  incubated  with  vehicle  (Veh)  or  5  mg/ml  5A-­SM  for  four  days.  
Purkinje  cells  were  labeled  with  calbindin  (green)  and  cholesterol  with  filipin  (blue).  Images  
were  taken  from  lobules  3-­6.  Dashed  lines  outline  Purkinje  cell  soma.  Scale  bar  =  50  µm.   61	  
Figure  2-­10  5A-­SM  distribution  in  the  brain  after  ICV  injection.  Seven  week  old  Npc1  
I1061T  mice  were  injected  ICV  with  vehicle  (Veh)  or  5A-­SM-­DiD.  One-­week  post  injection  
confocal  microscopy  was  used  to  visualize  distribution  of  DiD  (red)  and  DNA  (blue).  Images  
of  the  cerebellum,  brainstem,  cortex,  and  hippocampus  are  shown  (regions  of  images  
indicated  below  in  the  cartoon).  Scale  bars  =  100  µm.  .........................................................  62	  
Figure  2-­11  Cellular  distribution  of  5A-­SM  after  ICV  injection.  Npc1  I1061T  mice  received  
intraventricular  injections  with  vehicle  (Veh)  or  5A-­SM-­DiD.  Confocal  microscopy  was  used  
to  analyze  co-­localization  of  DiD  (red)  in  cerebellum  with  (a)  Purkinje  neurons  (calbindin),  (b)  
astrocytes  (GFAP),  or  (c)  microglia  (Iba1).  Scale  bar  =  50  µm.  ...........................................  63	  
Figure  2-­12  5A-­SM  removes  sphingomyelin  from  Niemann-­Pick  type  A  fibroblasts.  (a)  
Control  (CTRL)  and  Niemann-­Pick  A  (NPA)  primary  fibroblasts  were  incubated  with  
[3H]sphingomyelin  for  24  h,  followed  by  treatment  with  0.75  mg/ml  5A-­SM  or  vehicle  (Veh).  
Radioactivity  in  media  and  cell  fractions  was  determined  by  liquid  scintillation  counting.  (b)  
CTRL  and  NPA  primary  fibroblasts  were  loaded  with  NBD-­sphingomyelin,  then  treated  for  
48  hrs  with  vehicle  (Veh),  cyclodextrin  (Cyclo),  or  0.75  mg/ml  5A-­SM.  NBD-­sphingomyelin  
intensity  quantified  at  right.  Scale  bar  =  20  µm.  (c)  SRS  microscopy  was  used  to  image  total  
endogenous  lipids  in  CTRL  and  NPA  cells  with  the  indicated  treatments.  Quantified  at  right.  
Scale  bar  =  20  µm.  Data  are  mean  ±  s.e.m.  from  (a,  b,  c)  three;;  *p≤.05,  ***p≤.001,  
****p≤.0001.  (a)  Student’s  t-­test  (t=6.04);;  (b,  c)  One-­way  ANOVA  with  Tukey  posthoc  test  (F,  
df=(b)  55.57,  3;;  (c)  8.285,  3).  ................................................................................................  64	  
Figure  3-­1  ApoA-­I  mimetic  peptide  structure,  sHDL  assembly  and  analytical  
characterization.  (a)  Amino  acid  sequence  for  5A,  18A  and  22A  peptide.  (b)  A  lyophilized  
mixture  of  ApoA-­I  peptide  and  DMPC  or  DPPC  at  1:0.5,  1:1,  1:1.5,  and  1:2  peptide:  lipid  
wt/wt  ratio  was  hydrated  in  PBS  and  thermocycled  at  50  ∘C  to  assemble  sHDL  particles.  (c)  
The  purity  of  sHDL  particles  was  determined  using  gel  permeation  chromatography  and  
particle  size  was  assessed  by  dynamic  light  scattering.  .......................................................  84	  
Figure  3-­2  sHDL  purity  and  size  distribution.  The  purity  of  sHDL  particles  was  determined  
using  gel  permeation  chromatography  (a,  b)  and  particle  size  was  assessed  by  dynamic  
light  scattering  (c,  d)  at  1  mg/mL  concentration.  ...................................................................  85	  
Figure  3-­3  ApoA-­1  mimetic  peptides  efflux  [3H]Sphingomyelin  from  human  NPA  
fibroblast  cells  in  a  dose  and  time-­dependent  manner.  NPA  cells  were  loaded  with  1  
µCi/mL  [3H]Sphingomyelin  diluted  into  media  containing  fetal  bovine  serum  for  24  h.  Cells  
were  washed  with  PBS  and  treated  with  (a)  0.03,  0.3  or  0.75  mg/mL  of  5A,  18A,  22A,  or  
vehicle  (media)  diluted  in  lipoprotein-­deficient  media  for  24  hr;;  (b)  0.75  mg/mL  of  5A,  18A,  
22A  or  vehicle  (media)  diluted  in  lipoprotein-­deficient  media  for  6,  24  or  48  hr.  Radioactivity  
in  media  and  cell  fractions  was  counted  and  the  %  [3H]Sphingomyelin  efflux  was  calculated  
by  dividing  the  media  counts  by  total  media  plus  cell  counts  and  multiplied  by  100.  Non-­
specific  (vehicle)  efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  ±  s.e.m,  
N=3.  ......................................................................................................................................  86	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Figure  3-­4  Cellular  viability  of  NPA  cells  after  the  treatment  with  peptides  or  sHDL  
nanoparticles.  Viability  of  NPA  primary  fibroblasts  after  24  hr  treatment  with  vehicle  
(media),  5A,  18A,  22A,  22A-­DMPC  (1:0.5,  1:1,  1:1.5,  1:2)  or  22A-­DPPC  (1:0.5,  1:1,  1:1.5,  
1:2).  Vehicle  group  viability  was  set  to  100%.  Data  are  mean  ±  s.e.m.,  N=3.  Statistical  
differences  between  vehicle  and  other  groups  was  calculated  using  unpaired  Student’s  t-­
test;;  ns,  not  significant,  *p≤.05,  **p≤.01,  ****p≤.0001.  ..........................................................  87	  
Figure  3-­5  [3H]Sphingomyelin  efflux  by  ApoA-­I  peptides  from  human  NPB  fibroblast  
cells.  NPB  cells  were  loaded  with  [3H]Sphingomyelin  as  described  in  Fig.  3-­3  and  treated  
with  0.75  mg/mL  of  5A,  18A,  22A  or  vehicle  (media)  diluted  in  lipoprotein-­deficient  media  for  
24  hr.  Radioactivity  in  media  and  cell  fractions  was  counted  and  the  %  [3H]Sphingomyelin  
efflux  was  calculated  by  dividing  the  media  counts  by  total  media  plus  cell  counts  and  
multiplied  by  100.  Non-­specific  (vehicle)  efflux  was  subtracted  from  each  treatment  group.  
Data  are  mean  ±  s.e.m,  N=3.  ...............................................................................................  88	  
Figure  3-­6  [3H]Sphingomyelin  efflux  in  human  NPA  fibroblast  cells  by  sHDL.  NPA  cells  
were  loaded  with  [3H]Sphingomyelin  as  described  in  Fig.  3-­3  and  treated  with  0.75  mg/mL  
of  22A,  22A-­DMPC  (1:0.5,  1:1,  1:1.5,  1:2)  or  22A-­DPPC  (1:0.5,  1:1,  1:1.5,  1:2)  for  24  hr.  
Radioactivity  in  media  and  cell  fractions  was  counted  and  the  %  [3H]Sphingomyelin  efflux  
was  calculated  by  dividing  the  media  counts  by  total  media  plus  cell  counts  and  multiplied  by  
100.  Non-­specific  (vehicle)  efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  
±  s.e.m.,  N=3.  Statistical  differences  between  22A  peptide  and  each  sHDL  treatment  were  
calculated  using  one-­way  ANOVA;;  *p≤.05,  **p≤.01,  ***p≤.001,  ****p≤.0001.  .......................  89	  
Figure  3-­7  Differences  in  [3H]Sphingomyelin  efflux  between  wild  type  (WT)  and  NPA  
cells.  WT  and  NPA  cells  were  loaded  with  [3H]Sphingomyelin  and  treated  with  0.75  mg/mL  
of  5A,  22A,  22A-­DMPC  (1:0.5)  or  22A-­DPPC  (1:0.5)  for  24  hr  as  described  in  Fig.  2.  Data  
are  mean  ±  s.e.m.,  N=3.  Statistical  differences  between  WT  and  NPA  treatments  in  each  
group  was  calculated  using  Student’s  t-­test;;  ns,  not  significant,  *p≤.05.  ..............................  90	  
Figure  3-­8  Sphingomyelin  efflux  from  NPA  cells  using  label-­free  LC-­MS  method.  (a)  NPA  
and  WT  cells  were  cultured  without  externally  added  sphingomyelin.  The  concentration  of  
sphingomyelin  (16:0)  in  WT  and  NPA  cells  was  quantified  using  LC-­MS  and  normalized  to  
total  protein  concentration  in  cells.  (b)  NPA  cells  were  treated  with  0.75  mg/mL  of  22A,  22A-­
DMPC  (1:0.5),  22A-­DPPC  (1:0.5)  or  vehicle  (media)  control  diluted  in  lipoprotein-­deficient  
media  for  24  hr.  Sphingomyelin  concentration  in  the  media  and  cells  was  determined  by  LC-­
MS.  Percent  (%)  sphingomyelin  efflux  was  calculated  by  dividing  the  media  sphingomyelin  
concentration  by  total  media  plus  cell  concentration  and  multiplied  by  100.  Non-­specific  
(vehicle)  efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  ±  s.e.m,  N=3.  
Statistical  differences  between  WT  and  NPA  groups  was  calculated  using  Student’s  t-­test  (a)  
and  between  22A  versus  sHDL  groups  (b)  using  one-­way  ANOVA;;  **p≤.01.  ......................  91	  
Figure  3-­9  ABCA1  transporter  expression  in  NPA  cells  is  required  for  efficacy  of  22A  
peptide.  (a)  Primary  NPA  fibroblasts  were  treated  with  vehicle  (NT),  5A,  22A,  22A-­DMPC  
(1:0.5)  or  22A-­DPPC  (1:0.5)  at  0.75  mg/mL  for  24  hr.  ABCA1  mRNA  expression  was  
analyzed  by  qPCR.  (b)  NPA  cells  were  treated  for  two  consecutive  days  with  the  following  
siRNAs:  non-­targeting  (NT)  and  ABCA1.  ABCA1  mRNA  expression  was  analyzed  by  qPCR.  
(c)  Following  siRNA  knockdown,  cells  were  treated  with  0.75  mg/mL  22A  for  24  hr.  The  
concentration  of  sphingomyelin  effluxed  into  media  was  quantified  using  LC-­MS  and  
normalized  to  total  protein  concentration  in  cells  for  each  group.  Data  are  mean  ±  s.e.m.,  
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Abstract  
Niemann-­Pick  disease  (NPD)  is  a  fatal  lipid  storage  disorder  that  results  in  an  
accumulation  of  unesterified  cholesterol  (type  C)  or  sphingomyelin  (types  A  and  B)  in  
late  endosomes  and  lysosomes.  Inherited  defects  in  NPC1  or  NPC2  genes  are  
responsible  for  NPD  type  C  (NPC)  while  mutations  in  SMPD1  gene  cause  NPD  types  A  
(NPA)  and  B  (NPB).  To  date,  NPD  management  is  largely  symptomatic  with  only  few  
therapies  in  clinical  trials.  Therefore,  the  main  objective  of  this  dissertation  was  to  
develop  safe  and  effective  therapeutics  for  the  treatment  of  NPA/B  and  NPC.  In  NPD,  
the  defects  in  cholesterol  and  sphingomyelin  metabolism  cause  a  panel  of  cellular  
problems  including  markedly  decreased  levels  of  high-­density  lipoproteins  (HDL)  
responsible  for  the  extracellular  lipid  transport.  The  body  produces  HDL  as  an  8-­12  nm  
nanoparticle  composed  of  a  lipid  membrane  wrapped  around  by  a  belt  of  Apolipoprotein  
A-­I  (ApoA-­I).  Several  synthetic  HDL  (sHDL)  particles  made  of  ApoA-­I  or  ApoA-­I  mimetic  
peptides  complexed  with  various  phospholipids  have  been  previously  tested  in  patients  
for  the  treatment  of  atherosclerosis,  where  sHDL  has  been  found  safe  at  doses  up  to  
100  mg/kg  following  intravenous  administration.  Applying  the  same  strategy  to  NPD,  we  
proposed  that  ApoA-­I  mimetics  (peptide  or  sHDL)  could  be  effective  and  rapidly  
translatable  therapeutic  approaches  for  the  treatment  of  NPD.    
In  the  second  chapter,  we  investigated  the  therapeutic  potential  of  ApoA-­I  
mimetic  peptides  and  sHDL  in  NPC.  Nanoparticles,  particularly  5A-­SM  sHDL,  were  
effective  at  reducing  cholesterol  accumulations  in  human  NPC  cells  and  resulted  in  the  
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rescue  of  peripheral  disease  with  intraperitoneal  route  in  NPC1  mice.  However,  the  
correction  of  motor  function  was  not  detected.  A  direct  brain  administration  of  sHDL  
reduced  cholesterol  storage  in  neurons  of  NPC1  mice  suggesting  that  the  alternative  
delivery  routes,  treatment  durations,  or  sHDL  composition  were  still  needed  to  be  
investigated. 
In  the  third  chapter,  we  used  a  similar  strategy  to  NPC.  We  identified  a  peptide,  
22A,  and  sHDL  capable  of  reducing  sphingomyelin  levels  in  human  NPA  cells.  
Moreover,  the  ATP-­binding  cassette  A1  transporter  was  found  to  be  involved  in  
sphingomyelin  efflux  from  cells.  Intravenous  administration  of  22A  to  wild  type  mice  
rapidly  mobilized  sphingomyelin  from  tissues  into  circulation.  In  addition  to  
sphingomyelin,  peptide  and  sHDL  could  both  mobilize  cholesterol,  which  was  found  to  
be  elevated  in  NPA  disease.  Together,  our  data  showed  that  ApoA-­I  mimetics  might  
represent  a  novel  therapeutic  approach  for  NPA  disease.    
In  the  fourth  chapter,  we  systematically  evaluated  the  effect  of  both  peptide  
sequence  and  phospholipid  composition  of  sHDL  on  nanoparticle’s  ability  to  mobilize  
and  esterify  cholesterol  in  vitro  and  in  vivo.  Historically,  sHDL  drug  discovery  efforts  
were  mainly  focused  on  optimizing  peptide  sequences  rather  than  understanding  how  
both,  peptide  and  lipid,  influence  sHDL  pharmacokinetic  and  pharmacodynamic  profiles.  
Two  sets  of  sHDL  were  designed  having  either  identical  phospholipid  but  variable  
peptide  sequences  with  different  plasma  stability,  or  identical  peptide  and  phospholipids  
with  variable  fatty  acid  chain  length  and  saturation.  The  results  indicated  that  the  
phospholipid  component  in  sHDL  played  a  major  role  in  cholesterol  mobilization  in  vivo  
and  should  not  be  overlooked  in  the  design  of  future  sHDL.  
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In  conclusion,  the  findings  from  these  studies  provide  a  solid  foundation  for  the  
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Chapter  1:  Introduction  
  Apolipoprotein  A-­I  (ApoA-­I)  
Human  ApoA-­I  is  a  highly  a-­helical  polypeptide  with  a  molecular  weight  of  28-­kDa  
secreted  by  the  liver  and  small   intestine.  ApoA-­I  functions  to  stabilize  the  phospholipid  
bilayer   in   high-­density   lipoproteins   (HDL)   as   well   as  mediate   lipid   transport,   receptor  
recognition,   and   activation   of   lecithin:cholesterol   acyltransferase   (LCAT)   for   the  
conversion  of  free  cholesterol  to  cholesteryl  ester  [1,  2].  Biophysical  and  crystallographic  
studies  suggest  that  lipid-­free  ApoA-­I  has  two  domains,  N-­terminal  (1-­187)  and  C-­terminal  
(188-­243),   each   having   unique   interactions   with   lipids   and   proteins.   In   solution,  
hydrophobic   regions   of   ApoA-­I   face   inward  while   hydrophilic   regions   interact  with   the  
aqueous   environment.   ApoA-­I   is   an   amphipathic   alpha-­helix   composed   of   22   and   11  
amino  acid  repeats  with  most  of   them  separated  by  the  helix-­breaking  proline  residue,  
which  allows  the  protein  to  be  flexible  around  the  periphery  of  HDL  particles  [3].  Lipid-­free  
and   lipid-­poor  ApoA-­I  bind  phospholipids  and  cholesterol  via   the  ATP-­binding  cassette  
transporter  A1  (ABCA1)  on  membranes,  forming  several  classes  (discoidal  and  spherical)  
of   nascent   HDL   particles   (Fig.   1-­1).   Mutations   in   ApoA-­I   lead   to   Tangier   disease  
characterized   by   severe  HDL   deficiency   confirming   the   critical   role   of   ApoA-­I   in   HDL  
biogenesis  [4].      
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Figure  1-­1  ApoA-­I  conformation  on  discoidal  and  spherical  HDL  particles.  ApoA-­I  is  
arranged  in  a  double  belt  in  disks  and  trefoil  in  spheres.  Figure  taken  from  [5].  
  
  High-­Density  Lipoproteins  (HDL)  
High-­density   lipoproteins   (HDL)   are   heterogeneous   nanoparticles   (7-­12   nm   in  
diameter)  composed  of  proteins  (apolipoproteins)  and  lipids  that  transport  cholesterol  in  
the  intravascular  and  extravascular  compartments.  HDL  particles  are  synthesized  by  the  
liver  and   intestine   to  mediate  cholesterol   transport   from  peripheral  cells   to   the   liver   for  
excretion   from   the   body   via   the   reverse   cholesterol   transport   (RCT).   Epidemiological  
evidence  suggests  that  the  level  of  HDL  in  circulation  is  inversely  correlated  with  the  risk  
of  coronary  heart  disease  (CHD)  [6].  There  have  been  numerous  unsuccessful  attempts  
to  develop  therapies  for  the  treatment  of  cardiovascular  disease  focused  on  raising  HDL  
concentration  in  plasma.  However,  new  evidence  suggests  that  HDL  composition  may  be  
as  more  important  than  its  concentration.  It  has  been  recognized  that  HDL  is  not  simply  
a  cholesterol  carrier,  but  rather  a  complex  molecule  with  many  functions  including  anti-­
inflammatory,  anti-­diabetic,  anti-­thrombotic,  and  anti-­oxidant  among  many  others  yet  to  
be  discovered  [7-­9].  
Approximately  70%  of  HDL  protein   is  apolipoprotein  A-­I  (ApoA-­I),  which  plays  a  
major  role  in  the  biogenesis  and  function  of  HDL  [10].  When  ApoA-­I  is  secreted  by  the  
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liver   (70%)   and   intestine   (30%),   it   binds   a   cholesterol   transporter,  ABCA1,   at   the   cell  
membrane  and  acquires  phospholipids   to   form  nascent  HDL  particles   (pre-­b  HDL)  as  
shown  in  Fig.  1-­2.  Subsequently,  nascent  HDL  interacts  with  ABCA1  transporter  to  efflux  
cholesterol  from  cells.  Another  mechanism  for  cholesterol  efflux  described  in  the  literature  
is  based  on   the   retroendocytosis  pathway   [11,  12].  Here,  ApoA-­I  binds   to   the  ABCA1  
transporter   at   the   plasma   membrane   followed   by   the   ABCA1/ApoA-­I   complex  
internalization  and  transport  to  late  endosomes/lysosomes  (LE/Ls).  In  LE/Ls,  ApoA-­I  picks  
up  lipids,  and  then  lipidated  ApoA-­I   is  resecreted  from  cells  through  exocytosis.  These  
two  pathways  may  operate  simultaneously  since  ABCA1  is  localized  in  both  LE/Ls  and  
the   plasma  membrane.  Once  HDL   has   acquired   some   cholesterol   via   ABCA1,   it   can  
interact   with   another   lipid   transporter   called   ATP-­binding   cassette   transporter   G1  
(ABCG1)   and   efflux   more   cholesterol   from   cells.   Then,   nascent   HDL   interacts   with  
lecithin:cholesterol   acyltransferase   (LCAT),   an   enzyme   responsible   for   cholesterol  
esterification,  leading  to  formation  of  larger  mature  HDL  particles.  Mature  (spherical)  HDL  
consists   of   apolipoproteins   (45-­55%   by   mass),   phospholipids   (26-­32%),   esterified  
cholesterol   (15-­20%),   free  cholesterol   (3-­5%),  and   triglycerides  (5%).  Mature  HDL  can  
deliver   esterified   cholesterol   (EC)   cargo   directly   to   the   liver   for   elimination   through  
scavenger  receptor  class  B  type  I  (SR-­BI),  or  it  can  transfer  EC  to  low-­density  lipoproteins  
(LDL)  by  interacting  with  cholesterol  ester  transfer  protein  (CETP)  for  elimination  by  the  
liver  following  LDL  receptor-­mediated  (LDL-­R)  uptake.    
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Figure  1-­2  Reverse  cholesterol  pathway  (RCT).  Figure  taken  from  [13].  
  
  ApoA-­I  and  ApoA-­I  Mimetic  Peptide-­based  HDL  Therapeutics  
ApoA-­I-­based  HDL  therapeutics.  Human  population  studies  have  shown  that  HDL  
levels  are  inversely  associated  with  CVD  risk,  where  even  a  1  mg/dL  increase  in  HDL-­
cholesterol  (HDL-­C)  translates  into  a  2-­3%  risk  reduction  for  subsequent  coronary  events  
[14].  This  data  prompted  a  number  of  large  clinical  trials  to  investigate  the  role  of  drugs  
aimed  at  raising  HDL-­C  levels  to  remove  cholesterol  from  arterial  plaques.  Initially,  HDL  
therapies  were  mainly  based  on  the  infusion  of  reconstituted  HDL  (rHDL)  composed  of  
purified   human   ApoA-­I   or   ApoA-­IMilano   (mutated,   R173C)   in   complex   with   various  
phospholipids.  The  first  rHDL  product  tested  in  humans  was  SRC-­rHDL  by  ZLB  Central  
Laboratory.   ApoA-­I   isolated   from   human   plasma   was   lipidated   with   soybean  
phosphatidylcholine  (PC)  using  the  cholate  dialysis  method  [15].  Soybean  PC  was  used  
in   rHDL   preparation   because   this   was   the   only   phosphatidylcholine   available   at   high  
quality   for  parenteral  use.  A  Phase  I  clinical   trial   in  40  healthy  volunteers  showed  that  
SRC-­sHDL  at  40  mg/kg  was  safe  and  well  tolerated  [16,  17].  A  Phase  II  trial  of  CSL-­111  
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(ZLB  Central  Laboratory  acquired  by  CSL  Behring)  in  183  patients  showed  toxicity  at  a  
dose  of  80  mg/kg  dose  and  reformulation  of  CSL-­111  into  CSL-­112  with  reduced  lipid  to  
protein  ratio  took  place  [18,  19].  CSL-­112  was  found  to  be  safe  and  well-­tolerated  at  doses  
up  to  135  mg/kg  and  capable  of  acutely  enhancing  cholesterol  efflux  [20].  Currently,  a  
Phase  III  clinical  trial  (ClinicalTrials.gov)  for  CSL-­112  is  still  ongoing  in  17,400  patients  for  
the  reduction  of  major  adverse  cardiovascular  events.  
The  limited  availability  of  human  blood  for  ApoA-­I  purification  necessitated  the  use  
of  recombinantly  produced  protein  in  E.  coli.  In  1998,  Esperion,  developed  a  new  rHDL  
formulation,   ETC-­216,   composed   of   ApoA-­IMilano  and   1-­palmitoyl-­2-­oleoyl-­sn-­glycero-­3-­  
phosphatidylcholine  (POPC)  at  1:1  protein  to  lipid  weight  ratio.  Five  weekly  infusions  of  
ETC-­216  at  15  and  45  mg/kg  reduced  coronary  plaque  volume  by  4.2%  and  were  safe  
and  well  tolerated  at  all  doses  [21].  Another  rHDL  product  containing  rhApoA-­I  was  CER-­
001   (Cerenis)   composed   of   rhApoA-­I   in   complex   with   sphingomyelin   (SM)   and  
dipalmitoylphosphatidyl-­glycerol  (DPPG)  at  1:2.7:0.1  ratio  of  ApoA-­I:SM:DPPG  by  weight.  
Similar  to  ETC-­216,  CER-­001  was  non-­toxic  at  all  doses  tested  (3,6  and  12  mg/kg  once  
per  week  for  6  weeks)  [22,  23].    
ApoA-­I   mimetic   peptide-­based   HDL   therapeutics.   ApoA-­I   mimetic   peptides   are  
amphipathic  a-­helixes  designed   to  mimic  ApoA-­I   function.  The   first  peptide,  18A,  was  
developed   by   Anantharamaiah   et   al.   and   contained   18   amino   acids   sequence  
(DWLKAFYDKVAEKLKEAF)  [24].  However,  18A  peptide  was  not  tested  in  humans.  The  
non-­lipidated  ApoA-­I  mimetic  peptide,  D-­4F  (Ac-­DWFKAFYDKVAEKFKEAF-­NH2),  which  
was  a  modified  version  of  18A  and  made  from  all  D-­amino  acids  to  ensure  protection  from  
proteolysis,  was   tested   in   the  clinic.  The   first  study  of  D-­4F   in  high-­risk  cardiovascular  
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patients  included  a  single  oral  administration  of  either  4.3  or  7.14  mg/kg,  which  were  both  
ineffective.  The  second  unsuccessful  trial  was  based  on  13  daily  injections  of  D-­4F  and  
up   to   7.14   mg/kg   [25].   Another   amphipathic   ApoA-­I   mimetic   peptide,   ETC-­642  
(PVLDLFRELLNELLEALKQKLK),  was  developed  by  Esperion  to  be  an  activator  of  LCAT  
enzyme  when  reconstituted  into  rHDL.  This  peptide  contained  22  amino  acids  complexed  
with  SM  and  dipalmitoyl-­phosphatidylcholine  (DPPC)  at  1:1:1  ETC-­642:SM:DPPC  ratio.  
The  Phase  I  clinical  trial  of  ETC-­642  rHDL  infusion  in  patients  with  stable  atherosclerosis  
was  found  to  be  safe  and  tolerated  up  to  20  mg/kg  dose.  Further  information  for  ETC-­642  
has   not   been  made   public   [26].   Other   ApoA-­I  mimetic   peptides   well-­described   in   the  
literature   include   reverse   4F,   ATI-­5261,   and   5A.   All   of   these   peptides   showed   great  
promise  in  animal  models  and  need  to  be  evaluated  in  humans  to  determine  their  efficacy  
[27].  
  
  HDL  in  Niemann-­Pick  Diseases  
Niemann-­Pick  diseases  (NPD)  are  rare  and  severe  lipid  storage  disorders  with  no  
FDA-­approved   treatments.   They   are   caused   by   loss   of   function   mutations   in  
endolysosomal  enzymes  leading  to  an  accumulation  of  lipids  and  foam  cell  infiltration  in  
tissues  [28].  Mutations  in  the  SMPD1  gene  cause  NPD  types  A  and  B,  where  an  abnormal  
accumulation   of   sphingomyelin   originates   from   the   insufficient   activity   of   the   acid  
sphingomelinase  (ASM)  enzyme  [29].  Children  with  type  A  NPD  die  in  infancy  by  age  3-­
4  while  individuals  with  type  B  (non-­neuropathic)  survive  into  adulthood  [30].  NPD  type  C  
is  caused  by  mutations  in  NPC1  (95%  of  cases)  or  NPC2  genes,  which  encode  proteins,  
NPC1  and  NPC2,  required  for  lysosomal  export  of  unesterified  cholesterol  [31].  In  addition  
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to   cholesterol,   sphingolipids   (e.g.,   sphingomyelin   and   glycosphingolipids)   also  
accumulate  in  late  endosomes  (LE)  and  lysosomes  (Ls)  together  leading  to  progressive  
neurological  dysfunction  and  death  during  childhood  or  later  in  life  [32].    
The  accumulated  cholesterol  in  LE/Ls  originates  from  the  uptake  of  LDL  through  
receptor-­mediated  endocytosis  on  the  plasma  membrane  [33].  LDL  carrying  cholesteryl  
ester  traffics  through  endosomes/lysosomes,  where  the  hydrolysis  by  acid  lipase  releases  
free  cholesterol.  Cholesterol  homeostasis  machinery  senses  elevated  cholesterol  levels  
via   a   negative   feedback   loop   regulated   by   sterol   regulatory   element   binding   proteins  
(SREBPs)  that  directly  activate  genes  involved  in  the  synthesis  and  uptake  of  cholesterol  
and  in  lipogenesis  [34].  Also,  increases  in  cholesterol  are  recognized  by  liver  X  receptor  
(LXR)  transcription  factors  [35].  Activation  of  LXR  up-­regulates  a  membrane  transporter,  
ABCA1,  which  is  responsible  for  cholesterol  efflux  from  cells  to  nascent  HDL.  Compared  
to  cholesterol,  sphingomyelin  in  lysosomes  comes  not  only  from  extracellular  (lipoprotein  
endocytosis)  but  also  from  intracellular  (autophagy,  membrane  recycling  or  phagocytosis)  
sources.   Major   molecular   species   of   sphingomyelin   are   16:0   and   24:1   [36].  
Sphingomyelin  and  cholesterol  have  high  affinity   for  one  another  and   therefore   reside  
together  in  raft  and  non-­raft  regions  of  the  cell  [37,  38].  The  ABCA1  transporter  mobilizes  
both   cell   phospholipids   (e.g.,   phosphatidylcholine   and   sphingomyelin)   as   well   as  
cholesterol  to  lipid-­poor  ApoA-­I  [39].  This  transporter  is  located  on  membranes  and  traffics  
between  the  plasma  membrane  and  membranes  of  intracellular  vesicles,  including  LE/Ls  
[40,   41].   It   has   been   shown   in   macrophages   that   free   cholesterol   from   LE/Ls   is   the  
preferential  source  for  ABCA1-­mediated  efflux  that  requires  functional  NPC2  protein,  but  
not  NPC1   [42,  43].  Thus,   the  ABCA1   transporter   is  a  key  mediator  of  cholesterol  and  
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sphingomyelin  exit  from  LE/Ls  compartments  and  might  represent  a  potential  therapeutic  
target  in  Niemann-­Pick  diseases.      
Niemann-­Pick   C.   NPD   type   C   is   an   autosomal   recessive   lysosomal   storage  
disease   characterized   by   an   intracellular   accumulation   of   unesterified   cholesterol   and  
sphingolipids   (Fig.   1-­3)   [44-­46].   NPC   is   a   genetically   and   clinically   heterogeneous  
neurovisceral  disease  affecting  1   in  89,000   individuals   [47].   It  occurs  sporadically  and  
causes  progressive,  disabling  neurological  symptoms  such  as  vertical  supranuclear  gaze  
palsy,   dysmetria,   dysarthria,   dysphagia,   cerebellar   ataxia,   and   seizures   [48-­50].  Most  
cases  of  NPC  disease  are  diagnosed  early  in  childhood  (age  2-­15  years),  but  increasing  
numbers   of   patients   are   now   being   recognized   with   adult   (age   >   15   years)   onset   of  
symptoms.   In  patients  with  adult   onset,   the  disease   typically  presents  with  movement  
disorders,  psychosis,  and  early  cognitive  decline.  NPC  is  a  result  of  mutations  in  one  of  
two   genes,   NPC1   (in   95%   of   cases)   or   NPC2   (5%   of   cases),   with   clinically  
indistinguishable  phenotypes  [51].  The  NPC1  gene  encodes  for  a  large  1278  amino  acid  
protein  with  13  transmembrane  helices  [52].  The  disease  causing  mutations  mostly  occur  
in  the  C-­terminal  cysteine-­rich  luminal  domain  (45%)  with  I1061T  being  the  most  frequent  
mutation,  present  in  15-­20%  of  all  disease  alleles  [53].  This  particular  mutation  leads  to  
NPC1  mislocalization  and  degradation  related  to  protein  misfolding  [54].  The  NPC2  gene  
encodes  a  small  132  amino  acid  soluble  lumenal  protein,  which  binds  cholesterol  in  1:1  
stoichiometry   and,  when  mutated,   it   looses   its   ability   to   bind   cholesterol   [55].  Several  
groups  have  postulated  a   theory  of   “hydrophobic  hand-­off”   transfer  of  cholesterol   from  
NPC2  to  NPC1  [52,  56].  In  this  model,  NPC2  binds  cholesterol  in  the  lysosomal  lumen  
followed  by   interaction  with  NPC1  to  achieve  cholesterol  export   from   lysosomes.  NPC  
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disease   severity   depends   on   the   type   of   mutation   an   individual   carries   ranging   from  
neonatal  to  adult.                  
  
Figure  1-­3  Cholesterol  and  sphingosine  metabolism  in  NPC.  Abbreviations:  
GSL,  glycosphingolipid;;  LDL;;  low  density  lipoprotein;;  LDLR,  low  density  lipoprotein  receptor;;  
SM,  sphingomyelin;;  Cer,  ceramide;;  Sph,  sphingosine;;  SphK1,  sphingosine  kinase  1;;  
S1P.  sphingosine-­1-­phosphate;;  S1PRs,  S1P  receptors;;  CE;;  cholesterol  esters;;  FC,  free  
cholesterol;;  ACAT,  cholesterol  acyltransferase;;  SPL,  sphingosine-­1-­phosphate  lyase;;  
PE,  phosphatidylethanolamine;;  Hex,  hexadecenal.  Figure  taken  from  [44].  
  
Currently,   there   are   no   FDA-­approved   drugs   for   NPC.   In   the   past,   disease  
treatments  have  included  palliative  care  such  as  anti-­seizure  medication,  anticholinergic  
drugs  for  dystonia  and  tremor,  and  antidepressants  or  antipsychotics  for  mood  disorders.  
However,   fairly   recently   substrate   reduction   therapy   aimed   at   decreasing   the  
concentration   of   accumulated   lipids   in   LE/Ls   has   been   tested   on   patients.   N-­
butyldeoxynojirimycin   (miglustat)   is   a   small   imino   sugar   that   inhibits   the   synthesis   of  
glycosphingolipids   (secondary   to   cholesterol)   shown   to   accumulate   in   NPC   cells   and  
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cause  decreased  lysosomal  calcium  uptake  leading  to  impaired  endocytic  function  [57-­
59].  Miglustat  is  approved  in  Europe  for  NPC  disease,  but  not  in  the  United  States  due  to  
inconclusive   clinical   data   [60].   Hydroxypropyl-­b-­cyclodextrin   (cyclodextrin),   a  
pharmaceutical   excipient   that   non-­discriminatively   binds   cholesterol,   is   another   drug  
currently  being  tested  in  patients  [61].  The  hydrophobic  cavity  of  the  cyclodextrin  molecule  
is   capable   of   accommodating   cholesterol   molecules,   and   incubation   of   NPC   patient  
fibroblasts  with  cyclodextrin  leads  to  a  reduction  in  cellular  cholesterol  as  measured  by  
filipin   staining   [62].   Repeated   subcutaneous   (SC)   administration   of   cyclodextrin   at  
extremely  high  doses  (4000  mg/kg)  in  mice  decreases  cholesterol  levels  in  the  liver  and  
brain,   slows   Purkinje   cell   loss,   and   delays   the   onset   of   neurological   disease   when  
administered  to  mice  before  maturation  of  the  blood-­brain  barrier  (BBB)  [63-­65].  However,  
cyclodextrin  has  does  not  cross  the  BBB  in  adult  animals  and  additional  studies  in  a  NPC  
feline   model   using   repeated   intracranial   (IC)   dosing   show   significant   rescue   of   CNS  
symptoms,   but   fail   to   control   peripheral   disease   [66,   67].   Thus,   co-­administration   of  
cyclodextrin  by  IC  (4000  mg/kg)  and  SC  (1000  mg/kg)  routes  results  in  optimal  disease  
control.   However,   high   doses   of   cyclodextrin   necessary   for   correction   of   neurological  
dysfunction  in  a  NPC  feline  model  are  also  associated  with  pulmonary  toxicity  and  hearing  
loss  owing  to  the  non-­specific  nature  of  cyclodextrin  as  a  cholesterol  scavenger  [68].  In  
human   clinical   trials,   hearing   loss   has   emerged   as   a   dose-­limiting   toxicity   following  
intrathecal  administration,  highlighting  the  urgent  need  for  safer  therapeutics,  particularly  
ones  amenable  to  peripheral  administration  [69-­71].    
Niemann-­Pick  A  and  B.  NPA  and  NPB  are  caused  by  ASM  deficiency  that  results  
in   the   progressive   accumulation   of   sphingomyelin   in   lysosomes.   ASM   is   a   70kDa  
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glycoprotein  localized  in  lysosomes  which  operates  at  pH  4.5-­5.5.  ASM  hydrolyzes  SM  
derived   from  either   the   cellular  membranes   (recycling,   autophagy  or   phagocytosis)   or  
exogenous  circulating  lipoproteins  (endocytosis)  to  phosphocholine  and  ceramide  (Fig.  
1-­4)   [72].   Sphingomyelin   accumulation   leads   to   systemic  manifestations   such   as   liver  
dysfunction,   hepatosplenomegaly,   infiltrative   lung   disease,   and   anemia   [73].   Very   low  
ASM  activity  (<5%  of  normal  levels)  in  NPA  makes  this  type  of  lysosomal  storage  disorder  
more   severe,   with   sphingomyelin   accumulations   within   visceral   tissues   and   brain  
compared  to  non-­neuropathic  NPB  type  [74].  Currently,  more  than  180  mutations  have  
been  identified  in  SMPD1  gene  that  cause  NPA/B  disease,  with  DR608,  R496L,  L302P,  
and  H421Y  being  the  most  common  [75].  Several  animal  models  have  been  established  
to  study  ASM  deficiency  including  ASM  knockout,  transgenic  NPB,  and  knock-­in  NPA/B  
(deltaR608,  R496L)  models  [75-­78].    
  
Figure  1-­4  Schematic  diagram  of  NPA/B  molecular  mechanism.  
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There  are  no  FDA-­approved  therapies  for  NPA  and  NPB  disease.  However,  the  
enzyme  replacement  therapy  with  recombinant  human  ASM  (rhASM)  is  currently  being  
tested   in   NPB   patients   [79,   80].   Rapid   production   of   sphingomyelin   catabolites   (e.g.,  
ceramide,   sphingosine   1-­phosphate)   necessitates   careful   substrate   debunking   using  
lower  doses  (3  mg/kg)  of  rhASM  to  prevent  toxicity.  Dose  escalation  studies  in  patients  
have  yielded  positive  results  without  serious  adverse  events;;  reductions  in  sphingomyelin  
storage,  spleen  and  liver  volumes  as  well  as  improvements  in  lipid  profile,  lung  disease,  
and   quality   of   life   have   been   achieved   [81].   Although   rhASM   treatment   shows   great  
promise  for  NPB  patients,  this  therapy  will  require  biweekly  enzyme  infusions,  and  it  will  
not  work  for  NPA  patients  with  central  nervous  system  symptoms  [82].  Thus,  it  is  critical  
to  continue  research  to  develop  novel  therapeutic  strategies.  
HDL   Functionality   in   Niemann-­Pick   Disease.   Cholesterol   and   sphingomyelin  
trafficking  defects  in  NPD  patients  lead  to  markedly  reduced  (>  2-­fold)  HDL  levels  and  a  
pro-­atherogenic  lipid  profile  characterized  by  elevated  LDL  and  triglycerides  as  shown  in  
Table  1-­1  [83-­85].  The  underlying  cause  of  HDL  deficiency  appears  to  have  a  different  
origin  in  NPC  versus  NPA/B.  The  cholesterol  trafficking  defect  in  NPC  leads  to  impaired  
regulation  of  cholesterol  synthesis  and  metabolism  gene  expression,  including  HMG-­CoA  
reductase,  HMG-­CoA  synthase,  low  density  lipoprotein  receptor  (LDL-­R),  and  LXR  [84].  
LXR  regulates  the  expression  of  the  ABCA1  transporter  which  in  turn  is  responsible  for  
the  rate-­limiting  step  of  pre-­b  HDL  formation  [86,  87].  Therefore,  low  levels  of  ABCA1  in  
NPC  lead  to  reduced  concentration  of  circulating  HDL.  Similar  to  NPC,  NPA/B  patients  
have   highly   atherogenic   lipid   profiles   manifested   as   elevated   triglyceride   and   LDL-­
cholesterol   along   with   low   HDL-­cholesterol   levels   [85].   However,   ABCA1   transporter  
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expression  is  normal  in  these  patients  and  therefore  cannot  be  the  reason  for  low  HDL  
[83].   In   turn,   HDL   in   NPA/B   patients   is   highly   enriched   with   sphingomyelin,   a   known  
inhibitor  of  the  LCAT  enzyme  [88].  Without  LCAT  being  able  to  esterify  cholesterol,  small  
and  immature  HDL  particles  have  a  short  circulation  half-­life  and  are  quickly  eliminated  
possibly  by  liver  leading  to  their  low  overall  levels  in  the  periphery.    
  
Table  1-­1  Mean  lipid  concentrations  in  male  and  female  NPA,  NPB,  and  NPC1  
patients  [84,  89].    








Cholesterol              
Type  A   253  (65)   241  (47)   <170   >200  
Type  B   237  (71)   213  (52)        
Type  C1   146  (33)   154  (37)        
HDL-­C              
Type  A   16  (5)   23  (12)   >45   <35  
Type  B   20  (7)   24  (11)        
Type  C1   30  (10)   35  (11)        
LDL-­C              
Type  A   156  (57)   164  (54)   <110   >130  
Type  B   169  (62)   145  (49)        
Type  C1   91  (32)   91  (43)        
Triglycerides              
Type  A   207  (79)   198  (87)   <125   >125  
Type  B   235  (96)   169  (90)        
Type  C1   126  (53)   152  (68)        
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  Research  Scope    
ApoA-­I  has  been  recognized  as  a  key  player  in  reverse  cholesterol  transport,  the  
movement   of   cholesterol   from   peripheral   tissues   to   the   liver   for   elimination,   where   it  
solubilizes   lipids   to   form   HDL   particles   and   acts   as   an   activator   of   LCAT.   ApoA-­I   is  
effective   in   promoting   cholesterol   efflux   from   arterial   wall   macrophages   through   the  
ABCA1   transporter.   A   number   of   ApoA-­I-­based   therapeutics   for   the   treatment   of  
cardiovascular  disease  have  reached  clinical  trials,  with  CSL-­112  currently  in  Phase  III.  
ApoA-­I   has   been   conventionally   complexed  with   phospholipids   such   as   soybean   PC,  
POPC,  DPPC   or   SM   to   form   synthetic/reconstituted  HDL   (sHDL)   in   order   to   improve  
ApoA-­I  stability  in  vivo.  The  costly  production  of  ApoA-­I  either  purified  from  human  blood  
or  recombinantly  produced  in  bacteria  prompted  a  search  for  cheaper  ApoA-­I  alternatives.  
One   such   product   was   ETC-­642,   was   a   22   amino   acid   peptide   with   no   sequence  
homology  to  ApoA-­I  that  was  able  to  form  8-­12  nm  HDL  particles  and  efflux  cholesterol  
from   macrophages.   To   maximize   cholesterol   efflux   through   the   ABCA1   transporter,  
another   ApoA-­I  mimetic   peptide,   5A,  was   developed   and   tested   in   pre-­clinical   animal  
models.  Given   that  ApoA-­I  mimetic  peptides  are  effective  at  solubilizing  phospholipids  
and  cholesterol  efflux  from  cells,  the  work  presented  here  will  demonstrate  the  novel  utility  
of   ApoA-­I   mimetics   (peptides   and   sHDL)   for   the   treatment   of   a   rare   cholesterol   and  
sphingomyelin   storage   disorder   called   Niemann-­Pick   disease.   Moreover,   peptide   and  
phospholipid  composition  in  sHDL  will  be  examined  to  define  the  component  of  sHDL  that  
drives  its  pharmacodynamics  (cholesterol  efflux)  in  vivo.  
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  Thesis  Overview  
The  main  goal  of  this  thesis  is  to  explore  the  ability  of  ApoA-­I  mimetics  to  be  tailored  
for   cholesterol   or   sphingomyelin   efflux   in   Niemann-­Pick   disease.   To   accomplish   this,  
different   ApoA-­I   mimetic   peptides   will   be   explored   alone   and   in   complex   with  
phospholipids  (sHDL)  in  Niemann-­Pick  type  C  and  type  A  models.  This  thesis  consists  of  
five  chapters  focused  on  how  the  composition  of  ApoA-­I  mimetics  (peptide  and  sHDL)  
influences  its  phospholipid  and  cholesterol  efflux  properties.      
   Chapter   1   is   an   introduction   describing   ApoA-­I,   its   role   in   the   formation   of  
endogenous   HDL   and   lipid   transport.   Then,   a   brief   discussion   of   sHDL   therapies   is  
presented  and  followed  by  an  overview  of  the  Niemann-­Pick  disease.  Finally,  a  literature  
review  of  what  is  known  about  HDL  in  Niemann-­Pick  disease  concludes  this  chapter.  
Chapter  2  of  this  thesis  focuses  on  the  discovery  of  an  sHDL  composition  for  the  
treatment   of   Niemann-­Pick   disease   type   C,   which   is   characterized   by   excessive  
accumulation  of  cholesterol  in  late  endosomes  and  lysosomes.  Initial  studies  are  focused  
on   the  design,   optimization,   and  exploration   of   sHDL  mechanism  of   action   in   primary  
human   fibroblast   cells.   In   this   chapter,   we   demonstrate   a   dose-­dependent   rescue   of  
cholesterol  storage  that  is  sensitive  to  sHDL  lipid  and  peptide  composition,  enabling  the  
identification  of  compounds  with  a  range  of  therapeutic  potency.  This  is  accompanied  by  
extensive   characterization   of   sHDL   efficacy   in   the   mouse   model   of   NPC1   disease.  
Findings  from  this  study  can  be  further  used  to  optimize  sHDL  composition  to  maximize  
its  therapeutic  potential  in  NPC.        
Chapter   3   assesses   the  utility   of  ApoA-­I  mimetics   (peptides   and   sHDL)   for   the  
treatment   of   Niemann-­Pick   disease   type   A,   which   is   characterized   by   excessive  
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accumulation  of  sphingomyelin   in   late  endosomes  and   lysosomes.   In   this  chapter,   the  
efflux   of   sphingomyelin   from   primary   NPA   human   fibroblast   cells   to   ApoA-­I   mimetic  
peptide  acceptors  and  sHDL  is  examined  in  two  assays  (radioactive  and  label-­free).  Lipid-­
free   or   lipid-­poor   ApoA-­I   mimetics   are   found   to   be   efficacious   at   scavenging  
sphingomyelin   from   NPA   cells.   We   also   demonstrate   that   the   ABCA1   transporter  
contributes   to   sphingomyelin   efflux   from   cells.   Finally,   in   vivo   assessment   of   ApoA-­I  
mimetic  peptide  and  lipid-­poor  sHDL  using  wild  type  mice  shows  the  ability  of  a  peptide  
to  mobilize  sphingomyelin  from  tissues  into  circulation.  Together,  these  studies  provide  
proof-­of-­concept   data   to   support   the   therapeutic   potential   of   ApoA-­I   mimetics   for   the  
Niemann-­Pick  Disease  type  A.  Findings  from  this  work  can  be  applied  to  in  vivo  model  of  
NPA  disease.  
Chapter  4  presents  a  systematic  evaluation  of  the  effect  of  both  peptide  sequence  
and   phospholipid   composition   of   sHDL   on   particle’s   ability   to   mobilize   and   esterify  
cholesterol  in  vitro  and  in  vivo.  Historically,  sHDL  drug  discovery  efforts  were  focused  on  
optimizing  peptide  sequences  for  interaction  with  cholesterol  cellular  transporters  rather  
than   understanding   how   both   sHDL   components,   peptide   and   lipid,   influence   its  
pharmacokinetics   (PK)  and  pharmacodynamic   (PD)  profiles.  We  designed   two  sets  of  
sHDL  having  either  identical  phospholipid  but  variable  peptide  sequences  with  different  
plasma   stability,   or   identical   peptide   and   phospholipids   with   variable   fatty   acid   chain  
length   and   saturation.   Our   data   highlight   the   complexity   of   the   reverse   cholesterol  
transport  and  that  the  phospholipid  composition  of  sHDL  is  the  driving  force  for  cholesterol  
mobilization  in  vivo.  This  work  lays  the  foundation  for  future  studies  in  appropriate  disease  
models.  
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Chapter  5  is  a  summary  of  the  dissertation  main  findings  and  future  direction  for  
the  projects.  
Chapters  2-­4  were  prepared  in  a  manuscript  format.  Chapter  2  was  published  in  
BMC  Medicine.  The  manuscript  for  Chapter  3  will  be  submitted  for  publication  shortly  after  
the  dissertation  defense.  Chapter  4  was  published  in  the  Journal  for  Pharmacology  and  
Experimental  Therapeutics.
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Background:  Niemann-­Pick  Disease  type  C  is  a  fatal  and  progressive  
neurodegenerative  disorder  characterized  by  the  accumulation  of  unesterified  
cholesterol  in  late  endosomes  and  lysosomes.  We  sought  to  develop  new  therapeutics  
for  this  disorder  by  harnessing  the  body’s  endogenous  cholesterol  scavenging  particle,  
high-­density  lipoprotein  (HDL).    
Methods:  Here  we  design,  optimize,  and  define  the  mechanism  of  action  of  synthetic  
HDL  (sHDL)  nanoparticles.    
Results:  We  demonstrate  a  dose-­dependent  rescue  of  cholesterol  storage  that  is  
sensitive  to  sHDL  lipid  and  peptide  composition,  enabling  the  identification  of  
compounds  with  a  range  of  therapeutic  potency.  Peripheral  administration  of  sHDL  to  
Npc1  I1061T  homozygous  mice  mobilizes  cholesterol,  reduces  serum  bilirubin,  reduces  
liver  macrophage  size,  and  corrects  body  weight  deficits.  Additionally,  a  single  
intraventricular  injection  into  adult  Npc1  I1061T  brains  significantly  reduces  cholesterol  
storage  in  Purkinje  neurons.  Since  endogenous  HDL  is  also  a  carrier  of  sphingomyelin,  
we  tested  the  same  sHDL  formulation  in  the  sphingomyelin  storage  disease  Niemann-­
Pick  type  A.  Utilizing  stimulated  Raman  scattering  microscopy  to  detect  endogenous  
unlabeled  lipids,  we  show  significant  rescue  of  Niemann-­Pick  type  A  lipid  storage.    
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Conclusions:  Together,  our  data  establish  that  sHDL  nanoparticles  are  a  potential  new  
therapeutic  avenue  for  Niemann-­Pick  Diseases.  
  
  Background  
Niemann–Pick  Disease  type  C  is  a  fatal  lysosomal  storage  disorder  that  
causes  progressive  neurodegeneration  along  with  visceral  organ  involvement.  
Symptom  onset  and  disease  severity  are  variable,  but  patients  commonly  develop  
hepatosplenomegaly,  cognitive  decline,  and  seizures,  culminating  in  death  in  the  
second  -­  third  decades  of  life  [90,  91].  Niemann-­Pick  C  patients  have  loss-­of-­function  
mutations  in  the  NPC2  (~5%)  or,  more  commonly,  NPC1  (~95%)  proteins.  In  the  late  
endosome/lysosomal  compartment  (LE/Lys),  LDL  derived  unesterified  cholesterol  is  
bound  by  NPC2  and  transferred  to  the  transmembrane  NPC1  protein  [92,  93].  Using  a  
poorly  defined  mechanism,  NPC1  exports  unesterified  cholesterol  from  LE/Lys.  
Unesterified  cholesterol  then  moves  to  other  sites  within  the  cell  where  it  alters  
membrane  dynamics  or  is  utilized  for  steroid  production  [93].  In  patients  with  
Niemann-­Pick  C,  mutations  in  NPC1/NPC2  prevent  intracellular  lipid  trafficking  and  
cause  characteristic  cholesterol  storage  [94].  A  biochemically  similar  lipid  storage  
disease  arises  from  mutations  in  the  gene  encoding  the  lysosomal  enzyme  acid  
sphingomyelinase.  Deficiency  of  enzyme  activity  causes  Niemann-­Pick  Disease  types  
A  and  B,  in  which  the  storage  of  sphingolipids  and  cholesterol  in  LE/Lys  leads  to  
hepatosplenomegaly  and  varying  degrees  of  neurodegeneration  [95].  
   Endogenous  mechanisms  to  maintain  cellular  cholesterol  homeostasis  include  
the  removal  of  excess  cholesterol  by  high-­density  lipoprotein  (HDL)  particles.  
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Cholesterol  is  effluxed  from  peripheral  cells  by  nascent  HDL  particles  and  esterified  in  
plasma,  and  then  mature  HDLs  travel  to  the  liver  where  cholesterol  is  eliminated  in  the  
bile  [96].    Recent  work  has  taken  advantage  of  endogenous  HDL  function  for  the  
development  of  synthetic  HDL  (sHDL)  nanoparticles  as  potential  therapeutics  for  
cardiovascular  diseases  [19,  21,  97,  98].  These  nanoparticles  are  composed  of  the  HDL  
protein  apolipoprotein  A-­1  (ApoA1)  or  ApoA1  mimetic  peptides  surrounding  a  lipid  
bilayer  to  form  10-­12  nm  diameter  discoidal  lipoprotein  particles  [99,  100].  Chemical  
synthesis  of  sHDL  permits  modifications  that  alter  lipid  and  ApoA1  peptide  composition  
and  thereby  impact  potency,  pharmacokinetics  and  safety  [101-­104].  sHDL  
nanoparticles  were  initially  designed  for  removal  of  cholesterol  from  lipid-­laden  
atherosclerotic  plaques.  In  clinical  trials  involving  ~2,000  cardiovascular  disease  
patients,  sHDL  was  safe  and  well-­tolerated  [19,  21,  23,  105-­107],  and  a  large  phase  III  
clinical  trial  in  17,400  patients  is  currently  ongoing  
(https://clinicaltrials.gov/ct2/show/NCT03473223).    
Here,  we  developed  and  optimized  a  sHDL  nanoparticle  which  significantly  
reduces  the  accumulated  cholesterol  in  Niemann-­Pick  type  C  cells.  The  sHDL  contains  
a  37-­amino  acid  ApoA1  mimetic  peptide,  termed  5A,  and  sphingomyelin  (SM);;  these  
nanoparticles  were  originally  developed  for  the  treatment  of  atherosclerosis.  5A-­SM  
sHDL  at  1:1.15  (wt/wt)  peptide:lipid  ratio  is  safe  in  primates,  and  with  established  sterile  
manufacturing,  this  sHDL  is  well  positioned  for  rapid  clinical  translation  [108,  109].  We  
show  that  5A-­SM  sHDLs  are  non-­toxic  and  effective  at  reducing  cholesterol  storage  in  
Niemann-­Pick  C  patient  fibroblasts  and  brain  slice  cultures  from  Npc1  mutant  mice.  We  
establish  that  5A-­SM  requires  the  ATP-­binding  cassette  transporter  1  (ABCA1)  to  efflux  
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stored  cholesterol.  In  vivo  studies  using  Npc1  mutant  mice  show  evidence  of  target  
engagement  and  rescue  of  peripheral  phenotypes  and  neuronal  cholesterol  storage.  
Furthermore,  we  show  that  5A-­SM  also  rescues  sphingomyelin  storage  in  Niemann-­Pick  
type  A  fibroblasts.  Together,  these  studies  provide  proof-­of-­concept  data  to  support  the  




All  Npc1-­I1061T  mice  [110]  were  backcrossed  to  C57BL/6  (≥10  generations).  
Approximately  equal  number  of  males  and  females  were  used  for  all  experiments  and  
littermates  were  used  when  available.  Mice  were  randomly  assigned  to  vehicle  or  
experimental  groups.  All  procedures  involving  mice  were  approved  by  the  University  of  
Michigan  Committee  on  Use  and  Care  of  Animals  (PRO00008133)  and  conducted  in  
accordance  with  institutional  and  federal  guidelines.    
  
Reagents  
2-­hydroxypropyl-­β-­cyclodextrin  (H-­107)  and  amiloride  (A7410)  were  from  Sigma.  
EndoH  (P0702)  and  PNGaseF  (P0704)  were  from  New  England  Biolabs.  Dynasore  
(14061)  was  from  Cayman  Chemical;;  Human  HDL  (J64903)  and  acetylated  LDL  
(J65029)  were  from  Alfa  Aesar.  5A  peptide  (DWLKAFYDKVAEKLKEAF-­P-­
DWAKAAYDKAAEKAKEAA,  4078379)  was  from  Bachem  Americas  (Torrance,  CA).  
22A  peptide  (PVLDLFRELLNELLEALKQKLK)  was  synthesized  by  Genscript  
(Piscataway,  NJ).  Lipids  including  egg-­sphingomyelin  (SM,  Coastome  NM-­10),  1,2-­
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dimyristoyl-­sn-­glycero-­3-­phosphocholine  (DMPC,  Coastome  MC-­4040),  and  1-­palmitoyl-­
2-­oleoyl-­sn-­glycero-­3-­phosphocholine  (POPC,  Coastome  MC-­6081)  were  from  NOF  
America  Corporation.  1,1'-­Dioctadecyl-­3,3,3',3'-­tetramethylindodicarbocyanine,  4-­
chlorobenzenesulfonate  salt  (DiD,  D7757)  and  4-­(4-­(dihexadecylamino)styryl)-­N-­
methylpyridinium  iodide  (DiA,  D3883)  were  from  Invitrogen.  Cholesteryl  [1,2,6,7-­3H(N)]  
linoleate  (ART  1203)  and  sphingomyelin  [choline  methyl-­3H]  were  from  American  
Radiolabeled  Chemicals  (Saint  Louis,  MO).    N-­[6-­[(7-­nitro-­2-­1,3-­benxoxadiazol-­4-­
yl)amino]-­sphingosine-­1-­phosphocholine  (NBD-­Sphingomyelin,  810218P)  was  from  
Avanti  Polar  Lipids  (Alabaster,  AL).    
  
Antibodies  
(Antigen,  dilution,  vendor,  cat.  no.):  NPC1,  1:500,  Abcam,  ab134113;;  Actin,  
1:4000,  Sigma,  A544;;  LAMP1,  1:100,  Developmental  Studies  Hybridoma  Bank  
University  of  Iowa,  H4A3;;  Calbindin,  1:500-­1:2,000,  Sigma,  02724;;  GFAP,  1:500,  Dako,  
z0344;;  IBA1,  1:250,  Abcam,  ab5076;;  NeuN,  1:500,  Millipore,  abn78;;  EEA1,  1:400,  
abcam,  ab2900;;  F4/80,  1:400,  abcam,  ab6640.  
  
sHDL  synthesis  
sHDL  particles  were  prepared  using  a  lyophilization  method  where  peptide  (5A  or  
22A)  and  lipid  (SM,  DMPC  or  POPC)  were  dissolved  in  acetic  acid  at  1:1.5  wt/wt  ratio  and  
then  lyophilized  together  for  24  hr.  HDL  was  fluorescently  labeled  by  adding  4  µg  DiD  or  
DiA  per  1  mg  peptide  directly  to  the  acetic  acid  mixture  of  peptide  and  SM.  The  resulting  
lyophilized  dry  pellet  was  re-­hydrated  in  PBS,  pH  7.4,  to  a  final  peptide  concentration  of  
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10  mg/mL,   vortexed,   and   thermocycled  3  X  between  55°  C  and   room   temperature   to  
generate  sHDL  particles.  pH  was  adjusted  to  7.4  and  sHDLs  were  sterile  filtered  using  
0.22  μm  Millipore  filters.  Labeling  of  5A  peptide  in  sHDL  (5A-­SM-­DiA)  with  AlexaFluor  647  
dye  was  performed  using  Invitrogen  protein  labeling  kit  (A20173).  Purification  of  5A-­SM-­
DiA-­Alexa647  post-­labeling  was  done  on  the  size-­exclusion  column  supplied  in  the  kit,  
and   the   final   concentration   of   sHDL  was   determined   according   to   the  manufacturer’s  
instructions   using   plate   reader   measurements   (SynergyTM   NEO   HTS   Multi-­Mode  
Microplate  Reader,  Bio-­Tek).  
  
sHDL  characterization  
Fluorescently   labeled   sHDL   particles   were   analyzed   by   UPLC   (Waters   Aquity  
UPLC  BEH125   sec   1.7   µm,   4.6   x   150  mm   column)   equipped  with  UV   (220   nm)   and  
fluorescence   detectors   (ex/em   644/665   nm   DiD,   456/590   nm   DiA,   650/665   nm  
AlexaFluor647).  The  hydrodynamic  diameters  of  sHDL  were  determined  by  dynamic  light  
scattering  on  Zetasizer  Nano  ZSP,  Malvern  Instruments  (Westborough,  MA).  The  volume  
intensity  average  values  were  reported.  Transmission  electron  microscopy  images  were  
obtained  on  an  FEI  Morgagni  electron  microscope  run  at  100  kV  at  a  magnification  of  
22,000  x  (2.1Å/pixel)  and  then  recorded  on  a  Gatan  Orius  charge-­coupled  device  camera.  
sHDL  samples  (3  μL  of  2  µg/ml)  were  adsorbed  for  1  minute  to  a  glow  discharged  400-­
mesh  copper  grid  covered  with  carbon-­coated  colloidion  film  (Structure  Probe).  The  grids  
were  washed   twice  and   then  negatively  stained   in  0.07%  uranyl   formate.  22A  and  5A  
peptides,  SM,  POPC,  and  DMPC  lipids  combined  at  1:0.5,  1:1  and  1:2  wt/wt  ratios  were  
described  previously[101,  102].  
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Cells  
Cell  lines  were  obtained  from  the  NIGMS  Human  Cell  Repository  at  the  Coriell  
Institute  for  Medical  Research.  GM08399  was  used  as  a  control  (CTRL)  cell  line.  
Niemann-­Pick  C  cell  lines  with  mutations  in  the  NPC1  gene:  GM18453  (I1061T/I1061T),  
GM17912  (P1007A/T1036M),  GM03123  (I1061T/P237S);;  Niemann-­Pick  A  (NPA)  cell  
line  with  mutation  in  the  SMPD1  gene  GM00112  (L302P/L302P).  Cells  were  cultured  in  
MEM,  PSG,  and  20%  FBS  [111].  
  
Treatments  
Endocytosis  inhibitors:  Cells  were  pretreated  with  dynasore  (80  µM)  or  amiloride  
(1  mM)  for  30  minutes.  Cell  culture  media  was  replaced  with  fresh  media  containing  
vehicle  (saline),  dynasore,  or  amiloride  along  with  5A-­SM-­DiD  for  two  hr.  ImageJ  was  
used  to  quantify  DiD  label  intensity  inside  cells.    
sHDL  in  cells:  Cells  were  plated  24  hr  before  treatment.  At  the  start  of  treatment,  
cell  culture  media  was  replaced  with  media  containing  vehicle  or  sHDL.  Culture  media  
containing  vehicle  or  sHDL  was  refreshed  after  24  hr.      
sHDL  treatment  of  brain  slices:  Slices  were  treated  with  fresh  particles/media  
daily  at  a  concentration  of  5  mg/ml  for  a  period  of  four  days.  
  
siRNA  transfection  
Predesigned  ON-­TARGETplus  SMARTpools  containing  4  individual  siRNAs  per  
target  sequence  (Dharmacon  Non-­targeting  SMARTpool  D-­001810-­10-­05,  ABAC1  L-­
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004128-­00,  SR-­B1  L-­010592-­00)  were  transfected  using  TransIT-­X2®  (Mirus)  reagent  




A  bullet  blender  (Next  Advance)  was  used  to  homogenize  cell  lysates.  Protein  
concentrations  were  normalized  by  DC™-­protein  assay  (Bio-­Rad)  and  equal  amounts  of  
protein  were  loaded  into  4-­12  %  gradient  SDS  PAGE  gels  (Invitrogen).  After  
electrophoresis  and  transfer  onto  a  PVDF  membrane,  immunoreactivity  was  detected  
by  ECL  (Thermo  Scientific)  and  imaged  using  an  iBright  (Thermo  Fisher  Scientific).  
ImageJ  was  used  to  quantify  band  intensity  [111].    For  Endoglycosidase  H  assay,  
lysates  were  separated  into  three  reactions  containing:  negative  control  (NT),  EndoH  
(E)  (NEB  P0702L),  or  PNGaseF  (P)  (NEB  P0704L)  [111].  After  a  3  hr  incubation  at  37º  
C  samples  were  loaded  on  SDS  PAGE  gels  as  indicated  above.  
  
Filipin  Staining  
   After  treatment,  cell  membranes  were  labeled  with  wheat  germ  agglutinin®  
(Thermo  Fisher).  Cells  were  fixed  in  4%  PFA  for  20  min,  washed  3  X  in  PBS,  and  1  X  in  
glycine.  Unesterified  cholesterol  was  labeled  with  filipin  labeling  solution  for  2  hr.  Filipin  
labeling  solution:  5%  FBS  +  0.4%  DMSO+  0.03  mg/ml  (tissue)  or  0.1  mg/ml  (cells)  
filipin.  Slides  were  washed  3  X  with  PBS  and  mounted  with  ProLong®  Gold  (Thermo  
Fisher)  [111].    
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RT-­qPCR  
RNA  was  converted  to  cDNA  using  the  High  Capacity  Reverse  Transcription  kit  
(Applied  Biosystems  4368814).  Quantitative  real-­time  PCR  (RT-­qPCR)  was  conducted  
in  technical  triplicates  using  15  ng  cDNA,  TaqMan™  probes  (Thermo  Fisher)  for  human  
HMGCR  (Hs  00168302),  HMGCS1  (Hs  00940429),  ABCA1  (Hs  01059118),  ABCG1  (Hs  
00245154),  LDLR  (Hs  01092524),  NPC1  (Hs  00264835),  SCARB1  (SR-­B1)  (Hs  
00969821),  SREBF-­2  (SREBP)  Hs  01081778,  GAPDH  (loading  control)  (4325792),  and  
mouse  HMGCS  (Mm  01304569).  RT-­qPCR  was  performed  using  an  ABI  7900HT  
Sequence  Detection  System  and  relative  expression  calculated  by  the  2^  (-­delta  delta  
Ct)  method  using  SDS  software.  
  
Immunofluorescence  staining  
Cells  were  washed  3  X  with  HBSS  and  fixed  with  4%  PFA  for  20  min  at  room  
temperature.  Cells  were  washed  with  PBS  and  glycine  before  addition  of  blocking  
solution  (0.02%  saponin,  5%  normal  goat  serum  (NGS),  1%  BSA)  for  1  hr.  Slides  were  
incubated  with  primary  antibodies  overnight  at  4º  C,  washed  with  PBS  +  0.02%  saponin  
and  incubated  with  secondary  antibody  for  1  hr  [111].  Slides  were  mounted  with  
Vectashield  +  DAPI  (Vector  Laboratories).  For  slice  culture:  slices  were  floated  in  
HBSS+/+  in  6  well  plates  containing  Netwell™  Inserts  (Corning).  Samples  were  fixed  in  
4%  PFA  and  0.1%  Triton  X-­100  for  1  hr,  rinsed  3  X  in  PBS,  then  treated  for  10  min  of  
1.5  mg/ml  glycine.  After  three  washes  in  PBS,  slices  were  blocked  in  PBS  containing  
5%  NGS  for  1  hr  at  room  temperature.  Slices  were  labeled  with  primary  antibody  
(diluted  in  blocking)  overnight.  The  following  day,  slices  were  washed  3  X  in  PBS  and  
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labeled  with  Alexa  conjugated  secondary  (1:500)  for  1  hr.  After  3  washes  in  PBS,  slices  
were  stained  with  filipin  labeling  solution  for  2  hr,  washed  3  X  PBS  and  mounted  in  
ProLong  Gold  (ThermoFisher)  and  imaged  by  confocal  microscopy.  Calbindin  was  used  
to  outline  Purkinje  cells  and  filipin  intensity  was  calculated  using  ImageJ.  
  
Preparation  of  cerebellar  organotypic  slice  cultures  
Cerebellar  organotypic  slice  cultures  were  prepared  using  300  μM  thickness  
sagittal  brain  slices  [112].  Four  slices  per  brain  were  used  in  each  set  of  experiments,  
split  evenly  between  control  and  experimental  medium.  Two  slices  were  placed  together  
on  a  cell  culture  insert  (Millipore;;  0.4  μM  pore  size,  30  mm  diameter)  which  contained  
1.2  ml  slice  culture  medium  (either  control  or  experimental)  and  was  pre-­incubated  at  
37°  C  in  95%  O2/  5%  CO2  in  a  6-­well  plate.  Control  medium  contained  50%  minimal  
essential  medium  with  Earle’s  salts,  25%  horse  serum,  25%  Hank’s  balanced  salts  
solution,  25  mM  HEPES,  2  mM  L-­glutamine,  6.5  mg/ml  glucose.  Experimental  medium  
was  prepared  by  adding  nanoparticles  at  a  concentration  of  5  mg/ml  to  the  
aforementioned  control  medium.  Every  24  hr,  cell  culture  inserts  were  transferred  to  a  
new  6-­well  plate  which  was  pre-­incubated  at  37°  C  in  95%  O2/  5%  CO2  with  control  or  
experimental  medium,  as  described  above.  Imaging  and  analysis  of  Purkinje  neuron  
cholesterol  content  was  performed  after  96  total  hours  of  incubation.  In  all  cases,  wild  
type  and  NPC  samples  were  matched  so  that  slices  were  prepared  on  the  same  day  
and  using  the  same  reagents.    
Stereotaxic  mouse  ICV  bolus  delivery  
Stereotaxic  administration  of  nanoparticles  into  the  right  lateral  ventricle  via  an  
intracerebral  ventricular  (ICV)  injection  was  performed  on  mice  under  vaporized  
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isoflurane  anesthesia  according  to  IACUC  guidelines.  6-­7-­week-­old  mice  received  a  
single  ICV  bolus  injection  of  sHDL  or  vehicle  using  established  protocols  [111,  113].  
Each  anesthetized  mouse  received  a  small  scalp  incision  to  expose  the  skull  and  a  
small  burr  hole  was  drilled  relative  to  Bregma  suture:  anterior-­posterior  +0.3  mm,  medio-­
lateral  -­1.0  mm.  A  beveled  needle  (7758-­04,  Hamilton,  Reno,  NV)  connected  to  a  10  µL  
syringe  (7653-­01,  Hamilton,  Reno,  NV)  was  placed  dorso-­ventral  -­3.0  mm  at  a  rate  of  1  
mm/sec.  A  three-­minute  wait  was  allotted  for  the  brain  to  seal  around  the  needle  and  
prevent  backflow  of  treatment  around  the  injection  site.  A  total  of  10  µL  vehicle  or  sHDL  
at  a  concentration  of  100  mg/ml  was  delivered  at  an  infusion  rate  of  0.5  µL/sec  using  an  
injection  pump  (UMC4,  World  Precision  Instruments,  Inc.,  Sarasota,  FL).    Five  minutes  
after  the  infusion  was  completed,  the  needle  was  retracted  at  a  rate  of  1  mm/sec  and  
the  incision  site  was  sutured  with  synthetic  non-­absorbable  sutures  (1011209,  Henry  
Schein,  Melville,  NY).  Mice  were  recovered  in  a  temperature  controlled-­environment  
and  following  surgery,  the  mouse  weight,  grooming  activity,  and  home  cage  activity  
were  recorded  for  up  to  7  days  according  to  IACUC  guidelines.    
  
Microscopy  
Epifluorescence:  Filipin  was  imaged  on  a  Zeiss  Axio  Imager  Z1  microscope  with  
an  automated  stage.  Cells  were  focused  in  the  green  channel  (wheat  germ  agglutinin)  
and  16  tiled  images  were  captured  per  experiment.  Images  with  ≥  90%  cell  confluence  
were  quantified  using  NIH  ImageJ  software  [111].  
Confocal  imaging  of  cells:  Fluorescently  labeled  sHDL  particles  were  imaged  on  
a  Nikon  A-­1  confocal  microscope.  Co-­localization  coefficients  were  calculated  using  
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Nikon  elements  software  (Pearson).  Brightness  and  contrast  was  applied  equally  across  
the  entire  image  to  both  control  and  experimental  groups  using  Photoshop.    
Macrophages  were  outlined  in  F4/80-­stained  sections  of  liver  and  area  was  
quantified  using  ImageJ  by  an  investigator  blinded  to  genotype  and  treatment.  
Confocal  imaging  of  tissue:  One-­week  post  intraventricular  injection,  vehicle  or  
5A-­SM  treated  mice  were  perfused  with  saline  and  tissues  were  placed  in  4%  PFA  
overnight.  The  liver  and  right  hemisphere  of  the  brain  were  embedded  in  OCT,  frozen,  
and  cut  into  7μm  thick  sections.  Sections  were  permeabilized  (0.1%  triton/10%  NGS/1%  
BSA  in  PBS)  for  10  min  and  placed  into  blocking  buffer  (10%  NGS/1%  BSA  in  PBS)  for  
50  min.  Sections  were  placed  in  primary  antibody  overnight  at  4°C,  washed  three  times  
in  PBS  for  5  min,  then  incubated  in  secondary  antibody  for  1  hr  at  room  temperature.  
Sections  were  stained  with  filipin  and  imaged  on  a  Nikon  A-­1  confocal  microscope.  
Purkinje  neuron  soma  were  defined  using  a  calbindin-­DK28  antibody  and  filipin  was  
quantified  using  ImageJ.    
Stimulated  Raman  scattering  (SRS)  microscopy:  Cell  monolayers  were  imaged  
at  2845  cm-­1  Raman  shift  wavenumber  to  generate  a  greyscale  image  channel.  Images  
acquired  at  the  2845  cm-­1  are  chemically  selective  for  lipids,  stimulating  vibrational  
resonance  of  the  CH2  symmetric  stretching  mode  [114].  Individual  fields-­of-­view  (FOVs)  
for  lipid  quantification  were  generated  and  quantified  using  a  two-­layer  automated  
thresholding  method  to  avoid  selection  bias.  Over  a  full  2  mm  X  2  mm  SRS  image,  a  
250-­pixel  X  250  pixel  sliding  window  with  100-­pixel  step  size  was  used  to  detect  FOVs  
with  greater  than  90%  cellular  confluence.  Mean  background  pixel  intensity  values  for  
each  image  were  used  to  set  the  FOV  threshold  for  background  (i.e.  media)  and  
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foreground  (i.e.  cells).  Only  FOVs  with  a  foreground/background  ratio  greater  than  90%  
were  included  for  lipid  quantification.  After  selection  of  FOVs,  a  second  thresholding  
procedure  was  used  to  segment  intracellular  lipid  droplets,  which  have  high  2845cm-­1  
SRS  signal  compared  to  the  remainder  of  the  intracellular  contents.  For  each  FOV,  a  
ratio  between  the  area  of  intracellular  lipid  to  total  intracellular  space  was  calculated  and  
normalized  to  the  number  of  cells  within  each  image.    
  
Amplex  Red  
The  Amplex®  Red  Cholesterol  Assay  Kit  A12216  (Invitrogen)  was  used  to  
quantify  total  free  cholesterol  following  the  manufacturer’s  instructions.  
  
Cell  death  
Cell  viability  was  assessed  using  Promega  CellTiter  96  Aqueous  One  Solution  cell  
proliferation  colometric  assay  (G3580).  Briefly,  Niemann-­Pick  C  cells  were  cultured  in  96-­
well   plates   at   10,000   cells   per   well   for   24   hr,   washed   3   X  with   PBS,   and   treated   as  
indicated  with  compounds  diluted  in  media  for  24  hours.  Cells  were  washed  3  X  with  PBS,  
and   re-­suspended   in   media   supplemented   with   Promega   CellTiter   96   reagent   (20   µl  
reagent  per  100  µl  of  media).  After  45  min  incubation  at  37o  C,  absorbance  was  read  at  
490  nm  using  a  microplate  reader.  Each  treatment  was  performed  in  triplicate  and  the  
average  absorbance  reading  of  non-­treated  (Veh)  cells  was  set   to  100%.  The  percent  
viability  was  determined  by  dividing  the  average  absorbance  of  treated  over  non-­treated  
cells  and  multiplying  by  100.    
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Sphingomyelin  loading  
C6-­NBD  sphingomyelin  was  dissolved  in  100  %  ethanol  to  make  a  10  mM  stock  
solution.  Cells  were  treated  with  40  μM  C6-­NBD  sphingomyelin  in  cell  culture  media  
overnight.  The  following  day  (t=0),  wells  were  briefly  washed  2  X  with  PBS  and  fresh  
media  without  C6-­NBD  sphingomyelin  was  added.    At  t=0  and  t=24  hr,  cells  were  
treated  with  fresh  media  containing  vehicle  (saline)  or  5A-­SM.    
  
Radioactive  cholesterol  efflux  assay  
Preparation  of  [3H]cholesteryl  linoleate-­loaded  acLDL  
Cholesteryl   [1,2,6,7-­3H(N)]   linoleate   (60   Ci/mmol)   was   loaded   into   acetylated  
human  LDL  (acLDL)  according  to  procedure  adapted  from  Brown  et  al  [115].  Briefly,  30  
μCi  (0.5  nmol)  cholesteryl  [1,2,6,7-­3H(N)]  linoleate  in  toluene  was  evaporated  to  dryness  
under  a  stream  of  nitrogen  gas.  Then,  a  thin  film  of  cholesteryl  [1,2,6,7-­3H(N)]  linoleate  
was   dissolved   in   10   µl   DMSO   followed   by   the   addition   of   100   μl   acLDL   (5   mg   of  
protein/ml).  The  mixture  was  incubated  for  2  hr  at  37°  C  with  gentle  shaking  to  incorporate  
cholesteryl  [1,2,6,7-­3H(N)]  linoleate  into  acLDL  and  then  dialyzed  at  4°  C  against  20  mM  
Tris/HCl,   0.3  mM  EDTA,   0.15  M  NaCl,   pH   7.4   using   3.5K  MWCO   slide-­A-­Lyzer  mini  
device   (ThermoFisher   88400).   Cholesteryl   [1,2,6,7-­3H(N)]   linoleate-­acLDL   mixture  
routinely  contained  90-­95%  of  starting  radioactivity  as  determined  by  scintillation  counting  
before  and  after  dialysis.    
Cholesterol  efflux  assay  
Niemann-­Pick  C  fibroblast  cells  were  grown  in  culture  media  until  confluency.  On  
day  1,  75,000  cells  were  plated  in  24-­well  plates  and  grown  for  24  hr   in  0.5  ml  culture  
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media.  On  day  2,  cells  were  washed  with  PBS,  pH  7.4,  1  X  at   room  temperature  and  
grown  overnight   in  media  containing  lipoprotein-­deficient  serum  (10%  v/v)   in  DMEM  to  
upregulate  LDL  receptors.  On  day  3,  cells  were  washed  with  PBS,  pH  7.4,  2  X  and  labeled  
with  cholesteryl  [1,2,6,7-­3H(N)]  linoleate-­acLDL  for  24  hr  in  DMEM  (no  phenol  red)/BSA  
(1  mg/ml)/P-­S  media  (0.5  ml)  containing  1  µCi  of  [3H]Cholesteryl  linoleate  per  1  ml  media.  
On  day  4,  labeled  cells  were  washed  with  PBS,  pH  7.4,  3  X  to  remove  cholesteryl  [1,2,6,7-­
3H(N)]  linoleate  not  taken  up  by  cells.  Radioactive  cholesterol  was  effluxed  from  cells  for  
24  hr  using  vehicle  (media),  5A  peptide  (0.75  mg/ml),  5A-­SM  HDL,  5A-­DMPC,  5A-­POPC  
(0.75  mg/ml)  or  cyclodextrin  (1  mM)  diluted   in  DMEM/BSA/P-­S.  On  day  5,  media  from  
each  well  was  transferred  into  separate  Eppendorf  tubes  and  centrifuged  at  3,000  rpm  
for  10  min  to  remove  any  detached  cells.  The  remaining  cells  on  the  plate  were  lysed  with  
0.1%  SDS/   0.1M  NaOH  solution   for   2   hr   at   room   temperature.  Radioactive   counts   of  
media   and   cell   fractions   were   measured   separately   using   a   Perkin   Elmer   liquid  
scintillation  counter.  Percent  cholesterol  effluxed   from  cells  was  calculated  by  dividing  
media  counts  by  the  total  sum  of  media  and  cell  counts  and  then  multiplying  by  100%.  
Non-­specific  cholesterol  efflux  by  vehicle  was  subtracted  from  all  data.            
  
In  vivo  cholesterol  mobilization  
Total  serum  cholesterol  concentrations  from  seven  week  old  Niemann-­Pick  C  mice  
pre-­  and  2  h  post-­treatment  with  100  mg/kg  5A-­SM  i.p.  were  analyzed  enzymatically  by  a  
colorimetric   cholesterol   oxidase   assay   (Wako   Chemicals,   Richmond,   VA)   using  
microplate  reader.  
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Distribution  of  mobilized  cholesterol  in  lipoproteins  
Serum   samples   from  Niemann-­Pick  C  mice   collected   at   baseline   and   2   h   post  
treatment  with  100  mg/kg  5A-­SM  i.p.  were  analyzed  to  assess  the  cholesterol  distribution  
between  VLDL,  LDL  and  HDL  lipoprotein  fractions.  Separation  of  lipoproteins  from  serum  
was   performed   on   a  Waters   HPLC   system   equipped   with   a   Superose   6,   10/300   GL  
column  (GE  Healthcare,  Piscataway,  NJ)  and  a  fraction  collector.  Serum  samples  were  
injected  onto  the  HPLC  and  eluted  with  saline  solution  pH  7.4  at  1  ml/min.  Eluent  fractions  
containing  different  lipoproteins  were  post-­column  reacted  in  the  HPLC  with  an  enzymatic  
solution  for  total  cholesterol  detection  [116].    
  
Radioactive  sphingomyelin  efflux  assay    
Cells  (40,000  cells/well)  were  cultured  for  24  hr  in  24-­well  plates  and  then  
incubated  with  1  µCi  (80  Ci/mmol)  sphingomyelin  [choline  methyl-­3H]  per  1  ml  media.  
After  24  hr,  cells  were  washed  with  PBS,  pH  7.4,  3  X  followed  by  the  treatment  with  
vehicle  or  0.75  mg/ml  5A-­SM  in  culture  media.  Radioactivity  in  media  and  cells  was  
counted  using  a  PerkinElmer  scintillation  counter.  Percent  sphingomyelin  effluxed  from  
cells  was  calculated  by  dividing  media  counts  by  the  total  sum  of  media  and  cell  counts  
and  then  multiplying  this  number  by  100%.  Non-­specific  sphingomyelin  efflux  by  vehicle  
was  subtracted  from  all  data.  
  
Serum  analysis  
Whole  blood  was  collected  and  allowed  to  clot  for  5  min  in  BD  microtainer®  SST  
gold  cap  tubes  (365967).  Tubes  were  centrifuged  for  5  min  at  3,000  X  g  to  remove  the  
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Significance  (P<0.05)  was  determined  by  Graphpad  Prism  7.0.  Figure  legends  
indicate  when  unpaired  Student’s  two  tailed  t-­test,  one-­way,  or  two-­way  ANOVA  with  
Tukey  or  Bonferroni  posthoc  analysis  were  used.  All  error  bars  are  s.e.m.  Graphpad  




Design  and  synthesis  of  sHDL  nanoparticles  
ApoA1  enwraps  lipids  into  10-­12  nm  nanodiscs  forming  endogenous  HDL  [117].  
These  particles  contain  a  heterogeneous  mixture  of  saturated  and  unsaturated  
phospholipids,  with  each  lipid  having  distinct  cholesterol  binding  properties  [118].  
Relative  to  full-­length  ApoA1  protein,  use  of  synthetic  ApoA1  mimetic  peptide  is  
beneficial  due  to  the  ease  of  manufacturing,  enhanced  quality  control,  and  lower  cost  
[99].  We  utilized  the  ApoA1  mimetic  peptide  5A,  which  is  designed  to  maximize  
cholesterol  efflux  by  ABCA1  [108].  Using  phospholipids  with  differing  affinities  for  
cholesterol  [119],  we  developed  a  panel  of  sHDLs  containing  various  5A:lipid  
formulations,  including  sphingomyelin  (SM),  a  saturated  phospholipid  (DMPC,  1,2-­
dimyristoyl-­sn-­glycero-­3-­phosphocholine),  or  an  unsaturated  phospholipid  (POPC,  1-­
palmitoyl-­2-­oleoyl-­glycero-­3-­phosphocholine).    
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All  sHDLs  (5A-­SM,  5A-­POPC,  and  5A-­DMPC  at  1:1.5  wt/wt  ratio)  were  prepared  
by  co-­lyophilization  and  thermocycling  (Figure  2-­1a)  [101].  The  lyophilization  and  
thermocycling  processes  are  highly  efficient,  and  we  did  not  detect  marked  differences  
in  the  expected  and  actual  ratios  of  peptide  to  lipid  (Table  2-­1).    sHDL  particles  had  an  
average  diameter  of  10-­12  nm  (5A-­SM  and  5A-­DMPC)  as  determined  by  dynamic  light  
scattering  (Figure  2-­1b).  Hydrophobic  uncomplexed  lipids  spontaneously  form  ≥100  nm  
liposomes.  Large  liposomes  were  not  detected  by  dynamic  light  scattering  (data  not  
shown)  indicating  a  highly  efficient  incorporation  of  lipids  into  sHDL.  sHDLs  also  
exhibited  the  expected  size  and  disc-­like  morphology  by  transmission  electron  
microscopy  (Figure  2-­1c).    sHDL  “stacking”  by  transmission  electron  microscopy  is  likely  
an  artifact  of  sample  preparation  since  dynamic  light  scattering  revealed  monomeric  
sHDL  in  solution.  
  
sHDLs  rescue  cholesterol  storage  in  Niemann-­Pick  type  C  fibroblasts  
   To  assess  the  activity  of  sHDL  on  Niemann-­Pick  type  C  patient  cells,  we  used  
the  fluorescent  dye  filipin  to  label  accumulated  unesterified  cholesterol.  We  analyzed  
filipin  staining  intensity  in  Niemann-­Pick  C  fibroblasts  following  treatment  with  vehicle,  
5A  peptide  alone,  or  sHDLs  composed  of  5A-­POPC,  5A-­SM,  or  5A-­DMPC.  Treatment  
with  5A  peptide  alone  did  not  significantly  alter  filipin  intensity  over  48  hrs  (Fig.  2-­2a,  2-­
2b).  In  contrast,  both  5A-­SM  and  5A-­DMPC  significantly  rescued  stored  cholesterol  in  a  
dose-­  and  time-­dependent  manner  in  three  independent  lines  of  Niemann-­Pick  C  
primary  fibroblasts  (Fig.  2-­2a,  2-­2b,  2-­3a).  sHDL  composed  of  5A-­POPC  yielded  a  more  
modest  and  less  consistent  rescue,  demonstrating  that  lipid  composition  impacts  
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biological  activity.  The  beneficial  effects  of  sHDL  treatment  were  confirmed  using  an  
amplex  red  assay  to  measure  total  cellular  cholesterol  (Fig.  2-­2c).  Assessment  of  cell  
viability  following  treatment  showed  no  significant  changes,  except  for  mild  toxicity  from  
5A-­DMPC  (Figure  2-­3b).  Taken  together,  these  studies  demonstrate  sHDL  activity  and  
tolerability,  and  given  the  investigational  new  drug  status  of  5A-­SM,  prompted  further  
analysis  of  SM-­containing  sHDLs.    
   Although  the  lipid  content  of  sHDL  is  a  strong  determinant  of  cholesterol  efflux,  
the  composition  of  the  ApoA1  mimetic  peptide  is  also  important  for  sHDL  function  [104].  
In  order  to  investigate  the  impact  of  the  ApoA1  mimetic  peptide  on  sHDL’s  ability  to  
reduce  cellular  cholesterol  storage,  nanoparticles  were  prepared  with  another  peptide,  
22A  [105,  120].  Both  5A  and  22A  peptides  have  no  sequence  homology  with  
endogenous  ApoA1  and  were  optimized  differently:  5A  peptide  was  selected  to  
maximally  efflux  cholesterol  by  ABCA1,  while  22A  peptide  was  selected  to  maximize  
cholesterol  esterification  within  sHDLs  in  plasma  [103,  105,  108].    
Raising  the  lipid  to  peptide  ratio  increases  sHDL’s  size  and  its  capacity  to  accept  
cholesterol  [102].  It  is  generally  believed  that  larger  sHDL  particles  efflux  cholesterol  
through  scavenger  receptor  B-­1  (SR-­B1)  [121].  To  examine  the  effect  of  peptide  
sequence  and  peptide:lipid  ratio  on  cholesterol  removal,  we  generated  a  panel  of  
sHDLs  containing  5A  or  22A  and  various  peptide:SM  ratios.  Filipin  analysis  revealed  
significant  cholesterol  reducing  activity  of  sHDLs  containing  5A-­SM  but  not  22A-­SM.  
Moreover,  we  found  that  a  1:1.5  wt/wt  ratio  of  5A:SM  was  optimal  at  reducing  filipin  
intensity  (Figure  2-­2d).  
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   To  determine  which  cholesterol  transporter  is  primarily  responsible  for  5A-­SM  
mediated  removal  of  unesterified  cholesterol  from  Niemann-­Pick  C  cells,  we  performed  
expression  analysis  of  NPC  patient  fibroblasts.  In  contrast  to  ABCG1,  expression  of  
ABCA1  and  SR-­B1  were  readily  detected  by  qPCR  (Figure  2-­3c).  Next,  we  treated  
primary  fibroblasts  with  non-­targeting  siRNAs  (siNT),  or  siRNAs  targeting  SR-­B1  (siSR-­
B1)  or  ABCA1  (siABCA1).  5A-­SM  efficiently  rescued  cholesterol  storage  after  treatment  
with  either  siNT  or  siSR-­B1,  but  not  after  treatment  with  siABCA1  (Figure  2-­2e).  As  
siRNAs  significantly  reduced  expression  of  target  genes  (Figure  2-­3d),  this  analysis  
confirmed  that  5A-­SM  requires  ABCA1  to  function.  Notably,  increasing  cholesterol  
content  of  5A-­SM  reduced  its  effect  on  clearance  of  unesterified  cholesterol  (Figure  2-­
2f).  Consistent  with  this  observation,  incubation  with  a  heterogeneous  pool  of  human  
plasma  HDL  (HuHDL)  containing  nascent  (cholesterol  poor)  and  mature  (cholesterol  
loaded)  HDL  failed  to  reduce  cellular  cholesterol  levels  (Figure  2-­2f).  These  data  
contrast  the  observation  that  the  cholesterol  reducing  agent  2-­hydroxypropyl-­beta  
cyclodextrin  (cyclodextrin)  preloaded  with  cholesterol  remains  effective  at  reducing  
unesterified  cholesterol  in  Niemann-­Pick  C  cells  [122-­124],  and  raise  that  possibility  that  
sHDL  and  cyclodextrin  have  distinct  mechanisms  of  action.    
  
5A-­SM  induces  the  expression  of  cholesterol  regulatory  genes  
   To  more  fully  define  the  biological  responses  triggered  by  sHDLs,  we  treated  
Niemann-­Pick  C  fibroblasts  with  increasing  doses  of  cyclodextrin  or  5A-­SM  and  
analyzed  the  expression  of  cholesterol  regulatory  genes.  A  48  hr  treatment  with  
cyclodextrin  did  not  alter  the  expression  of  HMGCR,  HMGCS1,  or  LDLR  (Figure  2-­4a).  
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This  is  consistent  with  previous  research  showing  cyclodextrin  causes  a  transient  
decrease  then  restoration  in  cholesterol  biosynthetic  genes  by  48  hrs  [122,  123,  125].  In  
contrast,  48  hrs  of  treatment  with  5A-­SM  or  5A-­DMPC  caused  a  dose-­dependent  
increase  of  cholesterol  biosynthetic  (HMGCR,  HMGCS1,  SREBP)  and  uptake  genes  
(LDLR)  in  three  independent  lines  of  patient  fibroblasts  (Figure  2-­4a,  2-­5a,  2-­5b).  
Additionally,  expression  of  the  cholesterol  export  gene  ABCA1  was  significantly  
decreased  (Figure  2-­4a,  2-­5a,  2-­5b).  Together,  these  data  suggest  that  sHDLs  
efficiently  extract  cholesterol  from  target  cells  and  act  at  different  time  scales  than  
cyclodextrin.      
Treatment  with  5A-­SM  also  significantly  increased  the  expression  of  NPC1  
mRNA  and  protein  (Figure  2-­4a,  2-­4b,  2-­5c,  2-­5d).  This  is  notable  since  multiple  groups  
have  shown  that  a  subset  of  NPC1  missense  mutants  are  functional  if  they  escape  ER  
degradation  and  traffic  to  LE/Lys  [126,  127].  To  determine  whether  the  induction  of  
NPC1  contributed  to  rescue  of  lipid  storage,  we  took  advantage  of  the  fact  that  the  
NPC1  protein  is  heavily  glycosylated.  These  glycans  are  modified  as  the  protein  traffics  
through  the  medial  Golgi,  rendering  them  resistant  to  cleavage  by  endoglycosidase  H  
(EndoH)  but  maintaining  sensitivity  to  PNGaseF.  As  expected,  wild  type  (WT)  NPC1  
protein  expressed  in  control  fibroblasts  was  resistant  to  EndoH  cleavage,  while  mutant  
NPC1  protein  from  patient  fibroblasts  was  sensitive  to  EndoH  (Figure  2-­4c).  Treatment  
with  5A-­SM  did  not  alter  the  sensitivity  of  mutant  NPC1  to  digestion  by  EndoH,  
indicating  that  the  accumulated  protein  did  not  traffic  to  LE/Lys  (Figure  2-­4c,  2-­5e).  We  
conclude  that  5A-­SM  removes  cholesterol  from  patient  fibroblasts  without  correcting  
mutant  NPC1  protein  trafficking  or  function.    
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5A-­SM  enters  cells  through  macropinocytosis  and  promotes  cholesterol  efflux  
   Cholesterol  is  loaded  into  nascent  HDL  particles  when  ApoA1  interacts  with  
receptors  such  as  ABCA1  at  the  plasma  membrane.  However,  a  prior  report  indicates  
that  ApoA1  and  ABCA1  may  be  endocytosed  as  a  complex  [128].  Studies  have  
suggested  that  ApoA1/ABCA1  endocytosis  is  required  for  removal  of  accumulated  LDL-­
derived  cholesterol  from  LE/Lys  [128,  129].  To  determine  if  5A-­SM  enters  cells  through  
endocytosis,  we  treated  Niemann-­Pick  C  patient  fibroblasts  with  5A-­SM  sHDLs  
containing  the  fluorescent  lipophilic  dye  DiD  (5A-­SM-­DiD).  Confocal  imaging  revealed  
little  5A-­SM-­DiD  signal  on  the  plasma  membrane,  yet  readily  identified  fluorescent  
signal  in  the  cytoplasm,  indicating  uptake  of  the  5A-­SM-­DiD  nanoparticles  (Figure  2-­6a).  
To  define  the  mechanism  of  uptake,  cells  were  pretreated  with  the  macropinocytosis  
inhibitor  amiloride  [130]  or  the  clathrin  and  caveolar  inhibitor  dynasore,  then  loaded  with  
5A-­SM-­DiD.  Dynasore  had  little  effect  on  5A-­SM-­DiD  uptake,  while  amiloride  
significantly  reduced  5A-­SM-­DiD  signal  intensity,  indicating  that  macropinocytosis  is  a  
major  route  of  5A-­SM-­DiD  endocytosis  (Figure  2-­6a).  Notably,  the  lipophilic  tag  DiD  was  
not  covalently  conjugated  to  5A-­SM;;  therefore,  the  punctate  cytoplasmic  pattern  of  
fluorescence  could  represent  DiD  dissociated  from  the  nanoparticle.  To  rule  out  this  
possibility,  we  synthesized  sHDLs  containing  5A  peptide  covalently  conjugated  to  
Alexa647  (5A-­Alexa647)  and  incorporated  the  lipophilic  dye  DiA  into  these  particles  
(5A:Alexa647-­SM:DiA).  After  2  hrs  incubation,  the  5A  and  DiA  signals  strongly  co-­
localized  (Figure  2-­6b)  indicating  that  the  internalized  5A-­SM  sHDL  particles  remained  
intact  inside  the  cell.    
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   Unesterified  cholesterol  that  accumulates  within  Niemann-­Pick  C  cells  resides  in  
LAMP1  positive  LE/Lys  [124].  To  determine  if  5A-­SM  traffics  to  this  compartment,  we  
conducted  a  time  course  and  analyzed  co-­localization  of  5A-­SM-­DiD  with  LAMP1  and  
filipin.  We  observed  that  a  fraction  of  5A-­SM-­DiD  co-­localized  with  LAMP1  and  filipin  
positive  lipid  storage  vesicles  over  a  period  of  2  hrs  (Figure  2-­6c).  At  this  time  point,  5A-­
SM-­DiD  did  not  co-­localize  with  the  recycling  endosome/early  endosome  marker  EEA1  
(Figure  2-­7),  possibly  because  it  had  already  traveled  past  this  compartment.  Whether  
lysosomal/filipin  positive  5A-­SM-­DiD  compartments  represent  the  primary  site  of  sHDL  
action  requires  further  investigation,  and  it  remains  possible  that  sHDLs  act  at  other  
intracellular  sites.  In  either  case,  we  sought  to  confirm  that  sHDL  uptake  was  
accompanied  by  efflux  of  stored  cholesterol.  To  accomplish  this,  patient  fibroblasts  were  
loaded  and  then  equilibrated  with  [3H]cholesteryl  linoleate  bound  to  LDL.  We  treated  
cells  with  5A  or  5A-­SM  for  24  hrs  and  then  measured  intracellular  and  extracellular  
[3H]cholesterol.  Incubation  with  5a  peptide  alone  resulted  in  ~20%  efflux  of  radiolabeled  
LDL-­derived  cholesterol  to  medium  (Figure  2-­6d).  Notably,  pre-­formed  5A-­SM  sHDL  
particles  were  much  more  effective  at  effluxing  LDL  [3H]cholesterol  than  5A  alone,  
resulting  in  release  of  ~60%  of  labeled  cholesterol  into  the  media.  In  contrast,  24  hr  
treatment  with  1  mM  cyclodextrin  resulted  in  a  modest  6.2%  ±  2.7  efflux  of  LDL-­derived  
cholesterol  at  this  early  timepoint.    This  is  in  line  with  previous  data  showing  that  
cyclodextrin  extracts  cholesterol  from  the  plasma  membrane  and  can  mobilize  it  from  
intracellular  stores  [124,  125,  131].    
  
5A-­SM  mobilizes  cholesterol  and  ameliorates  phenotypes  in  Niemann-­Pick  C  mice  
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     Based  on  the  significant  rescue  of  cholesterol  storage  observed  in  vitro,  we  
sought  to  determine  the  extent  to  which  administration  of  sHDLs  benefit  gene  targeted  
mice  homozygous  for  the  Npc1  I1061T  allele  (Niemann-­Pick  C  mice).  These  mice  
contain  the  most  common  Niemann-­Pick  C  disease-­causing  mutation  (I1061T).  Starting  
at  7  weeks  of  age  these  mice  develop  robust,  progressive  phenotypes  including  
cholesterol  accumulation,  Purkinje  neuron  loss,  motor  impairment  and  premature  death  
by  13  weeks  of  age  [110].  Niemann-­Pick  C  mouse  serum  collected  pre-­  and  two  hrs  
post-­intraperitoneal  (i.p.)  injection  of  5A-­SM  established  that  treatment  significantly  
increased  serum  cholesterol  content  (Figure  2-­8a).  High-­performance  liquid  
chromatography  (HPLC)  was  used  to  identify  cholesterol-­containing  fractions  (VLDL,  
LDL,  or  HDL).  Serum  cholesterol  was  distributed  in  all  lipoprotein  fractions  2  hrs  post  
5A-­SM  injection,  with  LDL  and  VLDL  particles  containing  the  most  cholesterol  (Figure  2-­
8b).  This  is  a  typical  lipoprotein  profile  after  sHDL  administration,  where  immediate  
HDL-­cholesterol  elevation  is  followed  by  transient  LDL/VLDL-­cholesterol  elevation  while  
cholesterol  is  metabolized,  returning  to  baseline  24  hrs  post-­treatment  [101,  102,  106].  
Consistent  with  data  showing  cholesterol  mobilization  into  the  serum,  a  single  injection  
of  5A-­SM  significantly  up-­regulated  the  cholesterol  biosynthetic  gene  HMGCS  in  the  
liver  (Figure  2-­8c),  similar  to  our  findings  in  patient  fibroblasts  (Fig.  2-­4a).  These  data  
provide  evidence  of  target  engagement  after  in  vivo  administration  of  sHDL  to  Niemann-­
Pick  C  mice.    
To  determine  whether  Niemann-­Pick  C  mice  showed  benefits  from  sHDL  
administration,  we  initially  focused  on  peripheral  disease  manifestations  that  might  be  
responsive  to  i.p.  administration.  Niemann-­Pick  C  mice  exhibit  significantly  elevated  
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serum  bilirubin  levels,  diminished  body  weight,  and  liver  macrophage  activation.  We  
analyzed  total  bilirubin  levels  in  seven-­week  old  WT  and  Niemann-­Pick  C  mice  48  hrs  
after  a  single  injection  of  vehicle  or  5A-­SM.  sHDL  administration  rescued  bilirubin  levels  
in  Niemann-­Pick  C  mice  without  altering  them  in  WT  littermates  (Figure  2-­8d).  Niemann-­
Pick  C  mice  also  exhibit  progressive  body  weight  loss  as  they  age  [110].  To  determine  
effects  on  this  disease  manifestation,  5A-­SM  or  vehicle  was  injected  i.p.  three  times  per  
week  from  7-­11  weeks  of  age,  and  the  change  in  weight  was  calculated  for  each  mouse  
for  the  duration  of  the  treatment  trial.  WT  mice  treated  with  either  vehicle  or  5A-­SM  
gained  ~2g  during  the  treatment  period,  whereas  vehicle  treated  Niemann-­Pick  C  mice  
failed  to  gain  body  weight.  In  contrast,  Niemann-­Pick  C  mice  treated  with  5A-­SM  
exhibited  a  significant  rescue  of  body  weight,  gaining  as  much  weight  as  WT  controls  
(Figure  2-­8e).  Administration  of  5A-­SM  also  significantly  reduced  liver  macrophage  size  
in  Niemann-­Pick  C  mice  (Figure  2-­8f).  While  i.p.  administration  of  sHDL  showed  
significant  benefits  for  these  peripheral  phenotypes,  it  did  not  correct  motor  phenotypes  
(Figure  2-­9a),  suggesting  poor  blood  brain  barrier  penetration.    
   The  Niemann-­Pick  C  mouse  motor  phenotypes  are  driven,  in  part,  by  loss  of  
cholesterol-­laden  cerebellar  Purkinje  neurons  [132,  133].  To  determine  whether  sHDLs  
could  rescue  cholesterol  storage  in  neurons,  we  treated  cultured  cerebellar  slices  from  
adult  WT  and  Niemann-­Pick  C  mice  with  vehicle  or  5A-­SM  for  four  days.  Slices  were  
fixed  and  co-­labeled  for  Purkinje  neurons  (calbindin)  and  cholesterol  (filipin).  Confocal  
imaging  demonstrated  that  treatment  of  Niemann-­Pick  C  brain  slices  significantly  
reduced  cholesterol  storage  in  Purkinje  neurons  (Figure  2-­8g,  2-­9b).  This  finding  
demonstrates  that  sHDLs  are  active  on  CNS  target  cells  if  they  gain  access  to  the  brain.  
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To  directly  test  CNS  activity,  we  performed  intraventricular  injections  in  6-­7  week  old  
Niemann-­Pick  C  mice  with  vehicle  or  5A-­SM  containing  the  fluorescent  dye  DiD  (5A-­
SM-­DiD),  a  manipulation  that  was  well  tolerated.  One-­week  post  injection  5A-­SM-­DiD  
signal  localized  to  the  cerebellum,  brain  stem,  cortex,  and  hippocampus  (Figure  2-­10).  
In  the  cerebellum  the  fluorescent  signal  from  DiD  localized  predominantly  to  astrocytes  
and,  to  a  lesser  extent,  microglia  at  this  time  point  (Figure  2-­11b,  2-­11c).  We  calculated  
Purkinje  neuron  soma  size  as  a  potential  indicator  of  in  vivo  toxicity  of  5A-­SM  one-­week  
post  injection.  Suggesting  little  toxicity,  Purkinje  neuron  soma  size  was  unchanged  with  
5A-­SM  treatment  (WT+Veh,  185±44;;  NPC+Veh,  207±57;;  and  NPC+5A-­SM,  206±61  
pixels).  One-­week  post-­injection,  we  observed  significant  reduction  of  cholesterol  
accumulation  in  Purkinje  neurons  in  Niemann-­Pick  C  mice  treated  with  sHDL  (Figure  2-­
8h).    
  
5A-­SM  reduces  accumulated  sphingomyelin  in  Niemann-­Pick  A  fibroblasts  
Both  cholesterol  and  sphingomyelin  utilize  the  ABCA1  transporter  to  efflux  from  
cells  into  an  HDL  acceptor  [134].  These  two  lipids  physically  interact  and  commonly  
traffic  together  [135].  This  suggested  that  sHDL  might  be  effective  at  rescuing  aberrant  
storage  of  sphingomyelin  as  well  as  cholesterol.  Sphingomyelin  is  normally  metabolized  
by  the  lysosomal  enzyme  acid  sphingomyelinase,  and  loss-­of-­function  mutations  in  the  
encoding  gene  result  in  sphingomyelin  accumulation,  causing  Niemann-­Pick  Disease  
types  A  and  B  [136].    
To  determine  whether  sHDL  was  capable  of  removing  stored  sphingomyelin  from  
cells,  Niemann-­Pick  A  and  control  primary  fibroblasts  were  loaded  with  
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[3H]sphingomyelin  for  24  hrs  and  then  treated  with  5A-­SM.  After  24  hrs,  5A-­SM  
promoted  the  efflux  of  twice  as  much  [3H]sphingomyelin  from  Niemann-­Pick  A  cells  
than  control  cells  (Figure  2-­12a).  To  confirm  this  observation,  Niemann-­Pick  A  
fibroblasts  were  loaded  overnight  with  fluorescent  NBD-­sphingomyelin.  Cells  were  then  
treated  with  vehicle,  cyclodextrin  or  5A-­SM  for  48  hrs  (Figure  2-­12b).  As  expected,  
control  cells  metabolized  NBD-­sphingomyelin  and  had  little  signal,  while  Niemann-­Pick  
A  cells  showed  marked  cytoplasmic  accumulation.  Remarkably,  5A-­SM  significantly  
reduced  NBD-­sphingomyelin  storage  in  mutant  cells.  In  contrast,  cyclodextrin  treatment  
was  ineffective,  consistent  with  previous  work  in  other  sphingolipidoses  [65].  
The  addition  of  exogenous  sphingomyelin  can  alter  membrane  dynamics  and  
impact  downstream  protein  function  [137,  138].  Therefore,  we  sought  to  determine  
effects  of  5A-­SM  on  endogenous  lipids  stored  in  Niemann-­Pick  A  cells.  To  detect  total  
lipids  in  a  live,  unfixed  state,  we  utilized  stimulated  Raman  scattering  (SRS)  microscopy.  
This  SRS  system  generates  virtual  histology  images  that  are  useful  for  a  variety  of  
applications,  including  the  clinical  setting  [139].  SRS  utilizes  an  excitation  and  pump  
beam  at  the  Raman  wave  number  for  CH2  bonds  to  rapidly  image  total  lipids  in  
biological  samples.  Since  sphingomyelin  contains  extensive  CH2  bonds,  we  developed  
SRS  cell  plating,  imaging,  and  analysis  procedures  for  Niemann-­Pick  A  fibroblasts.  SRS  
imaging  demonstrated  that  Niemann-­Pick  A  fibroblasts  had  double  the  lipid  signal  
intensity  compared  to  control  cells  (Figure  2-­12c).  Treatment  of  Niemann-­Pick  A  
fibroblasts  with  5A-­SM  rescued  this  lipid  storage,  whereas  treatment  with  cyclodextrin  
did  not.  Collectively,  these  data  show  that  5A-­SM  is  effective  at  reducing  sphingomyelin  
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storage  in  Niemann-­Pick  A  cells  and  suggest  that  sHDL  nanoparticles  may  be  
therapeutically  beneficial  for  the  family  of  Niemann-­Pick  diseases.  
  
  Discussion  
We  describe  an  innovative  approach  to  ameliorating  lipid  storage  in  the  
Niemann-­Pick  family  of  diseases  by  harnessing  the  activity  of  the  body’s  endogenous  
cholesterol  scavenging  particle,  HDL.  The  sHDL  particles  characterized  here  potently  
remove  stored  cholesterol  from  Niemann-­Pick  C  fibroblasts  (Figure  2-­2)  and  neurons  
(Figure  2-­8f).  The  particles  show  evidence  of  cholesterol  target  engagement  and  rescue  
disease  phenotypes  when  administered  to  Niemann-­Pick  C  mice  (Figure  2-­8).  The  10-­
12  nm  sHDL  nanodiscs  are  generated  at  high  purity  by  assembling  peptide-­lipid  
nanoparticles  by  a  co-­lyophilization  and  thermocycling  process  (Figure  2-­1).  Notably,  
the  degree  of  cholesterol  removal  was  affected  by  altering  the  constituent  ApoA1  
mimetic  peptide,  lipid,  and  peptide:lipid  ratio  (Figure  2-­2),  demonstrating  that  sHDLs  
provide  a  flexible  platform  that  can  be  tuned  to  adjust  therapeutic  potency.  Moreover,  
our  observation  that  the  sHDL  that  rescues  cholesterol  storage  in  type  C  disease  also  
rescues  sphingolipid  storage  in  type  A  disease  (Figure  2-­12)  raises  the  possibility  that  
alternative  sHDL  compositions  may  be  beneficial  for  additional  lipid  storage  disorders.  
The  initial  in  vivo  analyses  presented  here  provide  a  proof-­of-­concept  of  activity  for  a  
single  sHDL  formulation,  5A-­SM,  at  limited  points.  These  data  set  the  stage  for  
additional  analyses  in  Niemann-­Pick  animal  models,  including  comparisons  with  other  
therapies  currently  administered  to  patients  or  in  clinical  trial.      
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   Prior  studies  have  established  that  Niemann-­Pick  type  C  cells  have  normal  
ApoA1  receptor  binding,  endocytosis  and  re-­secretion  [140,  141],  yet  Niemann-­Pick  
patients  have  reduced  serum  HDL  levels  [140,  142-­146]  that  likely  worsen  lipid  storage.  
Previous  reports  have  also  demonstrated  that  Niemann-­Pick  type  C  cells  are  defective  
in  loading  cholesterol  into  ApoA1  [140,  141,  147].  Similarly,  we  noted  that  ApoA1  
mimetic  peptides  are  not  sufficient  for  reducing  Niemann-­Pick  C  cholesterol  storage  
(Figure  2-­2a,  b).  Our  strategy  bypassed  the  HDL  formation  deficiencies  in  disease  by  
utilizing  an  investigational  new  drug,  5A-­SM  sHDL,  that  exhibits  no  significant  cellular  
toxicity.  The  activity  of  alternative  sHDL  formulations  will  be  the  subject  of  future  
research.  Additionally,  the  extent  to  which  incorporation  of  ApoE  rather  than  ApoA1  
mimetic  peptides  and  the  addition  of  brain  targeting  peptides  enhance  therapeutic  
efficacy  in  the  CNS  remain  to  be  defined.  
While  the  rescue  of  cholesterol  storage  from  mutant  fibroblasts  required  
expression  of  ABCA1  (Figure  2-­2e),  fluorescently  labeled  sHDLs  readily  entered  cells  
by  macropinocytosis  (Figure  2-­6a).  The  lipid  and  peptide  constituents  of  the  
nanoparticles  remained  tightly  associated  within  cells  (Figure  2-­6b,  c),  with  some  
trafficking  to  LAMP1  and  filipin  staining  vesicles  (Figure  2-­6c).  Other  intracellular  sHDLs  
remained  outside  these  lipid  storage  vesicles,  and  the  precise  location  of  cholesterol  
loading  remains  to  be  determined.  In  contrast  to  LDL,  there  is  still  incomplete  
understanding  of  HDL  endocytosis  and  subcellular  trafficking  [148].  Interestingly,  
multiple  intracellar  pools  of  HDL  have  been  described.  After  endocytosis  HDL  can  be  re-­
secreted,  sent  to  the  lysosome,  or  trafficked  to  the  Golgi  before  re-­secretion  [148-­150].  
The  location  of  the  subcellular  pools  of  HDL  are  still  being  described  and  are  likely  cell  
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type  dependent.  Although  we  were  not  able  to  define  where  all  of  the  5A-­SM  localized  
within  cells,  treatment  with  sHDLs  did  trigger  cholesterol  efflux  (Figure  2-­6d),  a  finding  
that  may  reflect  release  of  cholesterol-­laden  nanoparticles  and/or  enhanced  lysosomal  
exocytosis.  
The  identification  of  therapeutic  rescue  of  lipid  storage  in  Niemann-­Pick  type  A  
cells  by  sHDL  was  greatly  facilitated  by  SRS  microscopy  (Figure  2-­12c).  This  technique  
was  used  to  circumvent  challenges  associated  with  labeling  endogenous  sphingolipids  
and  shortcomings  of  applying  exogenous  sphingolipids  to  study  intracellular  trafficking.  
We  were  not  able  to  identify  the  accumulated  lipid  species  by  current  technology  and  
cannot  exclude  the  possibility  that  sphingomyelin  correction  is  a  consequence  of  
cholesterol  removal.  However,  this  seems  unlikely  as  treatment  with  the  cholesterol-­
removing  agent  cyclodextrin  did  not  alter  sphingomyelin  accumulation  or  lipid  content  in  
Niemann-­Pick  type  A  cells  (Figure  2-­12b,  2-­12c).  Notably,  limited  techniques  allow  live  
cell  imaging  of  endogenous  lipids.  While  SRS  cannot  currently  delineate  lipid  
subspecies,  we  anticipate  that  continued  development  of  this  technology  will  enable  this  
process.  Moreover,  the  robust  rescue  of  lipid  storage  in  Niemann-­Pick  type  A  cells,  
along  with  the  amelioration  of  peripheral  phenotypes  in  Niemann-­Pick  C  mice  following  
i.p.  administration,  are  particularly  encouraging  in  the  context  of  Niemann-­Pick  type  B.  
Niemann-­Pick  B  is  characterized  by  peripheral  organ  system  phenotypes,  but  not  CNS  
involvement.  Even  with  the  successful  removal  of  sphingomyelin  in  Niemann-­Pick  A  
cells  by  5A-­SM,  future  research  is  needed  to  establish  the  optimal  sHDL  formulation  for  
removing  stored  lipids  in  this  disorder.  
  
   48  
Our  study  demonstrates  a  proof  of  concept  that  sHDL  significantly  reduce  lipid  
storage  in  both  Niemann-­Pick  C  and  A.  Future  work  will  assess  the  long-­term  effects  of  
sHDL  in  NPC  and  NPA/NPB  mouse  models.  Considering  the  safety  of  sHDL  in  clinical  
trials,  correction  of  peripheral  phenotypes  would  justify  testing  large  animals  and  
perhaps  in  patients  with  these  disorders.  As  such,  our  data  suggest  that  5A-­SM  or  other  
sHDLs  may  be  therapeutically  beneficial  for  patients  with  Niemann-­Pick  Diseases  and  
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Figure  2-­1  Synthesis  and  characterization  of  sHDL  nanoparticles.  (a)  A  lyophilized  
mixture  of  5A  peptide  and  sphingomyelin  (SM)  was  hydrated  in  PBS  and  thermocycled  to  
assemble  sHDL  particles.  (b,  c)  Particle  size  distribution  was  analyzed  by  (b)  dynamic  light  
scattering  for  1  mg/mL  of  5A-­SM,  5A-­DMPC  or  5A-­POPC  sHDL  or  (c)  transmission  electron  
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5A-­SM  1   11.96   6.12   1:0.5   1:0.51  
5A-­SM  2   10.13   8.91   1:1   1:1.14  
5A-­SM  3   10.84   15.26   1:1.5   1:1.41  
5A-­POPC   9.33   13.5   1:1.5   1:1.45  
5A-­DMPC   11.51   17.28   1:1.5   1:1.50  
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Figure  2-­2  sHDLs  require  ABCA1  to  remove  accumulated  cholesterol  from  
Niemann-­Pick  C  fibroblasts.  (a-­f)  Primary  fibroblasts  homozygous  for  NPC1  I1061T  were  
treated  with  various  sHDL  formulations.  Plasma  membranes  are  outlined  with  dashed  lines.  (a,  
b)  Accumulation  of  unesterified  cholesterol  was  visualized  by  filipin  staining  (a)  following  48  hr  
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treatment  with  increasing  doses  (representative  images  of  0.75  mg/ml)  of  vehicle  (Veh),  5A  
peptide,  5A-­POPC,  5A-­SM,  and  5A-­DMPC  (quantified  below)  or  (b)  with  0.75  mg/ml  sHDL  at  
various  time  points.  (c)  Effects  of  48  hr  treatment  with  sHDL  (0.75  mg/ml),  5A  peptide  or  vehicle  
(Veh)  on  total  cellular  cholesterol  were  measured  using  the  Amplex  Red  assay.  (d)  The  ratio  of  
5A  or  22A  peptide  to  sphingomyelin  (SM)  was  altered  during  synthesis  and  the  effect  of  
peptide:SM  ratio  on  cholesterol  removal  was  determined  by  filipin  staining  (48  hr  treatment).  (e)  
Cells  were  treated  for  two  consecutive  days  with  the  following  siRNAs:  non-­targeting  (NT),  
ABCA1,  or  SR-­B1,  and  concurrently  treated  with  vehicle  (Veh)  or  5A-­SM.  Cholesterol  storage  
was  determined  by  filipin  staining.  (f)  Cells  were  treated  with  cyclodextrin  (Cyclo),  5A-­SM,  or  5A-­
SM  preloaded  with  increasing  amount  of  cholesterol  content  (5%-­20%  total  lipid  weight),  or  
human  HDL  (HuHDL).  Cholesterol  storage  was  assessed  by  filipin  staining  48  hr  after  
treatment.  Data  are  mean  ±  s.e.m.  from  (a,  b,  e)  three,  (c)  five,  (d)  5-­8,  or  (f)  4-­6  independent  
experiments.  n.s.,  not  significant,  *p≤.05,  **p≤.01,  ***p≤.001,  ****p≤.0001  by  (a,  b)  Two-­way  
ANOVA  with  Bonferroni  posthoc  test  (F,  df=(a)  33.53,  df=4;;  (b)  32.88,  4),  (c-­f)  One-­way  ANOVA  
with  Tukey  posthoc  test(F,  df=(c)  13.98,  4;;  (d)  6.96,  8;;  (e)  22.5,  6;;  (f)  6.94,  5).  (a)  Dash  lines  







































Figure  2-­3  sHDLs  rescue  cholesterol  storage  in  Niemann-­Pick  C  patient  
fibroblasts.  (a)  Primary  human  fibroblasts  with  compound  heterozygous  mutations  in  NPC1,  
encoding  I1061T/P237S  or  451ΔAG/Y825C,  were  treated  with  vehicle  (Veh)  or  0.75  mg/ml  of  
5A  peptide,  5A-­POPC,  5A-­DMPC,  or  5A-­SM  for  48  hrs.  Unesterified  cholesterol  was  labeled  
with  filipin  and  quantified.  (b)  Viability  of  Niemann-­Pick  C  patient  (I1061T/I1061T)  primary  
fibroblasts  after  24-­hour  treatment  with  vehicle  (Veh),  1  mM  cyclodextrin  (Cyclo),  0.75  mg/ml  of  
5A  peptide,  5A-­POPC,  5A-­DMPC,  or  5A-­SM.  (c)  qPCR  was  used  to  assess  expression  level  of  
ABCA1,  SR-­B1,  and  ABCG1  mRNAs  in  NPC1  I1061T  primary  fibroblasts.  (d)  NPC1  I1061T  
primary  fibroblasts  were  treated  with  siRNAs  against  ABCA1  (siABCA1)  or  SR-­B1  (siSR-­B1),  or  
with  non-­targeting  (NT)  siRNAs  for  48  hrs.  mRNA  expression  was  analyzed  by  qPCR.  Data  are  
mean  ±  s.e.m.  from  (a,  d)  three,  (c)  four  or  (b)  seven  independent  experiments.  (a,  b)  One-­way  
ANOVA  with  Tukey  posthoc  test  (F,  df=(a)  (Left)  4.015,  4;;  (Right)  6.603,  3;;  (b)  4.171,  5).  (d)  
Student’s  t-­test  (t=(ABCA1)  3.20,  (SR-­B1)  3.69).  n.s.,  not  significant,  *p≤.0.05,  **p≤.01.  
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Figure  2-­4  sHDLs  modulate  cholesterol  regulatory  genes.  (a)  Primary  fibroblasts  
homozygous  for  NPC1  I1061T  were  treated  with  vehicle  (Veh),  cyclodextrin  (cyclo),  or  5A-­SM  at  
the  indicated  concentrations  for  48  hours.  HMGCR,  HMGCS1,  ABCA1,  LDLR,  SREBP,  or  NPC1  
mRNA  expression  was  analyzed  by  qPCR.  (b,  c)  NPC1  protein  in  control  (CTRL)  and  NPC1  
I1061T  (NPC)  fibroblasts  was  analyzed  by  (b)  western  blot  (quantified  at  right)  or  (c)  digested  
with  endoglycosidase  H  (E),  PNGase  F  (P),  or  not  treated  (NT)  and  analyzed  by  western  blot.  
Data  are  mean  ±  s.e.m.  from  three  independent  experiments.  n.s.,  not  significant,  *p≤.05,  
**p≤.01,  ***p≤.001,  ****p≤.0001  relative  to  Veh  by  (a)  One-­way  ANOVA  with  Tukey  posthoc  test  
(F,  df=(HMGCR)  27.43,  df=5;;  (HMGCS1)  24.75,  5;;  (ABCA1)  43.54,  5;;  (LDLR)  9.4,  5;;  (SREBP)  
7.0,  5;;  (NPC1)  12.41,  4.  (b)  student’s  t-­test  t=3.83,  df=2.  
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Figure  2-­5  sHDLs  induce  the  expression  of  cholesterol  regulatory  genes.  (a)  
Primary  human  fibroblasts  with  (a,  c)  I1061T/P237S,  P1007A/T1036M,  or  (b)  I1061T/I1061T  
NPC1  alleles  were  treated  with  vehicle  (Veh),  (a,  c)  0.75  mg/ml  5A-­SM,  or  (b)  increasing  
concentrations  of  5A-­DMPC  for  48  hrs.  mRNA  expression  of  cholesterol  regulatory  genes  was  
analyzed  by  qPCR.  (d,  e)  NPC1  protein  levels  from  P1007A/T1036M  fibroblasts  treated  with  
vehicle  (Veh)  or  5A-­SM  were  analyzed  by  western  blot  for  (d)  total  levels  or  (e)  digested  with  
endoglycosidase  H  (E),  PNGaseF  (P)  or  not  treated  (NT).  Data  are  mean  ±  s.e.m.  from  three  
independent  experiments.  (a,  d)  Student’s  t-­test  (t=(a)  I1061T/P237S  (HMGCR)  5.71;;  
(HMGCS1)  38.35;;  (ABCA1)  17.92;;  (LDLR)  3.91;;  (SREBP)  1.173;;  P1007A/T1036M  (HMGCR)  
3.31;;  (HMGCS1)  6.43;;  (LDLR)  4.53;;  (d)  4.329);;  (b,  c)  One-­way  ANOVA  with  Tukey  posthoc  test  
(F,  df=(b)  (HMGCR)  10.73,  2;;  (HMGCS1)  21.72,  2;;  (ABCA1)  75.05,  2;;  (LDLR)  89.24,  2;;  
(SREBP)  10.7,  2;;  (c)  (Left)  9.78,  2;;  (Right)  5.23,  2).  n.s.,  not  significant,  *p≤.0.05,  **p≤.01,  
****p≤.0001.  
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Figure  2-­6  5A-­SM  is  endocytosed  and  increases  cholesterol  efflux.  (a-­d)  NPC1  
I1061T  fibroblasts  were  treated  with  the  indicated  sHDL  for  (a-­c)  2  or  (d)  24  hours.  (a)  Cells  
were  pre-­treated  with  dynasore  (80  µM),  amiloride  (1  mM)  or  vehicle  (Veh)  for  30  minutes,  and  
then  incubated  with  fresh  media  containing  5A-­SM-­DiD  plus  dynasore,  amiloride  or  vehicle  for  
two  hours.  Plasma  membranes  are  outlined  with  dashed  lines.  5A-­SM-­DiD  (red)  intensity  is  
quantified  at  the  right.  (b)  Cells  were  treated  with  sHDL  composed  of  5A-­Alexa647  (green)  and  
DiA  (red)  incorporated  into  the  SM  fraction.  Following  2  hours  incubation,  cells  were  labeled  with  
NucStain  (blue)  and  imaged  by  confocal  microscopy.  Pearson  co-­localization  coefficient  =  0.75  
±  0.01.  (c)  Cells  were  incubated  with  5A-­SM-­DiD  (red)  for  1,  1.5,  and  2  hours,  fixed,  stained  for  
LAMP1  (green)  and  filipin  (blue),  and  imaged  by  confocal  microscopy.  Representative  images  
from  2  hours  post  treatment.  Pearson  co-­localization  coefficient  quantified  below.  (d)  Cells  were  
pre-­treated  for  24  hours  with  acetylated  LDL  containing  [3H]cholesteryl  linoleate  to  specifically  
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deliver  cargo  to  the  lysosomal  compartment.  Following  24  hour  equilibration,  cells  were  treated  
for  24  hour  with  0.75  mg/ml  5A  peptide  or  5A-­SM.  Radioactivity  in  media  and  cell  fractions  was  
determined  by  liquid  scintillation  counting  and  values  were  normalized  to  vehicle  treated  group.  
Data  are  mean  ±  s.e.m.  from  three  independent  experiments.  n.s.,  not  significant,  *p≤.05,  
**p≤.01,  ****p≤.0001  by  (a)  One-­way  ANOVA  with  Tukey  posthoc  test  relative  to  Veh  or  5A  
(F=10.74,  df=2);;  (c)  Two-­way  ANOVA  with  Bonferroni  posthoc  test(F,  df=  23.63,  2).  (d)  student’s  
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Figure  2-­7  5A-­SM  does  not  co-­localize  with  EEA1  at  two  hours  post  treatment.  NPC1  
I1061T  fibroblasts  were  treated  with  0.75  mg/ml  5A-­SM-­DiD  (red)  for  two  hours.  Cells  were  fixed  
and  stained  for  EEA1  (green)  and  nuclei  (blue).  Representative  images  from  2  hours  post  
treatment.  Scale  bar  =  50  µm.  
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Figure  2-­8  5A-­SM  mobilizes  cholesterol  in  vivo  and  ameliorates  disease  
phenotypes.  (a)  Serum  cholesterol  from  seven  week  old  Npc1  I1061T  homozygous  mice  pre-­  
and  2  hr  post-­treatment  with  100  mg/kg  5A-­SM,  i.p.  (b)  Pre-­  (dashed  line)  and  2  hr  post-­
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treatment  (solid  line)  serum  was  fractionated  by  HPLC  and  cholesterol  was  quantified  by  
cholesterol  oxidase  assay.  VLDL,  LDL,  and  HDL  fractions  are  indicated  by  arrows.  (c,  d)  Seven  
week  old  wild  type  (WT)  and  Npc1  I1061T  homozygous  (NPC)  mice  were  injected  i.p.  with  
vehicle  (Veh)  or  100  mg/kg  5A-­SM.  48  hrs  later  (c)  liver  HMGCS  transcript  levels  and  (d)  total  
serum  bilirubin  were  analyzed.  (e)  WT  and  Npc1  I1061T  mice  were  injected  i.p.  with  vehicle  
(Veh)  or  100  mg/kg  5A-­SM  three  times  per  week  from  7-­11  weeks  of  age.  The  change  in  weight  
of  each  mouse  from  week  7  (t=0)  to  week  11  (t=4)  was  quantified.  (f)  Seven  week  old  WT  and  
NPC  mice  were  injected  with  Veh  or  100  mg/kg  5A-­SM  three  times  per  week  for  two  weeks.  At  
nine  weeks  of  age  livers  were  stained  for  macrophages  using  F4/80  (green)  and  DNA  Hoechst  
(blue).  Macrophage  area  is  quantified  at  right.  Scale  bar  =  50  µm.  Violin  plot  shows  median  
(dashed  line),  25%  and  75%  (dotted  lines),  and  probability  density  (thickness).  (g)  Brain  slices  
from  8  week  old  Npc1  I1061T  mice  were  incubated  with  vehicle  (Veh)  or  5  mg/ml  5A-­SM  for  four  
days  and  filipin  levels  in  Purkinje  neuron  soma  were  quantified  (see  also  Additional  file  1:  Fig.  
S4b).  (h)  Six  to  seven  week  old  WT  and  Npc1  I1061T  mice  received  intraventricular  injections  
with  vehicle  (Veh)  or  5A-­SM-­DiD.  N:  WT=4,  NPC  Veh=5,  NPC  5A-­SM=4  mice.  One-­week  later  
cholesterol  levels  in  Purkinje  neuron  soma  (green)  were  analyzed  by  filipin  (blue)  staining.    
Dashed  lines  indicate  Purkinje  neuron  soma  (also  see  Additional  file  1:  Fig.  S6a).  Scale  bar  =  
50  µm.  Data  quantified  at  right.  Data  are  mean  ±  s.e.m.  from  (a,  b,  c)  three;;  (d)  genotype  and  
treatment:  number  of  mice,  WT+Veh=5,  WT  +  5A-­SM=3,  NPC+Veh=4,  NPC+5A-­SM=7;;  (e)  
genotype  and  treatment:  number  of  mice  at  9  wks  &  11  wks,  WT+Veh:  13  &  8,  WT  +  5A-­SM:  9  
&  8,  NPC+Veh:  6,  NPC+5A-­SM:  12  &  10  mice,  (f)  genotype  and  treatment:  number  of  mice,  
cells,  WT+Veh:  4,  301,  NPC+Veh:  4,  514,  NPC+5A-­SM:  3,  373  (g)  WT=93,  NPC  Veh=143,  
NPC+5A-­SM=  116  cells.  *p≤.05,  **p≤.01,  ***p≤.001,  ****p≤.0001.  (a,  c)  Student’s  t-­test  (t=(a)  
6.375,  (c)  5.23);;  (d,  f,  g,  h)  One-­way  ANOVA  with  Tukey  posthoc  test  (F,  df=(d)  13.28,  3;;  (f)  
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Figure  2-­9  Effects  of  5A-­SM  treatment.  (a)  Mice  were  treated  i.p.  with  vehicle  (Veh)  or  
100  mg/kg  5A-­SM  three  times  per  week  from  7  days  to  13  weeks  of  age.  Motor  function  was  
tested  every  other  week  from  7-­13  weeks  of  age  by  balance  beam.  Data  are  mean  ±  s.e.m.  from  
WT+Veh  (n=6-­10),  WT  +  5A-­SM  (n=5-­6),  NPC+Veh  (n=3-­5),  NPC+5A-­SM  (n=4)  mice.  Two-­way  
ANOVA  with  Bonferonni  posthoc  test  (F,  df=  (52.46,  3).  n.s.,  not  significant,  *p≤.0.05,  **p≤.01,  
***p≤.001,  ****p≤.0001.  (b)  Brain  slices  from  8  week  old  Npc1  WT  or  I1061T  (NPC)  mice  were  
incubated  with  vehicle  (Veh)  or  5  mg/ml  5A-­SM  for  four  days.  Purkinje  cells  were  labeled  with  
calbindin  (green)  and  cholesterol  with  filipin  (blue).  Images  were  taken  from  lobules  3-­6.  Dashed  
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Figure  2-­10  5A-­SM  distribution  in  the  brain  after  ICV  injection.  Seven  week  old  Npc1  
I1061T  mice  were  injected  ICV  with  vehicle  (Veh)  or  5A-­SM-­DiD.  One-­week  post  injection  
confocal  microscopy  was  used  to  visualize  distribution  of  DiD  (red)  and  DNA  (blue).  Images  of  
the  cerebellum,  brainstem,  cortex,  and  hippocampus  are  shown  (regions  of  images  indicated  
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Figure  2-­11  Cellular  distribution  of  5A-­SM  after  ICV  injection.  Npc1  I1061T  mice  
received  intraventricular  injections  with  vehicle  (Veh)  or  5A-­SM-­DiD.  Confocal  microscopy  was  
used  to  analyze  co-­localization  of  DiD  (red)  in  cerebellum  with  (a)  Purkinje  neurons  (calbindin),  
(b)  astrocytes  (GFAP),  or  (c)  microglia  (Iba1).  Scale  bar  =  50  µm.       
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Figure  2-­12  5A-­SM  removes  sphingomyelin  from  Niemann-­Pick  type  A  fibroblasts.  
(a)  Control  (CTRL)  and  Niemann-­Pick  A  (NPA)  primary  fibroblasts  were  incubated  with  
[3H]sphingomyelin  for  24  h,  followed  by  treatment  with  0.75  mg/ml  5A-­SM  or  vehicle  (Veh).  
Radioactivity  in  media  and  cell  fractions  was  determined  by  liquid  scintillation  counting.  (b)  
CTRL  and  NPA  primary  fibroblasts  were  loaded  with  NBD-­sphingomyelin,  then  treated  for  48  
hrs  with  vehicle  (Veh),  cyclodextrin  (Cyclo),  or  0.75  mg/ml  5A-­SM.  NBD-­sphingomyelin  intensity  
quantified  at  right.  Scale  bar  =  20  µm.  (c)  SRS  microscopy  was  used  to  image  total  endogenous  
lipids  in  CTRL  and  NPA  cells  with  the  indicated  treatments.  Quantified  at  right.  Scale  bar  =  20  
µm.  Data  are  mean  ±  s.e.m.  from  (a,  b,  c)  three;;  *p≤.05,  ***p≤.001,  ****p≤.0001.  (a)  Student’s  t-­










   65  
  
Chapter  3:  Rescue  of  Sphingomyelin  Storage  in  Niemann-­Pick  Disease  Type  A  by  
Apolipoprotein  A-­I  Mimetics  
  
  Abstract  
Niemann-­Pick  Disease  type  A  (NPA)  is  a  severe  lipid  storage  disorder  caused  by  
the  deficient  activity  of  the  acid  sphingomyelinase  enzyme.  NPA  is  characterized  by  the  
accumulation  of  sphingomyelin  (SM)  in  late  endosomes  and  lysosomes  leading  to  
progressive  neurological  dysfunction  and  hepatosplenomegaly.  Our  objective  was  to  
investigate  the  utility  of  synthetic  Apolipoprotein  A-­I  (ApoA-­I)  mimetics,  peptides  and  
synthetic  high-­density  lipoproteins  (sHDL),  designed  to  act  as  lipid  scavengers  for  the  
treatment  of  NPA.  We  identified  a  peptide  (22A)  and  sHDL  (22A-­DMPC  and  22A-­DPPC)  
capable  of  reducing  SM  levels  in  human  NPA  fibroblast  cells.  Moreover,  it  was  
determined  that  the  ATP-­binding  cassette  A1  transporter,  located  on  cellular  
membranes,  was  a  key  played  in  efflux  of  SM  from  NPA  cells.  Intravenous  
administration  of  22A  at  300  mg/kg  to  wild  type  mice  rapidly  mobilized  SM  from  tissues  
into  circulation.  In  addition  to  SM,  22A  and  22A-­sHDL  could  mobilize  cholesterol,  which  
was  found  to  be  elevated  in  NPA  disease.  Together,  our  data  shows  that  ApoA-­I  
mimetics  might  represent  a  novel  therapeutic  strategy  for  the  treatment  of  Niemann-­Pick  
Disease  with  acid  sphingomyelinase  deficiency.    
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  Background  
Niemann-­Pick  disease  type  A/B  (NPA/B)  is  a  rare  genetic  disorder  caused  by  
mutations  in  the  acid  sphingomelinase  (ASM)  enzyme  leading  to  abnormal  
accumulation  of  sphingomyelin  (SM)  and  other  lipids  in  late  endosomes  and  lysosomes  
(LE/Ls)  [30,  82].  SM  is  an  important  signaling  molecule,  and  it  is  an  integral  part  of  
cellular  membranes  [151].  The  inability  of  ASM  to  break  down  SM  into  ceramide  and  
phosphocholine  results  in  lipid  trafficking  defects  in  the  periphery  (NPA  and  NPB)  and  
brain  (NPA).  Visceral  manifestations  such  as  hepatosplenomegaly  and  pulmonary  
insufficiency  are  commonly  seen  in  both  NPA  and  NPB  patients,  yet  the  type  A  is  more  
severe  due  to  extreme  deficits  (<5%)  of  ASM  activity,  leading  to  premature  death  by  age  
3  [152,  153].  Currently,  there  are  no  FDA-­approved  drugs  for  NPA  and  NPB,  and  thus  
there  is  a  great  unmet  medical  need.  
NPA/B  patients  typically  have  decreased  levels  of  high-­density  lipoproteins  
(HDL),  which  are  responsible  for  cholesterol  and  phospholipid  efflux  from  cells  [83,  89].  
Moreover,  HDL  from  patients  is  highly  enriched  in  SM  compared  to  normal  controls,  
suggesting  the  increased  flux  of  SM  to  extracellular  lipoprotein  acceptors  [88].  The  body  
produces  HDL  as  an  8-­12  nm  nanoparticle  composed  of  a  lipid  membrane  wrapped  
around  by  a  belt  of  the  243  amino  acid  apolipoprotein  A-­I  (ApoA-­I)  [99].  When  ApoA-­I  is  
secreted  by  the  liver  and  intestines,  it  interacts  with  the  ATP-­binding  cassette  
transporter  A1  (ABCA1)  on  the  cell  membranes  to  form  nascent  HDL  particles  mainly  
from  phospholipids  such  as  SM  and  phosphatidylcholine.  Then,  ApoA-­I  and  
phospholipid-­rich  nascent  HDL  particles  circulate  in  the  periphery  to  efflux  excess  
cholesterol  from  cells  for  redistribution  or  elimination.  Previous  studies  have  shown  that  
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ApoA-­I  isolated  from  NPB  patients  is  able  to  form  nascent  HDL  particles  containing  SM  
when  incubated  with  human  NPB  cells,  suggesting  normal  availability  of  lysosomally  
sequestered  SM  to  its  extracellular  protein  acceptors  [88].  SM  content  of  HDL  is  also  
sensitive  to  ABCA1  gene  modulation  with  22  (R)-­hydroxycholesterol  and  9-­cis-­retionoic  
acid  and  thus  ABCA1  transporter  could  be  explored  as  a  gate  for  SM  flux.  Based  on  this  
data,  we  decided  to  investigate  the  efficacy  of  ApoA-­I  mimetic  peptides  and  synthetic  
HDL  particles  (sHDL)  for  their  ability  to  scavenge  SM  from  NPA/B  primary  human  
fibroblast  cells.    
Here,  we  examined  three  ApoA-­I  mimetic  peptides  (5A,  18A,  and  22A)  with  
different  amino  acid  composition.  One  peptide,  22A,  significantly  reduced  accumulated  
SM  in  human  Niemann-­Pick  type  A  and  B  fibroblast  cells  in  a  dose  and  time-­dependent  
manner.  This  peptide  was  originally  developed  by  Esperion  to  mimic  endogenous  ApoA-­
I  function  and  to  be  used  for  the  treatment  of  atherosclerosis  [27].  We  showed  that  22A  
was  non-­toxic  in  vitro  and  utilized  the  ATP-­binding  cassette  transporter  1  (ABCA1)  to  
efflux  stored  SM.  Synthetic  HDL  nanoparticles  composed  of  22A  and  
phosphatidylcholine  (DMPC  and  DPPC)  were  also  capable  of  scavenging  SM  in  vitro.  
Furthermore,  the  22A  peptide  and  lipid-­poor  22A-­sHDL  were  administered  into  wild  type  
mice  to  identify  whether  the  dose  and  degree  of  lipidation  was  important  for  SM  
mobilization  in  animals.  We  found  that  only  22A  peptide  at  300  mg/kg  rapidly  mobilized  
SM  into  circulation.  Higher  concentrations  of  sHDL  were  still  needed  to  be  examined  in  
vivo.  Moreover,  both  22A  and  sHDL  could  mobilize  cholesterol,  which  has  been  
previously  shown  to  become  accumulated  in  NPA  cells  [154].  Together,  these  studies  
provide  the  proof-­of-­concept  data  to  support  therapeutic  potential  of  22A  for  the  
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Niemann-­Pick  Disease  characterized  by  ASM  deficiency.  
  
  Methods  
Materials  and  animals  
22A  peptide  (PVLDLFRELLNELLEALKQKLK)  was  synthesized  by  Genscript  
while  5A  (DWLKAFYDKVAEKLKEAF-­P-­DWAKAAYDKAAEKAKEAA)  and  18A  (Ac-­
DWLKAFYDKVAEKLKEAF-­NH2)  were  synthesized  by  Bachem  Americas  Inc.  1,2-­
dimyristoyl-­sn-­glycero-­3-­phosphocholine  (DMPC),  1,2-­dipalmitoyl-­sn-­glycero-­3-­
phosphocholine  (DPPC),  sphingomyelin  (SM)  were  purchased  from  NOF  America  
Corporation  (White  Plains,  NY);;  Sphingomyelin  [choline  methyl-­3H]  were  from  American  
Radiolabeled  Chemicals  (Saint  Louis,  MO).  All  other  reagents  were  analytical  grade  and  
obtained  from  commercial  suppliers.  
All  work  performed  on  animals  was  in  accordance  with  and  approved  by  the  
Institutional  Animal  Care  and  Use  Facility  (IACUC)  at  the  University  of  Michigan,  Ann  
Arbor.  
  
Preparation  and  analytical  characterization  of  peptides  and  sHDL    
Each  peptide  (5A,  18A,  22A)  was  diluted  with  PBS  pH  7.4  to  10  mg/mL  
(accounted  for  the  net  peptide  content)  and  pH  adjusted  to  7.4  with  NaOH.  Synthetic  
HDL  (sHDL)  compositions  were  prepared  using  a  lyophilization  and  thermocycling  
method.  Briefly,  22A  and  DMPC,  DPPC  (1:0.5,  1:1,  1:1.5,  1:2  weight  ratio)  were  
dissolved  in  glacial  acetic  acid  and  freeze-­dried.  The  powder  was  rehydrated  with  PBS  
(pH  7.4)  and  then  the  suspension  was  cycled  between  50°C  (10  min)  and  room  
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temperature  (10  min)  until  a  clear  sHDL  solution  was  obtained.  The  pH  of  the  sHDL  
solution  was  adjusted  to  7.4  with  NaOH.  Synthetic  HDL  particles  were  analyzed  at  1  
mg/mL  by  gel  permeation  chromatography  (GPC)  for  purity  on  Tosoh  TSK  gel  
G3000SWxl  column  (Tosoh  Bioscience,  King  of  Prussia,  PA)  with  UV  detection  at  220  
and  280  nm  using  PBS  (pH  7.4)  as  a  mobile  phase  with  an  isocratic  flow  rate  of  1  
mL/min.  The  hydrodynamic  diameters  at  1  mg/mL  of  sHDL  particles  were  determined  
via  dynamic  light  scattering  (DLS)  using  Zetasizer  Nano  ZSP  (Malvern  Instruments,  
Westborough,  MA).    
  
Sphingomyelin  efflux  assays  
Cell  lines  were  obtained  from  the  NIGMS  Human  Cell  Repository  at  the  Coriell  
Institute  for  Medical  Research.  The  following  cell  lines  were  used:  GM08399  -­  control  
(WT),  GM03393  -­  and  Niemann-­Pick  B  (NPB),  and  GM00112  -­  Niemann-­Pick  A  (NPA)  
cell  line  L302P/L302P  mutation  in  the  SMPD1  gene.  Cells  were  cultured  in  DMEM,  
penicillin-­streptomycin,  and  FBS.  
Radioactive  sphingomyelin  efflux:  Cells  (50,000  cells/well)  were  cultured  for  24  hr  
in  24-­well  plates  and  then  incubated  with  1  µCi  (80  Ci/mmol)  sphingomyelin  [choline  
methyl-­3H]  per  1  mL  media.  After  24  hr,  cells  were  washed  with  PBS,  pH  7.4,  3  X  
followed  by  the  treatment  with  vehicle,  peptide  (5A,  18A,  22A)  or  22A-­sHDL  (22A-­
DMPC  or  22A-­DPPC)  in  culture  media.  Radioactivity  in  media  and  cells  was  counted  
using  a  PerkinElmer  scintillation  counter.  Percent  [3H]sphingomyelin  ([3H]SM)  effluxed  
from  cells  was  calculated  by  dividing  media  counts  by  the  total  sum  of  media  and  cell  
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counts  and  then  multiplying  this  number  by  100%.  Non-­specific  [3H]SM  efflux  by  vehicle  
was  subtracted  from  all  treatment  data.  
Non-­radioactive  sphingomyelin  efflux:  Cells  (50,000  cells/well)  were  cultured  for  
24  hr  in  24-­well  plates  and  then  treated  with  vehicle,  22A  or  22A-­sHDL  (22A-­DMPC  or  
22A-­DPPC)  for  24  hr.  Cells  were  trypsinized  (0.25%)  and  separated  for  lipid  and  protein  
analysis.  Protein  concentration  in  each  well  was  determined  using  BCA  assay  according  
to  the  manufacturer  instructions.  Lipids  from  cells  and  media  were  extracted  in  2:1  v/v  
chloroform:methanol,  placed  in  the  sonicator  bath  for  1  min,  centrifuged  for  5  min  at  
500xg,  and  then  chloroform  layer  was  removed  and  dried  under  nitrogen.  For  LC-­MS  
analysis,  lipids  were  dissolved  in  acetonitrile.  To  quantify  concentration  of  SM  in  each  
sample,  Waters  Acquity  UPLC  equipped  with  QDa  System  (Milford,  MA)  was  used.  
Chromatographic  separation  was  achieved  on  a  BEH300  1.7µm  HILIC  column  at  25  °C.  
The  flow  rate  was  set  at  0.65  mL/min.  A  gradient  elution  was  carried  out  with  mobile  
phase  A  (water,  0.1%  formic  acid),  mobile  phase  B  (acetonitrile,  0.1%  formic  acid)  and  
mobile  phase  C  (100  mM  ammonium  formate)  as  follows:  0–0.7  min  (5–17%  A),  (90–
78%  B),  and  (5-­5%  C);;  0.7-­0.71  min  (17-­5%  A),  (78-­90%  B)  and  (5-­5%  C);;  0.71-­3  min  
(17–17%  A),  (90–90%  B),  and  (5-­5%  C).  Mass  spectra  were  acquired  in  the  positive  ion  
mode  and  SM  was  integrated  at  704  m/z.  SM  standards  were  used  in  the  range  of  0.25-­
8  µg/mL  and  used  for  quantification  of  SM  in  the  extracted  samples.  Data  analysis  was  
performed  on  Waters  Empower  software  version  3,  2010  (Waters,  Milford,  MA).    
  
RT-­qPCR  
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Total  RNA  was  purified  using  GeneJET  RNA  Purification  Kit  (Thermo  Scientific)  
and  converted  to  cDNA  with  the  SuperScript  III  First-­Strand  Synthesis  System.  Taqman  
system  was  used  to  determine  mRNA  expression  levels  for  human  ABCA1  (Hs  
01059118)  and  normalized  to  18S  (control)  (Hs  03928990).  Expression  levels  relative  to  
control  (non-­treated)  were  calculated  by  the  2^  (-­delta  delta  Ct)  method.  
  
siRNA  transfection  
Predesigned  ON-­TARGETplus  SMARTpools  containing  4  individual  siRNAs  per  
target  sequence  (Dharmacon  Non-­targeting  SMARTpool  D-­001810-­10-­05,  ABCA1  L-­
004128-­00)  were  transfected  using  TransIT-­X2®  (Mirus)  reagent  at  t=0  and  t=24  hr.  
NPA  cells  were  treated  with  0.75  mg/mL  22A  peptide  after  the  second  transfection  (t=24  
hr).  RNA  and  SM  analysis  occurred  48  hr  after  the  first  transfection.    
  
Cellular  viability  
Cell  viability  was  assessed  using  Promega  CellTiter  96  Aqueous  One  Solution  cell  
proliferation  colometric  assay  (G3580).  Briefly,  Niemann-­Pick  A  cells  were  cultured  in  96-­
well  plates  at  10,000  cells  per  well  for  24  hr,  washed  three  times  with  PBS,  and  treated  
with  vehicle,  peptides,  and  sHDL  diluted  in  media  for  24  hours.  Cells  were  washed  three  
times  with  PBS,  and   re-­suspended   in  media  supplemented  with  Promega  CellTiter  96  
reagent  (20  µl  reagent  per  100  µl  of  media).  After  45  min  incubation  at  37  °C,  absorbance  
was  read  at  490  nm  using  a  microplate  reader.  Each  treatment  was  performed  in  triplicate  
and  the  average  absorbance  reading  of  non-­treated  (vehicle)  cells  was  set  to  100%.  The  
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percent  viability  was  determined  by  dividing  the  average  absorbance  of  treated  over  non-­
treated  cells  and  multiplying  by  100.    
  
In  vivo  PK/PD  study  
Healthy  male  C57BL/6J  mice  (8  weeks  old)  were  purchased  from  Charles  River  
Breeding  Laboratories  (Portage,  MI)  and  were  fed  a  standard  rodent  chow  diet.  To  
examine  the  impact  of  peptide  concentration  and  lipid  content  on  pharmacokinetic/  
pharmacodynamics  properties,  animals  were  randomly  assigned  to  four  groups  (n  =  
4/group)  of  75  mg/kg,  150  mg/kg,  and  300  mg/kg  of  22A  peptide  or  75  mg/kg  22A-­
DMPC  (1:1).  All  animals  were  fasted  overnight  before  peptide  dosing  via  tail  vein  
injection.  At  each  time  point  (pre-­dose,  1,  6  and  24  hrs)  blood  samples  (~0.1  mL)  were  
collected  from  the  jugular  vein  to  Microvette®  500  Z-­gel  tube  (Sarstedt  Inc,  German)  
and  centrifuged  at  10,000  rpm  for  10  min  at  4°C.  The  obtained  serum  samples  were  
stored  at  -­20°C  for  further  analysis.    
The  levels  of  SM  in  serum  samples  (25x  dilution)  were  determined  using  
fluorometric  assay  according  to  manufacturer  protocol  (Cell  Biolabs,  Inc,  CA,  USA)  and  
samples  were  analyzed  using  plate  reader  (SynergyTM  NEO  HTS  Multi-­Mode  
Microplate  Reader,  Bio-­Tek).  Fluorescence  was  read  at  550  nm  excitation  and  595  nm  
emission.  Background  fluorescence  value  was  subtracted  from  all  standards  and  
samples.  Cholesterol  levels  in  serum  samples  (10x  dilution)  were  measured  
enzymatically  (Wako  Chemicals,  Richmond,  VA)  as  described  in  the  manufacturer’s  
instructions  and  samples  were  analyzed  at  600  nm  on  the  plate  reader.  A  slope  was  
calculated  for  each  standard  curve/plate  and  SM  levels  in  samples  were  calculated  
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using  the  following  formula:  SM  or  cholesterol  (mg/dL)  =  (Corrected  sample  
fluorescence  /  Slope)  ×  Sample  dilution.  The  pharmacodynamic  effect  in  each  mouse  
was  determined  as  the  area  under  the  total  effect  curve  (AUEC)  using  trapezoidal  rule.  
Peptide  (22A)  concentration  in  serum  was  determined  by  LC-­MS.  The  10  µL  
serum  aliquots  were  combined  with  10  µL  of  2.4  mg/mL  of  internal  standard  (5A  
peptide).  Working  standard  solutions  (0-­100  µg/mL)  of  22A  were  prepared  using  blank  
mouse  serum.  Serum  proteins  were  precipitated  by  adding  methanol.  After  5  minutes,  
the  mixture  was  centrifuged  (12000  rpm  ×  10  min,  4°C)  and  supernatant  was  used  for  
analysis.  Samples  were  mixed  (1:1  v/v)  with  LC-­MS  mobile  phase  (80:20  v/v  
H2O:acetonitrile,  0.1%  formic  acid)  and  analyzed  on  Waters  Acquity  UPLC  equipped  
with  QDa  System  (Milford,  MA)  using  Acquity  UPLC  BEH  C18  1.7  μM  column  for  
separation.  The  mobile  phase  consisted  of  (A)  water  containing  0.1%  v/v  formic  acid  
and  (B)  acetonitrile  containing  0.1%  v/v  formic  acid.  The  mobile  phase  was  delivered  at  
0.3  mL/min  using  a  gradient  elution  of  20%  to  80%  B  during  0-­1.5  min,  and  80%  to  20%  
B  during  1.5-­3.5  min.  Mass  spectra  were  acquired  in  the  positive  ion  mode  with  the  
mass  range  set  at  m/z  150-­1250.  Data  analysis  was  performed  on  Waters  Empower  
software.  The  concentration  of  22A  peptide  in  each  sample  was  determined  from  the  
standard  curve.  Pharmacokinetic  parameters  such  as  maximum  serum  concentration  
(Cmax),  the  area  under  the  serum  concentration-­time  curve  (AUC),  elimination  half-­life  
(T1/2)  were  obtained  by  non-­compartmental  analysis.  
  
Statistical  analysis  
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Significance  of  difference  was  determined  by  Student’s  t-­test  for  comparing  two  
groups  or  by  one-­way  analysis  of  variance  (ANOVA)  for  comparing  multiple  groups.  All  
in  vitro  experiments  were  performed  in  triplicate  and  error  bars  were  reported  as  a  
standard  mean  error  (SEM)  unless  noted  otherwise.  P  <  0.05  was  considered  
statistically  significant.    
  
  Results  
Preparation  of  ApoA-­I  peptides  and  sHDL  nanoparticles  
In  our  studies,  we  utilized  three  ApoA-­I  peptides,  5A,  18A,  and  22A,  previously  
developed  and  well-­characterized  by  others  to  mimic  the  properties  of  the  full-­length  
ApoA-­I  protein  such  as  peptide  helicity,  lipid  binding,  and  cholesterol  efflux  [27].  These  
peptides  were  readily  available  in  large  quantities  compared  to  the  ApoA-­I  protein,  
which  required  recombinant  production.  The  amino  acid  composition  for  each  peptide  
as  shown  in  Figure  3-­1a  was  distinctive  from  one  another.  Peptide  18A  had  strong  lipid  
binding  and  good  capacity  to  efflux  phospholipids  and  cholesterol,  5A  peptide  was  
developed  to  promote  ABCA1  receptor-­mediated  efflux  of  cholesterol,  and  22A  peptide  
could  activate  the  lecithin:cholesterol  acyltransferase  (LCAT)  enzyme  involved  in  HDL  
particle  maturation.  Using  phospholipids  with  differing  chain  length,  we  prepared  a  panel  
of  sHDLs  DMPC  (1,2-­dimyristoyl-­sn-­glycero-­3-­phosphocholine)  or  DPPC  (1,2-­
dipalmitoyl-­sn-­glycero-­3-­phosphocholine)  containing  various  peptide:lipid  ratios.  The  
reason  for  varying  peptide  to  lipid  ratios  was  to  control  the  size  of  sHDL  and  its  ability  to  
bind  SM.  All  sHDLs  were  prepared  by  co-­lyophilization  and  thermocycling  (Figure  3-­1b)  
[101].  Particles  with  peptide:lipid  of  1:0.5,  1:1,  1:1.5,  and  1:2  w/w  had  an  average  
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diameter  of  6  nm,  7  nm,  8  nm,  and  9-­12  nm  respectively  as  determined  by  dynamic  light  
scattering  and  displayed  >98%  purity  as  measured  by  gel  permeation  chromatography  
(Figure  3-­1c,  3-­2).    
  
ApoA-­I  mimetic  peptides  reduce  lysosomal  sphingomyelin  in  patient  fibroblasts  
To  assess  the  activity  of  ApoA-­I  peptides  on  Niemann-­Pick  type  A  patient  cells,  
we  used  [3H]SM  and  media  supplemented  with  fetal  bovine  serum  to  load  lysosomes  in  
cells  as  previously  described  [155].  The  analysis  of  [3H]SM  effluxed  from  cells  into  
media  was  performed  by  scintillation  counting  following  the  treatment  with  vehicle  
(media),  5A,  18A,  or  22A  peptides  at  0.03,  0.3,  and  0.75  mg/mL  concentrations.  The  
vehicle  control  value  was  subtracted  from  each  peptide  measurement.  Treatment  with  
18A  peptide  (Figure  3-­3a)  displayed  70%  of  [3H]SM  efflux  at  0.75  mg/mL  compared  to  
25%  and  10%  efflux  for  22A  and  5A  peptides  respectively.  Additionally,  the  time-­
dependedent  [3H]SM  efflux  at  0.75  mg/mL  for  each  peptide  was  measured.  Around  24  
hr,  the  efflux  for  5A  and  22A  saturated,  but  18A  efflux  was  not  time  sensitive  (Figure  3-­
3b).  It  was  noted  that  18A  caused  significant  cell  death  at  all  concentrations  used.  This  
possibly  led  to  [3H]SM  releasing  into  media  and  giving  the  false  positive  results.  A  cell  
toxicity  assay  confirmed  that  at  0.75  mg/mL  only  ~40%  of  cells  were  viable  with  18A  
treatment  while  5A  and  22A  did  not  result  in  cell  death  (Figure  3-­4).  Differences  in  5A  
and  22A  efflux  of  [3H]SM  could  be  due  to  different  lipid  solubilization  kinetics.  Overall,  
the  experimental  data  strongly  suggested  that  22A  peptide  was  the  most  efficacious  at  
[3H]SM  efflux  from  NPA  cells.  Similar  results  were  obtained  with  NPB  fibroblasts  (Figure  
3-­5).  At  this  point,  we  chose  22A  as  the  lead  peptide  to  prepared  sHDL  particles.  
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Sphingomyelin  efflux  by  sHDL    
Both  cholesterol  and  SM  could  be  effluxed  from  cells  by  small  nascent  HDL  via  
ABCA1  transporter  [134].  These  two  lipids  physically  interact  and  commonly  traffic  
together  [135]  suggesting  that  small  sHDL  might  also  be  effective  at  reducing  the  SM  
load  in  cells.  Here  we  chose  two  phospholipids,  DMPC  and  DPPC,  which  have  different  
chain  length  and  degree  of  bilayer  rigidity  and  prepared  sHDL  with  22A  peptide  via  co-­
lyophilization  and  thermocycling  [156].  In  addition,  we  varied  peptide  to  lipid  ratio  by  
weight  (1:0.5,  1:1,  1:1.5,  and  1:2)  and  made  sHDL  of  6-­12  nm  in  size  to  closely  mimic  
nascent  HDL.  To  determine  whether  sHDL  could  remove  stored  SM,  NPA  and  control  
fibroblasts  were  loaded  with  [3H]SM  for  24  hrs  then  treated  with  vehicle  (media),  0.75  
mg/mL  22A-­DMPC,  and  22-­DPPC  at  variable  peptide:lipid  weight  ratio  (1:0.5,  1:1,  1:1.5,  
and  1:2).  The  vehicle  control  value  was  subtracted  from  each  sHDL  measurement.  After  
24  hrs,  22A-­DMPC  and  22A-­DPPC  particles  with  lower  lipid  content  (1:0.5)  could  efflux  
17.1%  and  12.4%  [3H]SM  respectively.  Larger  sHDL  particles  showed  lower  efflux  
(<12%)  possibly  due  to  lower  ability  to  interact  with  specific  efflux  transporter  such  as  
ABCA1  and/or  decreased  capacity  to  bind  SM  (Figure  3-­6).  Efflux  of  [3H]SM  from  the  
wild  type  (WT)  fibroblasts  by  peptides  (5A,  22A)  was  higher  than  that  of  NPA  cells,  
possibly  due  to  higher  concentration  of  easily  accessible  SM  located  on  the  plasma  
membranes  of  WT  cells  (Figure  3-­7).  The  efflux  of  [3H]SM  between  WT  and  NPA  cells  
when  treated  with  sHDL  was  not  significantly  different,  thus  highlighting  possibly  
distinctive  efflux  mechanisms  between  peptides  and  sHDL.  To  confirm  [3H]SM  efflux  
data,  we  set  up  a  second  non-­radioactive  assay  without  the  use  of  externally  added  SM.  
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First,  we  confirmed  that  NPA  cells  had  higher  SM  content  than  WT  cells  by  measuring  
SM  concentration  using  LC-­MS  (Figure  3-­8a).  It  was  found  that  NPA  cells  had  ~1.5-­fold  
higher  SM  concentration  than  WT  cells.  Next,  NPA  cells  were  treated  with  vehicle,  22A,  
22A-­DMPC  (1:0.5)  or  22A-­DPPC  (1:0.5)  at  the  highest  concentration  of  0.75  mg/mL  for  
24  hrs.  Lipids  were  extracted  from  cells  and  quantified  by  LC-­MS.  Results  showed  that  
the  percent  of  SM  efflux  from  cells  into  media  was  similar  to  [3H]SM  assay,  suggesting  
that  22A  and  22A-­sHDL  were  indeed  the  acceptors  of  SM  (Figure  3-­8b).  
  
ABCA1  transporter  is  needed  for  22A  peptide  efficacy  
To  examine  whether  ApoA-­I  mimetic  peptides  and  sHDL  effluxed  SM  via  ABCA1-­
medicated  mechanism  and  similar  to  that  of  endogenous  ApoA-­I  protein  and  nascent  
HDL,  we  treated  NPA  cells  with  vehicle,  peptide  (5A,  22A)  or  sHDL  (22A-­DMPC  or  22A-­
DPPC)  at  0.75  mg/mL.  According  to  Figure  3-­9a,  22A  increased  the  expression  of  
ABCA1  gene  1.5-­fold  and  sHDL  particles  decreased  its  expression  approximately  2-­
fold.  Our  results  were  partly  in  line  with  the  endogenous  mechanisms  where  newly  
secreted  ApoA-­I  typically  induced  the  expression  of  ABCA1  to  form  nascent  HDL  
particles  and  HDL  downregulated  the  expression  of  ABCA1  [157,  158].  To  further  
confirm  that  ABCA1  was  indeed  important  for  22A  efficacy,  we  performed  the  siRNA  
knockdown  of  ABCA1  gene  in  NPA  fibroblasts.  Figure  3-­9b  demonstrated  the  
successful  knockdown  of  ABCA1  (siABCA1)  expression  compared  to  the  treatment  with  
non-­targeting  siRNAs  (siNT).  Next,  we  used  LC-­MS  to  measure  differences  in  SM  efflux  
by  22A  in  NPA  cells  treated  with  siNT  or  siABCA1.  Our  data  indicated  that  ABCA1  
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knockdown  resulted  in  a  2-­fold  decrease  in  SM  efflux  compared  to  siNT  control  (Figure  
3-­9c).  This  suggested  that  ABCA1  was  indeed  in  part  responsible  for  SM  efflux  by  22A.  
To  investigate  other  biological  responses  triggered  by  peptides  and  sHDLs,  NPA  
fibroblasts  were  treated  with  vehicle,  5A,  22A,  22A-­DMPC  (1:0.5)  or  22A-­DPPC  (1:0.5)  
at  0.75  mg/mL.  Genes  responsible  for  SM  synthesis  and  breakdown  (SGMS1,  SGMS2,  
and  SMPD1)  were  assessed  (Figure  3-­10).  The  expression  of  SGMS1  and  SGMS2  (SM  
synthesis)  was  mostly  unaffected.  The  expression  of  SMPD1  (SM  breakdown)  was  only  
slightly  (~1.25-­fold)  upregulated  by  5A,  22A,  but  not  by  sHDL.    
  
In  vivo  pharmacokinetics  and  pharmacodynamics  of  22A  
Three  doses  of  22A  peptide  (75,  150,  and  300  mg/kg)  and  one  dose  of  22A-­
DMPC  1:1  (75  mg/kg)  were  administered  IV  into  healthy  mice  in  order  to  evaluate  the  
pharmacokinetics  and  pharmacodynamics  of  22A  peptide  and  22A-­sHDL  with  regards  
to  SM  mobilization.  IV  route  of  administration  was  selected  based  on  the  data  previously  
published  by  our  group  where  22A  peptide  injected  IP  at  75  mg/kg  was  not  effective  at  
mobilizing  phospholipids  from  healthy  rats  compared  to  IV  route  [159].  In  this  study,  we  
evaluated  the  doses  at  and  above  75  mg/kg  to  maximize  the  amount  of  SM  efflux  from  
tissues  into  circulation.  Furthermore,  22A-­DMPC  was  selected  at  1:1  peptide  to  lipid  
ratio  to  investigate  if  some  lipidation  of  22A  would  enhance  its  in  vivo  circulation  half-­life  
and  thus  SM  mobilization.  The  choice  for  DMPC  lipid  for  PK/PD  study  was  based  on  the  
degree  of  sHDL  purity  and  homogeneity  (size  distribution).  The  lower  concentration  of  
22A-­DMPC  at  75  mg/kg  was  evaluated  to  avoid  possible  liver  toxicity  due  to  strong  
cholesterol  efflux  capacity  of  sHDL  compared  to  free  peptide.  The  half-­life  of  22A  in  the  
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serum  at  75  mg/kg  and  150  mg/kg  was  4.5  ±  1.1  hrs  and  3.9  ±  1.2  hrs  respectively  
(Figure  3-­11a).  However,  the  half-­life  of  22A  at  300  mg/kg  was  9.7  ±  2.0  hrs,  which  was  
2-­fold  higher  compared  to  two  lower  doses.  This  was  most  likely  attributed  to  saturation  
of  the  elimination  mechanisms  in  mice.  The  area  under  serum  concentration  curve  
(AUC)  for  22A  at  75,  150,  and  300  mg/kg  dose  was  1571.9  ±  95.2,  4287.9  ±  529.3,  and  
9131.9  ±  368.0  mg*h/dL  accordingly.  At  the  24  hrs  time  point,  22A  peptide  administered  
at  300  mg/kg  was  still  present  in  circulation  while  the  other  two  peptide  concentrations  
were  not  detectable  at  24  hrs.  Compared  to  lipid-­free  22A,  peptide  in  sHDL  (22A-­
DMPC)  had  similar  half-­life  of  4.8  ±  0.7  hrs,  but  displayed  36%  higher  AUC  (2469.1  ±  
156.4  mg*h/dL),  which  could  be  attributed  to  differences  in  tissue  distribution  (Figure  3-­
11b).        
To  evaluate  pharmacodynamics  of  22A  peptide  and  sHDL,  cholesterol  and  SM  
concentrations  were  measured  enzymatically,  and  the  area  under  the  effect  curve  
(AUEC)  for  cholesterol  was  calculated.  While  SM  is  the  main  lipid  that  accumulates  in  
LE/Ls,  cholesterol  levels  have  also  been  found  to  be  elevated  in  NPA/B  patients,  so  
both  lipids  were  analyzed.  No  differences  were  found  in  SM  mobilization  between  75  
mg/kg  of  22A,  150  mg/kg  of  22A,  and  75  mg/kg  of  22A-­DMPC  treatments  (Figure  3-­12a,  
3-­12b).  Only  the  300  mg/kg  dose  of  22A  could  mobilize  SM  into  serum.  It  was  noted  that  
SM  concentration  at  pre-­dose  (t  =  0  hrs)  was  higher  compared  to  the  level  of  SM  at  1  
hrs  post-­22A  (75  and  150  mg/kg)  and  22A-­DMPC  (75  mg/kg)  treatments.  This  was  
observed  because  mice  were  fasted  only  4  hrs  at  t=0  (blood  collected  2  days  before  the  
treatment)  compared  to  8  hrs  right  before  the  treatment.  Food  was  given  to  animals  
after  the  blood  collection  at  6  hrs  time  point.  Finally,  mice  were  fasted  again  for  4  hrs  
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before  the  final  collection  at  t  =  24  hrs  post-­treatment.  Typically,  fasting  of  animals  is  
necessary  to  normalize  their  lipid  profile  before  the  treatment  and  our  protocol  only  
allows  prolonged  fasting  of  8  hrs  to  be  performed  once  per  week.  
The  cholesterol  trend  was  slightly  different  to  that  of  SM,  where  cholesterol  
mobilization  of  lipid-­free  22A  steadily  increased  was  steadily  increasing  (AEUC  =  
2550.5,  2939.2,  3194.4  mg*h/dL)  with  the  increase  of  22A  dose  (75,  150,  300  mg/kg)  
(Figure  3-­12c).  Differences  were  found  in  cholesterol  mobilization  between  22A  (AUEC  
=  2550.5  mg*h/dL)  and  sHDL  (AEUC  =  3149.5  mg*h/dL)  administered  at  the  same  dose  
of  75  mg/kg  (Figure  3-­12d).  Taken  together,  these  results  suggest  that  at  the  same  
dose  of  75  mg/kg,  sHDL  has  greater  ability  to  mobilize  SM  and  cholesterol  than  naked  
22A  peptide.  Yet,  greater  SM  mobilization  can  be  achieved  with  300  mg/kg  of  lipid-­free  
22A  without  pulling  substantial  amount  cholesterol  that  could  cause  liver  toxicity.    
  
  Discussion  
Here  we  present  a  novel  strategy  for  the  treatment  of  Niemann-­Pick  disease  type  
A  by  utilizing  the  body’s  natural  mechanism  of  SM  transport  from  cells  to  ApoA-­I  
extracellular  acceptors.  Lipid-­free  ApoA-­I  mimetic  peptides  or  ApoA-­I  peptide-­sHDL  
particles  have  the  ability  to  remove  SM  from  human  NPA  fibroblast  cells  as  detected  in  
two  independent  assays.  The  degree  of  SM  removal  in  cells  depends  on  the  type  of  
ApoA-­I  peptide  used  and  the  peptide  to  lipid  ratio  in  sHDL.  The  PK/PD  study  of  ApoA-­I  
peptide  and  sHDL  in  healthy  mice  shows  that  the  mobilization  of  SM  from  tissues  into  
circulation  can  be  achieved  by  modulating  ApoA-­I  peptide  concentration.    
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Previous  studies  by  our  group  in  Niemann-­Pick  disease  type  C  showed  that  
ApoA-­I  mimetic  peptides  were  not  sufficient  for  reducing  Niemann-­Pick  C  cholesterol  
storage,  possibly  due  to  defects  in  loading  cholesterol  into  ApoA-­I  acceptors  via  ABCA1  
transporter  [160].  Our  strategy  in  NPC  bypassed  the  HDL  formation  deficiencies  by  
utilizing  ApoA-­I  mimetic  peptide,  5A,  complexed  with  SM  for  optimal  cholesterol  binding.  
In  NPA,  however,  the  expression  of  ABCA1  gene  and  HDL  formation  are  normal  and  
SM  can  be  mobilized  from  cells  by  ApoA-­I  protein  [88].  Therefore,  ApoA-­I  mimetics  
(peptide  or  sHDL)  may  serve  as  potential  lipid  acceptors  in  NPA.    
In  our  studies,  three  ApoA-­I  mimetic  peptides  were  explored  for  SM  efflux  from  
NPA  cells.  We  chose  these  peptides  (5A,  18A,  and  22A)  based  on  the  differences  in  
their  functionality.  The  first  ApoA-­I  mimetic  peptide  described  in  the  literature  was  18A,  
characterized  by  good  capacity  to  efflux  phospholipids  and  cholesterol  [161].  
Unfortunately,  our  results  indicated  that  18A  was  cytotoxic  to  NPA  cells  possibly  due  to  
disruption  of  cellular  phospholipid  bilayer.  Another  peptide,  5A,  was  a  modified  version  
of  18A  containing  two  amphipathic  helixes  instead  of  one  that  were  kinked  by  a  proline  
residue  to  mimic  the  native  ApoA-­I  structure  [162].  These  helixes  in  5A  had  different  
lipid  affinities  to  reduce  potential  cellular  cytotoxicity.  The  third  peptide,  22A,  was  
developed  by  a  biotechnology  company  (Esperion)  as  part  of  ETC-­642  sHDL  product  to  
be  an  activator  of  LCAT  enzyme  responsible  for  HDL  maturation  [163].  Previous  data  
from  our  laboratory  showed  excellent  lipid  solubilization  properties  of  22A,  and,  most  
importantly,  it  has  been  previously  tested  in  humans  [164,  165].    
Nevertheless,  peptides  are  not  very  stable  in  vivo,  and  thus  the  alternative  
delivery  methods  have  been  widely  described  in  the  literature,  including  the  use  of  
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phospholipids  [166].  Endogenously,  ApoA-­I  first  interacts  with  ABCA1  transporter  and  
binds  lipids  such  as  phosphatidylcholine  and  SM  to  form  nascent  HDL  particles.  These  
small  HDL  are  very  potent  lipid  acceptors  [167].  Thus,  our  initial  studies  using  NPA  
fibroblasts  were  focused  on  determining  which  peptide  was  the  most  efficacious.  We  
found  that  22A  could  efflux  up  to  ~25%  of  SM  from  NPA  cells  and  utilized  ABCA1  
transporter.  Next,  we  prepared  sHDL  particles  with  22A  peptide  via  lyophilization  and  
thermocycling.  Phospholipids  for  sHDL  formation  were  chosen  based  on  their  transition  
temperatures  (Tm),  with  DMPC  having  a  lower  Tm  than  DPPC.  The  differences  in  Tm  
affect  the  fluidity  of  lipids  and  thus  the  structure  of  sHDL,  possibly  resulting  in  
differences  in  SM  binding.  The  peptide  to  lipid  ratio  in  sHDL  affects  the  size  of  sHDL  
and  the  capacity  to  incorporate  phospholipids.  Particles  of  5-­12  nm  in  size  were  
prepared  and  tested  in  NPA  cells.  Smaller  lipid-­poor  sHDL  effluxed  the  most  SM  from  
cells  regardless  of  phospholipid  type.    
Studies  conducted  in  our  laboratory  have  previously  established  that  the  physical  
state  of  22A  peptide  (lipid-­free  or  lipid-­bound)  and  its  route  of  administration  (IV  or  IP)  
affect  the  PK  and  PD  parameters  [159].  Tang  et  al.  has  shown  that  22A  administered  in  
rats  at  75  mg/kg  using  IP  route  was  not  effective  in  mobilizing  phospholipids  and  
cholesterol  regardless  of  its  state  of  lipidation.  However,  the  IV  dose  of  22A-­sHDL  at  75  
mg/kg  had  much  better  pharmacological  response.  Here,  we  evaluated  the  lipid-­free  
22A  peptide  using  IV  administration  route  at  three  doses  of  75,  150,  and  300  mg/kg  and  
lipid  poor  22A-­DMPC  sHDL  at  one  dose  of  75  mg/kg  in  healthy  mice.  Our  data  showed  
that  only  22A  peptide  at  300  mg/kg  was  able  to  mobilize  SM  into  blood  compartment.  In  
terms  of  cholesterol  mobilization,  150  and  300  mg/kg  of  22A  peptide  and  75  mg/kg  of  
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sHDL  worked  to  the  same  extent  while  22A  at  75  mg/kg  had  lower  efficacy.  
Interestingly,  at  24  hrs  post-­administration  of  22A  at  the  300  mg/kg  dose,  cholesterol  
and  SM  concentrations  in  serum  did  not  return  to  baseline.  This  is  most  likely  due  to  
saturation  of  peptide  elimination  mechanisms  supported  by  the  peptide  PK  profile.  
Overall,  this  data  suggested  that  22A  (300  mg/kg)  could  elicit  the  desired  
pharmacological  response.  Although  we  examined  healthy  mice  that  didn’t  accumulate  
SM  and  cholesterol,  the  information  obtained  from  this  work  could  still  help  guiding  
future  experiments  in  NPA  disease  models.  We  learned  that  the  concentration  and  
degree  of  22A  lipidation  could  be  customized  to  achieve  the  necessary  SM  binding,  PK,  
and  safety  profile.  Altogether,  this  data  supports  the  concept  of  ApoA-­I  peptide  mimetics  
as  potential  therapy  for  the  Niemann-­Pick  diseases  characterized  by  the  insufficient  
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   Figure  3-­1  ApoA-­I  mimetic  peptide  structure,  sHDL  assembly  and  analytical  
characterization.  (a)  Amino  acid  sequence  for  5A,  18A  and  22A  peptide.  (b)  A  lyophilized  
mixture  of  ApoA-­I  peptide  and  DMPC  or  DPPC  at  1:0.5,  1:1,  1:1.5,  and  1:2  peptide:  lipid  wt/wt  
ratio  was  hydrated  in  PBS  and  thermocycled  at  50  ∘C  to  assemble  sHDL  particles.  (c)  The  purity  
of  sHDL  particles  was  determined  using  gel  permeation  chromatography  and  particle  size  was  




















22A#DMPC 1:0.5 98.7 5.61± 1.5
22A#DMPC 1:1 97.4 7.31± 1.9
22A#DMPC 1:1.5 98.0 7.91± 2.3
22A#DMPC 1:2 98.1 9.41± 2.2
22A#DPPC 1:0.5 97.5 6.91± 2.0
22A#DPPC 1:1 90.5 7.61± 1.8
22A#DPPC 1:1.5 97.7 8.31± 2.0
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Figure  3-­2  sHDL  purity  and  size  distribution.  The  purity  of  sHDL  particles  was  
determined  using  gel  permeation  chromatography  (a,  b)  and  particle  size  was  assessed  by  
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Figure  3-­3  ApoA-­1  mimetic  peptides  efflux  [3H]Sphingomyelin  from  human  NPA  
fibroblast  cells  in  a  dose  and  time-­dependent  manner.  NPA  cells  were  loaded  with  1  µCi/mL  
[3H]Sphingomyelin  diluted  into  media  containing  fetal  bovine  serum  for  24  h.  Cells  were  washed  
with  PBS  and  treated  with  (a)  0.03,  0.3  or  0.75  mg/mL  of  5A,  18A,  22A,  or  vehicle  (media)  
diluted  in  lipoprotein-­deficient  media  for  24  hr;;  (b)  0.75  mg/mL  of  5A,  18A,  22A  or  vehicle  
(media)  diluted  in  lipoprotein-­deficient  media  for  6,  24  or  48  hr.  Radioactivity  in  media  and  cell  
fractions  was  counted  and  the  %  [3H]Sphingomyelin  efflux  was  calculated  by  dividing  the  media  
counts  by  total  media  plus  cell  counts  and  multiplied  by  100.  Non-­specific  (vehicle)  efflux  was  
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Figure  3-­4  Cellular  viability  of  NPA  cells  after  the  treatment  with  peptides  or  sHDL  
nanoparticles.  Viability  of  NPA  primary  fibroblasts  after  24  hr  treatment  with  vehicle  (media),  
5A,  18A,  22A,  22A-­DMPC  (1:0.5,  1:1,  1:1.5,  1:2)  or  22A-­DPPC  (1:0.5,  1:1,  1:1.5,  1:2).  Vehicle  
group  viability  was  set  to  100%.  Data  are  mean  ±  s.e.m.,  N=3.  Statistical  differences  between  
vehicle  and  other  groups  was  calculated  using  unpaired  Student’s  t-­test;;  ns,  not  significant,  
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Figure  3-­5  [3H]Sphingomyelin  efflux  by  ApoA-­I  peptides  from  human  NPB  
fibroblast  cells.  NPB  cells  were  loaded  with  [3H]Sphingomyelin  as  described  in  Fig.  3-­3  and  
treated  with  0.75  mg/mL  of  5A,  18A,  22A  or  vehicle  (media)  diluted  in  lipoprotein-­deficient  media  
for  24  hr.  Radioactivity  in  media  and  cell  fractions  was  counted  and  the  %  [3H]Sphingomyelin  
efflux  was  calculated  by  dividing  the  media  counts  by  total  media  plus  cell  counts  and  multiplied  
by  100.  Non-­specific  (vehicle)  efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  
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Figure  3-­6  [3H]Sphingomyelin  efflux  in  human  NPA  fibroblast  cells  by  sHDL.  NPA  
cells  were  loaded  with  [3H]Sphingomyelin  as  described  in  Fig.  3-­3  and  treated  with  0.75  mg/mL  
of  22A,  22A-­DMPC  (1:0.5,  1:1,  1:1.5,  1:2)  or  22A-­DPPC  (1:0.5,  1:1,  1:1.5,  1:2)  for  24  hr.  
Radioactivity  in  media  and  cell  fractions  was  counted  and  the  %  [3H]Sphingomyelin  efflux  was  
calculated  by  dividing  the  media  counts  by  total  media  plus  cell  counts  and  multiplied  by  100.  
Non-­specific  (vehicle)  efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  ±  
s.e.m.,  N=3.  Statistical  differences  between  22A  peptide  and  each  sHDL  treatment  were  
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Figure  3-­7  Differences  in  [3H]Sphingomyelin  efflux  between  wild  type  (WT)  and  
NPA  cells.  WT  and  NPA  cells  were  loaded  with  [3H]Sphingomyelin  and  treated  with  0.75  
mg/mL  of  5A,  22A,  22A-­DMPC  (1:0.5)  or  22A-­DPPC  (1:0.5)  for  24  hr  as  described  in  Fig.  2.  
Data  are  mean  ±  s.e.m.,  N=3.  Statistical  differences  between  WT  and  NPA  treatments  in  each  
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Figure  3-­8  Sphingomyelin  efflux  from  NPA  cells  using  label-­free  LC-­MS  method.  
(a)  NPA  and  WT  cells  were  cultured  without  externally  added  sphingomyelin.  The  concentration  
of  sphingomyelin  (16:0)  in  WT  and  NPA  cells  was  quantified  using  LC-­MS  and  normalized  to  
total  protein  concentration  in  cells.  (b)  NPA  cells  were  treated  with  0.75  mg/mL  of  22A,  22A-­
DMPC  (1:0.5),  22A-­DPPC  (1:0.5)  or  vehicle  (media)  control  diluted  in  lipoprotein-­deficient  media  
for  24  hr.  Sphingomyelin  concentration  in  the  media  and  cells  was  determined  by  LC-­MS.  
Percent  (%)  sphingomyelin  efflux  was  calculated  by  dividing  the  media  sphingomyelin  
concentration  by  total  media  plus  cell  concentration  and  multiplied  by  100.  Non-­specific  (vehicle)  
efflux  was  subtracted  from  each  treatment  group.  Data  are  mean  ±  s.e.m,  N=3.  Statistical  
differences  between  WT  and  NPA  groups  was  calculated  using  Student’s  t-­test  (a)  and  between  
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Figure  3-­9  ABCA1  transporter  expression  in  NPA  cells  is  required  for  efficacy  of  
22A  peptide.  (a)  Primary  NPA  fibroblasts  were  treated  with  vehicle  (NT),  5A,  22A,  22A-­DMPC  
(1:0.5)  or  22A-­DPPC  (1:0.5)  at  0.75  mg/mL  for  24  hr.  ABCA1  mRNA  expression  was  analyzed  
by  qPCR.  (b)  NPA  cells  were  treated  for  two  consecutive  days  with  the  following  siRNAs:  non-­
targeting  (NT)  and  ABCA1.  ABCA1  mRNA  expression  was  analyzed  by  qPCR.  (c)  Following  
siRNA  knockdown,  cells  were  treated  with  0.75  mg/mL  22A  for  24  hr.  The  concentration  of  
sphingomyelin  effluxed  into  media  was  quantified  using  LC-­MS  and  normalized  to  total  protein  
concentration  in  cells  for  each  group.  Data  are  mean  ±  s.e.m.,  N=3.  Statistical  differences  
between  NT  and  other  groups  was  calculated  using  one-­way  ANOVA  (a)  and  Student’s  t-­test  (b,  














































































































































Figure  3-­10  Relative  expression  of  sphingomyelin  metabolism  genes  SGMS1,  
SGMS2,  and  SMPD1.  Primary  NPA  fibroblasts  were  treated  with  vehicle  (NT),  5A,  22A,  22A-­
DMPC  (1:0.5)  or  22A-­DPPC  (1:0.5)  at  0.75  mg/mL  for  24  hr.  SGMS1,  SGMS2,  and  SMPD1  
mRNA  expression  was  analyzed  by  qPCR.  Data  are  mean  ±  s.e.m.,  N=3.  Statistical  differences  
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Figure  3-­11  Pharmacokinetic  analysis  of  22A  and  22A-­DMPC  in  mouse  serum.  
Healthy  male  C57BL/6J  mice  were  given  a  single  tail  vein  injection  of  (a)  75,  150  or  300  mg/kg  
of  22A  peptide  or  (b)  75  mg/kg  (based  on  peptide)  of  22A-­DMPC  at  1:1  peptide  to  lipid  ratio  by  
weight.  Blood  samples  were  collected  at  pre-­dose  and  1,  6,  and  24  h  after  peptide  or  sHDL  
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Figure  3-­12  Pharmacodynamic  analysis  of  (a,  b)  sphingomyelin  and  (c,  d)  
cholesterol  in  mouse  serum  after  22A  and  22A-­DMPC  administration.  Healthy  male  
C57BL/6J  mice  were  given  a  single  tail  vein  injection  of  75,  150  or  300  mg/kg  of  22A  peptide  (a,  
c)  or  75  mg/kg  (based  on  peptide)  of  22A-­DMPC  at  1:1  peptide  to  lipid  ratio  by  weight  (b,  d).  
Blood  samples  were  collected  at  pre-­dose  and  1,  6,  and  24  h  after  peptide  administration.  
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Chapter  4:  Phospholipid  Component  Defines  Pharmacokinetic  and  
Pharmacodynamic  Properties  of  Synthetic  High-­Density  Lipoproteins  
  
  Abstract  
Synthetic   high-­density   lipoprotein   (sHDL)   nanoparticles   composed   of  
apolipoprotein   A-­I   (ApoA-­I)   mimetic   peptide   and   phospholipids   have   been   shown   to  
reduce   atherosclerosis   in   animal   models.   Cholesterol   is   mobilized   from   atheroma  
macrophages   by   sHDL   into   the   blood   compartment   and   delivered   to   the   liver   for  
elimination.  Historically,  sHDL  drug  discovery  efforts  were  focused  on  optimizing  peptide  
sequences  for  interaction  with  cholesterol  cellular  transporters  rather  than  understanding  
how  both  sHDL  components,  peptide  and  lipid,  influence  its  pharmacokinetics  (PK)  and  
pharmacodynamic  (PD)  profiles.  We  designed  two  sets  of  sHDL  having  either  identical  
phospholipid  but  variable  peptide  sequences  with  different  plasma  stability,  or  identical  
peptide  and  phospholipids  with  variable  fatty  acid  chain  length  and  saturation.  We  found  
that  sHDL  prepared  with  proteolytically  stable  22A-­P  peptide  had  2-­fold  longer  circulation  
half-­time  relative  to  the  less  stable  22A  peptide.  Yet,  longer  half-­life  did  not  translate  into  
any  improvement  in  cholesterol  mobilization.  In  contrast,  sHDL  with  variable  phospholipid  
compositions   showed   significant   differences   in   phospholipid   PK,   with   distearoyl  
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phosphatidylcholine-­based  sHDL  demonstrating  the  longest  half-­life  of  6.0  h  relative  to  
1.0   h   for   palmitoyl-­oleoyl   phosphatidylcholine-­based   sHDL.   This   increase   in   half-­life  
corresponded   to   a   ~6.5-­fold   increase   in   the   area   under   the   curve   for   the   mobilized  
cholesterol.   Therefore,   the   phospholipid   component   in   sHDL   plays   a   major   role   in  
cholesterol  mobilization   in   vivo   and   should   not   be   overlooked   in   the   design   of   future  
sHDL.  
  Introduction  
Reverse  cholesterol  transport  (RCT)  is  a  mechanism  of  cholesterol  removal  from  
the   periphery   to   the   liver   for   elimination.   This   transport   starts   when   lipid-­poor  
apolipoprotein  A-­I  (ApoA-­I)  facilitates  extracellular  efflux  of  phospholipids  and  cholesterol  
through  the   transmembrane  ATP-­binding  cassette   transporter  A1  (ABCA1)  resulting   in  
formation  of  pre-­β  high-­density  lipoprotein  (HDL)  particles.  Then,  pre-­β  HDLs  interact  with  
lecithin:cholesterol   acyltransferase   (LCAT),   an   enzyme   responsible   for   cholesterol  
esterification,  leading  to  formation  of  larger  mature  HDLs.  Mature  HDLs  can  either  deliver  
esterified  cholesterol   (EC)  cargo  directly   to   the   liver   for  elimination   through  scavenger  
receptor  class  B  type  I  (SR-­BI)  or  transfer  EC  to  LDL  by  interaction  with  cholesterol  ester  
transfer  protein  (CETP)  for  the  elimination  by  the  liver  following  LDL  receptor-­mediated  
uptake.    
The  idea  of  using  reconstituted  (rHDL)  or  synthetic  (sHDL)  HDL  for  the  treatment  
of  cardiovascular  disease  has  been  prominent  in  the  past  20  years,  with  several  therapies  
reaching  clinical  trials  [19,  21,  25,  105].  While  some  clinical  trials  for  rHDL  products  were  
successful  [19,  21],  others  failed  [168,  169].  A  17,400-­patient  Phase  3  trial  (AEGIS-­II)  is  
currently   ongoing   for   CSL-­112   to   show   possible   reduction   of   major   adverse  
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cardiovascular   events   in   subjects   with   acute   coronary   syndrome   (clinicaltrials.gov,  
NCT03473223).  The  two  most  advanced  sHDL  products,  CSL-­112  and  CER-­001,  both  
contain  ApoA-­I  but  differ  in  their  lipid  composition.  CSL-­112  is  prepared  from  unsaturated  
soybean   phosphatidylcholine   while   CER-­001   is   composed   of   primarily   saturated  
sphingomyelin  [168].  Recently,  we  have  shown  that  the  type  of  phospholipid  used  in  sHDL  
preparation   is  critical   for   its  anti-­inflammatory  and  anti-­atherosclerotic  properties   [101].  
Several  other  studies  had  examined  the  effects  of  phospholipid  composition  on  the  ability  
of  sHDL  to  efflux  cholesterol  and  interact  with  LCAT  in  vitro  [170-­172],  yet  the  impact  of  
phospholipid  chain   length  and  saturation  on  sHDL  pharmacodynamics   in  vivo  has  not  
been  systematically  examined.    
In   contrast,   significant   body   of   research   had   been   performed   to   develop   short  
peptides  (2F  (18A),  D-­4F,  L-­4F,  5A,  22A,  and  ATI-­5261)  as  cost-­efficient,  safe  and  easily  
scalable  alternatives  to  a  full-­length  ApoA-­I  [26,  173-­178].  These  ApoA-­I  mimetic  peptides  
have   been   optimized   with   the   goal   to   improve   several   properties   such   as   ABCA1  
mediated   cholesterol   efflux,   ability   to   activate   LCAT   and   facilitate   cholesterol  
esterification,   enhance   anti-­oxidant   properties,   improve   chemical   stability   and   reduce  
hemolytic   side-­effects   [27,   162,   173,   179].   Most   ApoA-­I   mimetics   were   optimized   as  
“naked”  or   lipid-­free  peptides   in  vitro  and   in  vivo  and  only  a   few  studies  examined  the  
pharmacological  activity  of  peptide-­based  sHDL  [159,  162].  
Thus,  we  decided  to  systematically  evaluate  the  effect  of  both  peptide  sequence  
and  phospholipid  composition  of  sHDL  on  nanoparticle’s  ability  to  mobilize  and  esterify  
cholesterol  in  vitro  and  in  vivo.  For  our  studies,  we  used  the  first  ApoA-­I  mimetic  peptide  
(22A)  that  reached  clinical  trials  as  part  of  the  sHDL  product  called  ETC-­642  [164,  180].  
   99  
ETC-­642  contained  22A  ApoA-­I  mimetic  peptide,  which  was  optimized   for   its  ability   to  
bind  phospholipids  and  activate  LCAT  [120,  173].  While  ETC-­642  successfully  completed  
single  and  multiple  dose  trials  in  dyslipidemia  patients,  it  was  recently  discovered  by  us  
that  22A  peptide  undergoes  rapid  hydrolysis   in  plasma  to  form  the  21A  peptide,  which  
lacks  the  C-­terminal  lysine,  a  residue  potentially  important  for  LCAT  activation  [159,  175].  
We  hypothesized  that  the  addition  of  a  proline  moiety  after  the  labile  lysine  (22A-­P)  would  
be  able  to  protect  22A  from  proteolysis  and  result  in  longer  circulation  time  while  retaining  
LCAT  activity   in  vivo.  Thus,  we  prepared  a  set  of  sHDL  particles  using  22A,  21A,  and  
22A-­P  peptides  while  keeping  lipid  composition  constant.  
The  second  set  of  sHDL  was  prepared  by  varying  only  the  phospholipid  component  
and  keeping  the  peptide  component,  22A,  constant.  We  used  phospholipids  with  different  
chain   length  and  saturation   including  1-­palmitoyl-­2-­oleoyl-­sn-­glycero-­3-­phosphocholine  
(POPC),   1,2-­dimyristoyl-­sn-­glycero-­3-­phosphocholine   (DMPC),   1,2-­dipalmitoyl-­sn-­
glycero-­3-­phosphocholine   (DPPC)   or   1,2-­distearoyl-­sn-­glycero-­3-­phosphocholine  
(DSPC)  known  for   their  differences   in  cholesterol  binding  affinity  and  LCAT  interaction  
[119,  181,  182].  Phospholipids  with  longer,  saturated  fatty  acid  chains  such  as  DPPC  and  
DSPC  have  higher  affinity  for  cholesterol  binding  and  higher  physical  stability  due  to  their  
high   transition   temperatures   (Tm)   of   41°C   and   55°C,   respectively   [118,   119,   183].   In  
contrast,  unsaturated  phospholipids   like  POPC  (Tm=  -­2°C)  and  those  with  shorter   fatty  
acid   chains   like   DMPC   (Tm   =   23°C)   form   fluid   bilayers   at   physiological   temperature  
facilitating  LCAT-­sHDL  binding.  The  unsaturated  fatty  acids  are  superior  substrates  for  
LCAT   esterification   activity   [181,   184].   By   comparing   two   sets   of   sHDL   with   varying  
peptide  and  lipid  components  side  by  side,  we  expected  to  be  able  to  elucidate  the  relative  
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contribution  of  both  components  to  cholesterol  efflux  and  engagement  of  LCAT  in  vitro  as  
well  as  the  overall  pharmacokinetic  and  pharmacodynamic  behavior  of  sHDL  in  vivo.  
  Materials  and  Methods  
Materials  
22A  (PVLDLFRELLNELLEALKQKLK),  21A  (PVLDLFRELLNELLEALKQKL),  and  
22AP   (PVLDLFRELLNELLEALKQKLKP)   were   synthesized   by   Genscript   (Piscataway,  
NJ),   using   solid-­phase   Fmoc   (9-­fluorenylmethyl   carbamate)   protection   chemistry   and  
purified   with   reverse   phase   chromatography   (>95%   pure).   5A   peptide  
(DWLKAFYDKVAEKLKEAF-­P-­DWAKAAYDKAAEKAKEAA)  was  obtained  from  Bachem  
Americas   Inc   (Torrance,   CA).   Phospholipids   including   1,2-­dimyristoyl-­sn-­glycero-­3-­
phosphocholine   (DMPC),   1,2-­dipalmitoyl-­sn-­glycero-­3-­phosphocholine   (DPPC),   1,2-­
distearoyl-­sn-­glycero-­3-­phosphocholine   (DSPC),   and   1-­palmitoyl-­2-­oleoyl-­sn-­glycero-­3-­
phosphocholine   (POPC)   were   purchased   from   NOF   America   Corporation.   Ergosta-­
5,7,9(11),  22-­tetraen-­3β-­ol  (dehydroergosterol,  DHE),  cholesterol  oxidase  was  obtained  
from  Sigma-­Aldrich  (St.  Louis,  MO).  Cholesterol  (1,2-­3H(N)]  was  purchased  from  Perkin  
Elmer.  Anti-­human  ApoA-­I  horseradish  peroxidase-­conjugated  (HRP)  antibody  (1:1000  
dilution)  was  purchased  from  Meridian  Life  Science  (Memphis,  TN).  Recombinant  human  
lecithin   cholesterol   acyl   transferase   (LCAT)   was   kindly   provided   by   MedImmune  
(Gaithersburg,  MD).  All  other  materials  were  obtained  from  commercial  sources.  
  
Preparation  and  characterization  of  synthetic  high-­density  lipoproteins  
sHDL   composed   of   a   peptide   (22A,   21A,   or   22A-­P)   and   phospholipid   (DMPC,  
POPC,  DPPC,  or  DSPC)  were  prepared  by  a  co-­lyophilization  procedure  [156].  Briefly,  
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peptide  and  phospholipids  were  dissolved  in  glacial  acetic  acid,  mixed  at  1:2  w/w  ratio  of  
peptide:lipid,  and   lyophilized  overnight.  The  powder  was  hydrated  with  PBS  pH  7.4   to  
make  10  mg/mL  sHDL  and  cycled  between  55°C  (10  min)  and  room  temperature  (10  min)  
to   facilitate   sHDL   formation.   The   resulting   sHDL   complexes   were   analyzed   by   gel  
permeation  chromatography  for  purity  at  1  mg/mL  using  a  7.8  mm  x  30  cm  Tosoh  TSK  
gel  G3000SWxl  column  (Tosoh  Bioscience,  King  of  Prussia,  PA)  with  UV  detection  at  220  
nm.   The   HDL   hydrodynamic   diameters   were   determined   by   dynamic   light   scattering  
(DLS)  using  a  Zetasizer  Nano  ZSP,  Malvern  Instruments  (Westborough,  MA).  The  volume  
intensity   average   values  were   reported.   The   α-­helical   content   of   free   and   lipid-­bound  
peptide   was   determined   by   Jasco   J715   (Jasco,   Easton,  MD)   circular   dichroism   (CD)  
spectropolarimeter.  Samples  at  0.1  mg/mL  concentration  in  10  mM  phosphate  buffer  (pH  
7.4)  or  buffer  alone  were  loaded  into  a  quartz  cuvette  (d  =  0.2-­cm  path  length),  and  CD  
spectra  from  190  to  260  nm  were  recorded  at  37°C.  Buffer  spectra  were  subtracted  from  
each   peptide   or   sHDL   sample.   Data   analysis   was   conducted   using   CDPro   analysis  
software  and   the  percent  helical  content   for  each  sample  was  calculated  via  CONTIN  
analysis  method  with  the  reference  Soluble–Membrane  Protein  56  Data  Base  [185].    
  
Generation  of  helical  wheel  peptide  models  and  calculation  of  lipid  binding  parameters  
Helical  wheel  plots  of  22A,  21A,  and  22A-­P  peptides  were  created  by  Helixator  
(http://tcdb.org/progs/helical_wheel.php).   This   program   displayed   a   peptide   sequence  
looking  down  the  axis  of  the  alpha  helix  with  aliphatic  residues  shown  as  blue  circles.  The  
hydrophobic  momentum  of  22A,  21A,  and  22A-­P  peptides  was  calculated  using  the  3D  
Hydrophobic   Moment   Vector   Calculator   (http://www.ibg.kit.edu/HM/)   [186].   The   helix  
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stability   (ΔGhel),   transfer  energy   from  water   to  membrane   (ΔGtrans),  and  parameters  of  
spatial   positions   in  membranes   (tilt   angle   and  membrane   penetration   depth)   for   each  
ApoA-­I-­mimetic  peptide  were  calculated  by  the  Folding  of  Membrane-­Associated  Peptide  
(FMAP)  server  [187]  and  the  Positioning  of  Proteins  in  Membranes  (PPM)  server  [188].    
  
Cholesterol  efflux  assay  in  vitro  
Cholesterol  efflux  studies  were  performed,  as  described  by  Remaley  et  al.  [103].  
Briefly,  RAW  264.7,  BHK-­Mock  and  BHK  stably  transfected  with  human  ABCA1  cDNA  
cell  lines  were  labeled  for  24  h  with  1  µCi/mL  of  [3H]  cholesterol  in  minimum  Dulbecco’s  
modified  Eagle’s  medium  (DMEM),  containing  0.2  mg/ml  of  fatty  acid-­free  bovine  serum  
albumin  (BSA).  Then,  BHK-­MOCK  and  BHK-­ABCA1  cell  lines  were  treated  with  10  nM  
mifepristone   for   18   h   to   selectively   induce   the   expression   of   ABCA1   cholesterol  
transporter   for   BHK-­ABCA1.   ABCA1   transporter   was   not   selectively   induced   in   RAW  
264.7  cell  line.  Following  the  radiolabeling  or  induction  step,  peptides  (22A,  21A  or  22A-­
P)   or   sHDL   (21A-­DMPC,   22A-­P-­DMPC,   22A-­DMPC,   22A-­POPC,   22A-­DPPC   or   22A-­
DSPC)  were  added  at  0.01,  0.03  and  0.1  mg/mL  concentration  using  DMEM-­BSA  media.  
After  18  h  of  incubation  with  cholesterol  acceptors,  media  were  collected  and  cells  were  
lysed  in  0.5  ml  of  0.1%  SDS  and  0.1  N  NaOH  for  2  h.  Radioactive  counts  in  media  and  
cell   fractions   were   measured   by   liquid   scintillation   counting   (Tri-­Carb   2910   TR,  
PerkinElmer),  and  percent  cholesterol  efflux  was  calculated  by  dividing  media  counts  by  
the  sum  of  media  and  cell  counts.    
  
Phospholipid  lipolysis  by  LCAT  
   103  
The  rate  of  phospholipid  (POPC,  DMPC,  DPPC  or  DSPC)  lipolysis  was  evaluated  
by   incubating   15   µg/mL   of   rhLCAT   with   0.1   mg/mL   of   sHDL   (based   on   total   lipid  
concentration)  in  0.1  M  sodium  phosphate  buffer  pH  7.4  for  0,  5,  15,  30,  60,  90,  and  120  
min.   The   LCAT-­sHDL   reaction   aliquots   were   collected   into   methanol   (1:5   v/v)   and  
vortexed  to  stop  the  lipolysis  reaction  at  each  time  point.  The  amount  of  POPC,  DMPC,  
DPPC   or   DSPC   remaining   at   each   time   point   was   measured   by   Waters   UPLC-­MS  
equipped   with   QDa   Mass   Detector   (Milford,   MA).   Chromatographic   separation   was  
achieved  on  Acquity  BEH300  1.7  µm  HILIC  2.1  x  50  mm  column  with  gradient  elution  at  
0.65  mL/min:  mobile  phase  A  (H2O/0.1%  formic  acid),  mobile  phase  B  (acetonitrile/0.1%  
formic  acid)  and  mobile  phase  C  (100  mM  ammonium  formate)  as  follows:  0-­0.7  min  (5-­
17%  A,  90-­78%  B,  and  5-­5%  C),  0.7-­0.71  min  (17-­5%  A,  78-­90%  B,  and  5-­5%  C),  and  
0.71-­3  min  (17-­5%  A,  78-­90%  B,  and  5-­5%  C).  Mass  spectra  were  acquired  in  the  positive  
ion  mode  with  the  mass  range  set  at  m/z  150-­1250  and  POPC  was  detected  at  760.7  
amu,  DMPC  at  678.7  amu,  DPPC  at  734.7  amu,  and  DSPC  at  790.7  amu.  Data  analysis  
was   performed  with  Waters   Empower   software.   The   plot   of   POPC,  DMPC,  DPPC   or  
DSPC  area  under  the  curve  over  time  was  generated  for  each  sHDL  sample.  The  rate  of  
LCAT  lipolysis  (k)  was  calculated  from  the  linear  slope  of  the  log10  (concentration)  versus  
time.    
  
Cholesterol  esterification  by  LCAT  assay  
Two  different  sets  of  sHDL  containing  dehydroergosterol  (DHE)  was  prepared  via  
the   thin-­film   method.   Briefly,   the   first   set   was   made   from   POPC,   DPPC   and   DHE  
combined  at  a  4.5:4.5:1  molar  ratio  in  chloroform  and  then  mixed  with  peptide  (22A,  21A  
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or  22A-­P)  at  2:1  lipid:peptide  weight  ratio  in  methanol/water  (4:3  v/v).  The  second  set  was  
prepared  from  POPC,  DMPC,  DPPC  or  DSPC  and  DHE  at  a  9:1  molar  ratio  then  mixed  
with  22A  peptide  at  2:1  lipid:peptide  weight  ratio  in  methanol/water  (4:3  v/v).  The  solvent  
was   removed   under   nitrogen   flow   at   room   temperature   and   then   in   a   vacuum   oven  
overnight.   The   lipid   film  was   hydrated  with   20  mM   phosphate   buffer   containing   1mM  
EDTA  (pH  7.4)  followed  by  5  min  water  bath  sonication  at  room  temperature  and  probe  
sonication   (2  min  ×  50  w)   to   obtain   clear  DHE-­sHDL.  The   final  DHE  concentration   in  
peptide-­DHE-­sHDL  was  0.5  mM.  The  LCAT  assay  was  adapted  from  Homan  et  al.  [189]  
and  performed  in  384-­well  black  polystyrene  plates  in  triplicate.  Briefly,  8  μL  of  different  
concentrations   (0,  5,  10,  20,  40,  60,  and  100  μM)  of  DHE-­sHDL  (substrates)   in  assay  
buffer  (PBS  containing  1  mM  EDTA,  5  mM  β-­mercaptoethanol,  and  60  µM  albumin,  pH  
7.4)  preheated  to  37°C  were  incubated  with  8  μL  of  5  μg/mL  LCAT  in  dilution  buffer  (PBS  
with  1  mM  EDTA  and  60  µM  albumin,  pH  7.4)  preheated  to  37°C  in  triplicates.  The  plates  
were  incubated  at  37°C  with  gentle  shaking  (80  rpm/min)  for  different  lengths  of  time  (0,  
10,  and  20  min).  Reactions  were  stopped  by  adding  4  μL  of  stop  solution   (3.75  U/mL  
cholesterol  oxidase)  in  PBS  containing  1mM  EDTA  and  7%  Triton  X-­100.  Then,  the  plates  
were   incubated   at   37°C   with   shaking   (80   rpm/min)   for   another   1   h   to   quench   the  
fluorescence   of   unesterified   DHE.   The   fluorescence   was   measured   at   an   excitation  
wavelength  of  325  nm  and  an  emission  wavelength  of  425  nm  using   the  plate-­reader  
(SynergyTM  NEO  HTS  Multi-­Mode  Microplate  Reader,  Bio-­Tek).  A  standard  curve  was  
made  by  plotting   the   fluorescence  of  serially  diluted  DHE-­containing  sHDL  mixed  with  
LCAT  and  using  stop  solution  without  COx  versus   the  concentration   (μM)  of  DHE.  To  
calculate   the   concentration   (μM)   of   DHE   ester   for   each   reaction,   the   background  
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fluorescence   (0  μM  of  DHE)  was  subtracted   from  all   fluorescence  measurements  and  
then  divided  by  the  slope  (fluorescence/μM)  of  the  above  standard  curve.  To  calculate  
Vmax  and  Km,  the  concentrations  (μM)  of  DHE  ester  at  different  time  points  were  plotted  
against  time  (h),  and  the  initial  velocity  (V0,  μM  DHE-­ester/h)  was  the  slope  of  the  linear  
range  of  DHE-­ester  concentration  versus  time.  The  Vmax  and  Km  were  obtained  by  plotting  
V0   versus   DHE   concentration   and   then   analyzed   by   GraphPad   Prism   7   (nonlinear  
regression,  Michaelis-­Menten  model).  
  
Plasma  peptide  stability  
The  in  vitro  stability  of  22A,  21A,  and  22A-­P  peptides  was  assessed  by  the  addition  
of  2.5  µL  of  10  mg/mL  of  a  peptide  to  97.5  µL  of  fresh  rat  plasma  (K2  EDTA,  Innovative  
Research  Inc).  Immediately  after  the  addition  of  peptide  to  plasma,  10  µL  of  serum  was  
removed  to  serve  as  a  baseline  and  stored  at  -­20  °C.  Samples  were  incubated  at  37°C  
for  24  hours  with  shaking  at  240  rpm.  To  determine  peptide  concentration  at  0  and  24  h  
post  plasma  incubation,  10  µL  of  plasma  containing  a  peptide  or  working  standard  (0-­100  
µg/mL)  was  mixed  with  2  µL  of  2.4  mg/mL  internal  standard  (5A  peptide)  and  38  µL  of  
H2O.  Methanol   (200   µL)   was   added   to   precipitate   plasma   proteins.   The  mixture   was  
vortexed  for  10  s,  centrifuged  at  12,000  rpm  for  10  min  and  the  supernatant  was  collected  
for  LC-­MS  analysis.  Samples  were  mixed  (1:1  v/v)  with  LC-­MS  mobile  phase  (80:20  v/v  
H2O:acetonitrile,  0.1%  formic  acid)  and  analyzed  on  Waters  Acquity  UPLC  equipped  with  
QDa  System  (Milford,  MA)  using  Acquity  UPLC  BEH  C18  1.7  μM  column  for  separation.  
The  mobile  phase  consisted  of  (A)  water  containing  0.1%  v/v  formic  acid  and  (B)  methanol  
containing  0.1%  v/v  formic  acid.  The  mobile  phase  was  delivered  at  0.3  mL/min  using  a  
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gradient  elution  of  20%  to  80%  B  during  0-­1.5  min,  and  80%  to  20%  B  during  1.5-­3.5  min.  
Mass  spectra  were  acquired  in  the  positive  ion  mode  with  the  mass  range  set  at  m/z  150-­
1250.  Data  analysis  was  performed  on  Waters  Empower  software.  The  concentration  of  
22A,  21A  or  22A-­P  peptide  in  each  sample  was  determined  from  the  standard  curve.    
  
Peptide  pharmacokinetics,  cholesterol  mobilization,  and  esterification  in  vivo  
Healthy  male  Sprague-­Dawley  rats  (8  weeks  old)  were  purchased  from  Charles  
River  Breeding  Laboratories  (Portage,  MI)  and  were  fed  a  standard  rodent  chow  diet.  To  
examine   the   impact  of  peptide  composition  on  sHDL  PK/PD  properties,  animals  were  
randomly   assigned   to   two   groups   (n   =   4/group)   for   22A-­POPC/DPPC   and   22A-­P-­  
POPC/DPPC  administration.  To  examine  the  impact  of  lipid  composition  on  sHDL  PK/PD,  
animals  were  randomly  assigned  to  four  groups  (n  =  3/group)  for  22A-­POPC,  22A-­DMPC,  
22A-­DPPC,  and  22A-­DSPC  administration.  All  sHDL  particle  was  prepared  at  1:2  w/w  
peptide   to   phospholipid   ratios,   sterile   filtered   and   characterized   by   DLS   and   gel  
permeation  chromatography  for  size  and  purity  prior  to  animal  dosing.  All  animals  were  
fasted  overnight  before  sHDL  dosing  at  50  mg/kg  (based  on  peptide  concentration)  via  
tail   vein   injection.  At  each   time  point   (pre-­dose,  0.25,  0.5,  1,  2,  4,  8,  and  24  h)  blood  
samples  (~0.3  mL)  were  collected  from  the  jugular  vein  to  heparinized  BD  tubes  (Franklin  
Lakes,  NJ)  and  centrifuged  at  10,000  rpm  for  10  min  at  4°C.  The  obtained  serum  samples  
were  stored  at  -­20°C  for  further  analysis.    
The  levels  of  plasma  phospholipids  (PL),  total  cholesterol  (TC)  and  free  cholesterol  
(FC)   were   determined   enzymatically   (Wako  Chemicals,   Richmond,   VA)   using   a   plate  
reader   (SynergyTM   NEO   HTS   Multi-­Mode   Microplate   Reader,   Bio-­Tek).   Esterified  
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cholesterol  levels  (EC)  were  calculated  as  the  difference  between  TC  and  FC  levels  at  
each  time  point.  Briefly,  serum  samples  were  diluted  with  PBS  for  TC  and  FC  detection,  
or  with  MilliQ  water  for  PL  detection.  Defined  amounts  of  standards  or  diluted  samples  
were  transferred  to  96-­well  plates  (50  μL,  60  μL  and  20  μL  for  TC,  FC  and  PL  analyses,  
respectively),  and  assay  reagents  were  added  per  manufacturer’s  instructions.  The  plates  
were  gently  shaken  using  an  orbital  shaker  and  incubated  at  37˚C  for  5  minutes.  The  UV  
absorbance   at   600   nm  was  measured   by   a  Molecular   Devices   SpectraMax  M3   plate  
reader   (Sunnyvale,   CA).   Pharmacokinetic   parameters   were   also   obtained   by   non-­
compartmental  analysis.  The  pharmacodynamic  effect  in  each  rat  was  determined  as  the  
area   under   the   total   effect   curve   (AUEC)   using   trapezoidal   rule.   Secondary  
pharmacodynamic  endpoints,  maximal  effect  (Emax)  and  time  to  Emax  (Tmax,E)  were  also  
analyzed  to  compare  pharmacodynamic  effects.  
Peptide  (22A  or  22A-­P)  concentration  in  serum  was  determined  by  LC-­MS.  The  10  
µL   serum   aliquots   were   combined   with   10   µL   of   2.4  mg/mL   of   internal   standard   (5A  
peptide)  and  then  mixed  with  40  µL  ddH2O.  Working  standard  solutions  (0-­100  µg/mL)  of  
22A  and  22A-­P  were  prepared  as  described  above  for  plasma  samples  with  the  exception  
of   using   blank   rat   serum.   Plasma   proteins   were   precipitated   by   adding   180   μL   of  
methanol.  After  5  minutes,  the  mixture  was  centrifuged  (12000  rpm  ×  10  min,  4°C)  and  
100  µL  of  the  supernatant  was  used  for  analysis.  Each  sample  was  analyzed  by  LC-­MS  
as  described  above  in  the  plasma  peptide  stability  section.  Pharmacokinetic  parameters  
such  as  maximum  serum  concentration  (Cmax),  the  area  under  the  serum  concentration-­
time  curve  (AUC),  elimination  rate  constant  (K),  elimination  half-­life  (T1/2),  total  clearance  
(CL),  and  volume  of  distribution  (Vd)  were  obtained  by  non-­compartmental  analysis.  
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Remodeling  of  endogenous  lipoproteins  by  sHDL  in  human  plasma  
Remodeling  of  endogenous  lipoproteins  in  human  plasma  by  sHDL  was  assessed  
by   one-­dimensional   native   polyacrylamide   gel   electrophoresis   (1-­D   native   PAGE)  
following   sHDL   incubation   in   plasma.   Various   sHDL   (22A-­POPC,   22A-­DMPC,   22A-­
DPPC,  22A-­DSPC,  21A-­sHDL,  22A-­sHDL,  and  22A-­P-­sHDL)  at  1  mg/mL  concentration  
were  incubated  at  37°C  for  1  h  with  shaking  at  300  rpm.  The  sub-­classes  of  HDL  were  
separated  by  size  using  1-­D  native  PAGE  and  visualized  by  Western  Blot  using  the  anti-­
ApoA-­I  antibody.  Briefly,  samples  were  subjected   to  electrophoresis  using  Tris-­borate-­
EDTA  (TBE)  gradient   (4  –  20%)  acrylamide  mini-­gels.  For  each  well,  10  μL  of  human  
plasma  incubated  with  or  without  sHDL  was  mixed  with  10  μL  of  2X  TBE  sample  buffer,  
and  6  μL  of  the  resulting  mixtures  were  loaded  per  well.  Gels  were  run  at  200V.  Proteins  
were  transferred  to  polyvinylidene  difluoride  membrane  (PVDF)  and  incubated  overnight  
with  the  anti-­human  ApoA-­I-­HRP  conjugated  antibody.  Proteins  were  visualized  with  the  
enhanced  chemiluminescent  substrate  on  Protein  Simple  FluorChem  M  imaging  system  
(San  Jose,  CA).  
  
Statistical  analysis  
Significance  of  difference  was  determined  by  Student’s   t-­test   for  comparing  two  
groups   or   by   one-­way   analysis   of   variance   (ANOVA)  with  Dunnett’s   post-­hoc   test   for  
comparing  multiple  groups  with  22A  peptide  or  22A-­DMPC  as  the  control.  All  samples  
were  performed  in  triplicate  and  error  bars  were  reported  as  a  standard  mean  error  (SEM)  
unless  noted  otherwise.  P  <  0.05  was  considered  statistically  significant.    
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  Results  
Design  of  ApoA-­I  peptides  with  improved  plasma  stability  
Helical   wheel   plots   for   22A,   22A-­P,   and   21A   were   generated   to   assess   the  
amphipathic  nature  of  each  peptide.  The  hydrophobic  amino  acids  clustered  on  one  side  
of  the  helix  suggested  an  amphipathic  orientation  of  each  peptide  (Table  3-­1).  The  3D  
hydrophobic  moment   vector   calculations   were   performed   to   predict   and   compare   the  
interactions  of  each  peptide  with  lipid  membranes.  It  was  determined  that  the  hydrophobic  
moment  vectors  were  almost  identical  with  an  average  of  10.3  ±  0.7  A*kT/e.  Additionally,  
we  used  an  online  server   to  determine   the  helix   stability   (DGhel),   transfer  energy   from  
water   to   membrane   (DGtrans),   and   orientation   of   each   peptide   in   the   membrane  
(penetration   depth,   D).   Again,   we   did   not   find   large   differences   in   any   of   the  
aforementioned  parameters,  suggesting  that  the  absence  of  the  terminal  lysine  in  21A  or  
the  addition  of  proline  in  22A-­P  did  not  change  the  physical  properties  of  these  peptides  
compared  to  22A.  Next,  we  compared  the  plasma  stability  of  22A,  22A-­P,  and  21A  as  well  
as  their  abilities  to  bind  lipid  and  form  sHDL  particles.  We  found  that  while  22A  degrades  
in  plasma  with  only  48%  of  intact  peptide  remaining  after  24  h  incubation  at  37°C,  both  
22A-­P  and  21A  are  significantly  more  stable  with  89  and  97%  of  intact  peptide  remaining,  
respectively.  These  results  suggest  that  the  plasma  stability  of  22A  peptide  can  be  greatly  
improved   by   the   addition   of   a   bulky   proline,   while   computed   lipid   binding   properties  
remained  relatively  unchanged.    
  
Preparation  and  characterization  of  sHDL  particles  
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We   next   evaluated   the   ability   of   21A,   22A,   and   22A-­P   peptide   to   form  
homogeneous  sHDL  particles.  Synthetic  HDL  particles  were  prepared  by  combining  22A,  
21A  or  22A-­P  peptide  with  DMPC  at  1:2  w/w  peptide:lipid  ratio,  which  was  previously  used  
in  ETC-­642  formulation  resulting  in  the  formation  of  homogeneous  sHDL  particles  with  
approximately  10  nm  size  (Li  et  al.,  2015;;  Tang  et  al.,  2017).  All  three  peptides  formed  
homogeneous   sHDL   particles   with   average   diameters   of   approximately   10   nm   and   a  
narrow  polydispersity   index  of  0.17  ±  0.04  as  determined  by  DLS  (Figure  3-­1a).  Purity  
and   homogeneity   of   sHDL   size   distribution   were   evaluated   by   gel   permeation  
chromatography  (Figure  3-­1b).  All  three  sHDL  were  over  98%  pure,  and  negligible  levels  
of  the  free  peptide  (<2%)  were  observed  at  the  retention  time  of  ~11  min  (Table  3-­2).  The  
binding  of  a  peptide  to  phospholipid  was  also  confirmed  by  increased  helicity  of  22A,  21A  
and  22A-­P  in  sHDL  particles  (94,  91  and  82%)  relative  to  the  free  peptide  (77,  79  and  
77%)  as  measured  by  CD.  
We  also  altered  the  phospholipid  composition  of  22A  sHDL  to  study  its  impact  in  
vitro  and  in  vivo.  We  chose  four  lipids  with  different  physical  properties  such  as  transition  
temperature  (Tm)  and  affinity  for  cholesterol  (DSPC>DPPC>DMPC>POPC)  (Small,  1986;;  
Ramstedt  and  Slotte,  1999;;  Ohvo-­Rekilä  et  al.,  2002).  The  sHDL  complexes  were  formed  
by  combining  22A  peptide  with  individual  lipids  at  1:2  w/w  ratio  using  the  co-­lyophilization  
method.  All  were  highly  homogeneous  with  an  average  hydrodynamic  diameter  ranging  
between  8.3   to  10.5  nm,   low  polydispersity   index  and  gel  permeation  chromatography  
purity  greater  than  95%  (Figure  3-­1c,  3-­1d).  The  purity,  size,  and  polydispersity  levels  of  
sHDL  are  summarized   in  Supplemental  Table  1.  The  DMPC,  DPPC  and  DSPC-­based  
sHDL  had  smaller  hydrodynamic  diameters,  higher  GPC  purities,  and  sharper  GPC  peaks  
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relative  to  22A-­POPC.  The  presence  of  free  peptide  (<1%,  retention  time  ~11.3  min)  and  
liposome  impurities  (<2%,  retention  time  ~5.5  min)  were  observed  for  22A-­POPC,  which  
also  had  the  largest  average  particle  size  and  broadest  size  distribution.  Because  POPC  
has  the  lowest  Tm  of  -­2  °C,  it  exists  in  a  fluid  gel  state  at  room  temperature,  which  likely  
impacts  22A-­POPC  stability.    
  
Lipid  composition  of  sHDL  impacts  macrophage  cholesterol  efflux  
We  next   examined  how   the  C-­terminal  modifications   in   22A-­P  and   21A   impact  
cholesterol   efflux   abilities   relative   to   22A,   either   as   free  peptides   or   reconstituted   into  
sHDL.   Radioactive   cholesterol   was   loaded   into   BHK   cell   line   stably   transfected   with  
human  ABCA1  transporter  and  peptides  were  incubated  with  the  cells  at  0,  0.01,  0.03,  
and  0.1  mg/mL.  The  same  experiment  was  repeated  using  the  control  BHK-­Mock  cell  line  
to  assess  cholesterol  efflux  by  passive  diffusion.  Then,  the  non-­specific  cholesterol  efflux  
values  were  subtracted  from  the  data  obtained  for  each  peptide  with  ABCA1  transfected  
cells   to   reveal   receptor   specific   cholesterol   efflux   (Figure   3-­2a).   All   three   peptides  
exhibited  concentration-­depended  cholesterol  efflux  with  only  minor  differences  (<  5%)  
observed,   indicating  that  modifications  at  the  C  terminal  end  of  22A  did  not  affect   lipid  
binding   and   ABCA1   transporter   interaction.   Then,   the   three   peptide   sequences   were  
assembled   into   sHDL   and   their   abilities   to   efflux   cholesterol   from  macrophages  were  
examined   in  RAW  264.7   cell   line   (Figure   3-­2b).   Similar   to   free   peptide,  we   observed  
concentration-­dependent   cholesterol   efflux   with   only   minor   differences   (<   5%)   at  
concentrations  tested.  
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To  explore   the   impact  of   the  phospholipid  component  of   sHDL  on  macrophage  
cholesterol   efflux,   22A-­POPC,   22A-­DMPC,   22A-­DPPC,   and  22-­DSPC  were   incubated  
with  RAW  264.7   cells.  Saturated   long   chain   length   phospholipids   such  as  DPPC  and  
DSPC  have  higher  physical  binding  affinity  to  cholesterol  relative  to  POPC  and  DMPC  
(Ramstedt   and   Slotte,   1999;;   Ohvo-­Rekilä   et   al.,   2002).   However,   the   transition  
temperature  of  POPC  and  DMPC  is  below  37°C,  thus  the  phospholipid  bilayer  is  in  liquid  
crystal  state  at  physiological  temperature  facilitating  cholesterol  partitioning  in  these  sHDL  
particles  at  the  cell  culture  conditions  (Davidson  et  al.,  1995).  As  expected,  we  observed  
greater  cholesterol  efflux  to  POPC  and  DMPC-­based  sHDL  relative  to  DPPC  and  DSPC-­
based  sHDL  likely  due  to  differences  in  lipid  fluidity  at  37°C  (Figure  3-­2c).  Whereas  22A-­
DPPC  and  22A-­DSPC  did  not  have  any  significant  differences   in  cholesterol  efflux  as  
concentration   increased,   22A-­POPC   and   22A-­DMPC   show   sHDL   concentration-­
dependent   increase   in   cholesterol   efflux.   Interestingly,   22A-­DMPC   showed   the   most  
effective  cholesterol  efflux  capability   from  as   low  as  36%  at  0.01  mg/mL  to  as  high  as  
61.8%  at  0.1  mg/mL  concentration.  Membrane  transporters  such  as  ABCG1/G4  and  SR-­
BI  are  known  to  play  a  major  role  in  cholesterol  efflux  to  HDL  rather  than  lipid-­free  protein  
and  may  contribute  to  the  differences  seen  between  sHDL  in  our  study  [190,  191].  Taken  
together,   the   phospholipid   composition   of   sHDL   appears   to   play   a   significant   role   in  
cholesterol  efflux  from  macrophages  in  cell  culture.  
  
Peptide  and  lipid  composition  both  impact  sHDL  interaction  with  LCAT  
Following  cholesterol  efflux  from  macrophages,  sHDL  particles  interact  in  plasma  
with  LCAT  [192].  It  is  expected  that  both  lipid  and  peptide  composition  of  sHDL  will  have  
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an  effect  on  LCAT  interaction.  The  fluidity  of  HDL  lipid  membrane  determines  the  ease  of  
LCAT  binding  to  HDL  particles  [193].  It  has  been  shown  that  LCAT  interaction  with  ApoA-­
I   is   critical   for  LCAT  activation,  especially   for   the   facilitation  of  acyltransferase  activity  
[194].  Whereas  some  ApoA-­I  mimetic  peptides  have  similar  LCAT  activation  ability  to  full-­
length   ApoA-­I,   others   fail   to   facilitate   EC   formation   [173,   195,   196].   The   presence   of  
positively  charged  clusters  on  the  C-­terminus  and  presence  of  hydrophobic  amino  acids  
at  positions  3,  6,  9  and  10,  and  net  peptide  charge  of  zero  are  believed  to  be  critical  to  
the  high  LCAT  activation  ability  of  22A  [164,  173].  To  examine  how  modification  of  22A  
and  lipid  composition  of  sHDL  impact  phospholipase  A2  activity  of  LCAT,  sHDL  were  co-­
incubated  with  enzyme  and  the  kinetics  of  reduction  of  phospholipid  concentration  was  
monitored  by  LC-­MS.  We   found   that  small  changes   in  22A  sequence  had  only   limited  
impact  on  phospholipase  A2  activity  (lipolysis)  activity  (Figure  3-­3a),  indicating  that  LCAT  
activation  by  a  C-­terminal  positive  cluster  on  the  peptide  might  not  be  critical  for  lipase  
activity.  In  contrast,  the  sHDL  lipid  composition  had  profound  effect  on  LCAT-­catalyzed  
phospholipid  lipolysis  (Figure  3-­3b)  with  the  rates  of  0.08,  0.08,  0.01,  and  0.0  h-­1  for  22A-­
POPC,   22A-­DMPC,   2A-­DPPC   and   22A-­DSPC,   respectively.   DSPC   and   DPPC,  
phospholipids  with  Tm  values  above  37°C,  had  minimal  lipolysis  likely  due  to  poor  LCAT  
binding  to  sHDL  and,  thus,  presumably  difficulty  in  the  accessibility  of  substrate  for  the  
enzymatic  reaction.    
Next,  we  assessed  the  impact  of  peptide  and  lipid  composition  of  sHDL  on  LCAT  
acyltransferase   activity   by   incorporating   a   fluorescent   cholesterol   analog   called  
dehydroergosterol  and  measuring  the  rate  of  sterol  esterification  by  LCAT.  Changes  in  C-­
terminus  of  22A  peptide  had  a  significant  effect  on  the  acyltransferase  activity  with  a  2.6-­
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fold  decrease   in   kcat   upon   the   loss  of   lysine   for   21A   (Figure  3-­3c).  The   rate  was  only  
decreased   by   30%   for   22A-­P-­HDL.   When   22A-­sHDL   was   complexed   with   different  
compositions  of  phospholipids,  acyltransferase  activity  of  LCAT  was  the  highest  for  22A-­
POPC  sHDL  (Figure  3-­3d).  Sterol  esterification  was  only   limited  for  22A-­DMPC  sHDL,  
while  no  activity  was  detected  for  22A-­DPPC  and  22A-­DSPC.  This  trend  was  similar  to  
the  differences  in  phospholipase  A2  activity  observed  for  sHDL  prepared  with  different  
lipids   (POPC   ≥   DMPC   >   DPPC   >   DSPC),   following   their   general   trends   in   Tm   and  
membrane  fluidity.    The  Michaelis-­Menten  parameter  estimates  for  the  LCAT  assay  and  
goodness  of  fit  are  provided  in  Table  3-­3.  The  assay  has  significant  run-­to-­run  variability,  
however,  the  samples  analyzed  within  a  single  experiment  (either  in  Figure  3-­3c  or  3-­3d)  
can  be  compared  between  each  other.    
  
Increase  in  peptide  plasma  half-­life  has  no  impact  on  cholesterol  mobilization  in  vivo  
To  evaluate  whether   in  vitro  peptide  stability  data  correlates  with   in  vivo  peptide  
pharmacokinetics  and  cholesterol  mobilization,  we  injected  healthy  Sprague  Dawley  rats  
with   22A-­POPC-­DPPC   or   22A-­P-­POPC-­DPPC   sHDL   at   50   mg/kg   based   on   peptide  
concentration  in  sHDL.  Animal  blood  samples  were  collected  before  sHDL  administration  
and  at  0.25,  0.5,  1,  2,  4,  8,  and  24  h  post-­dose.  The  peptide  concentrations  in  rat  serum  
were  determined  using  LC-­MS  (Figure  3-­4a).  The  noted  stability  of  22A-­P  when  incubated  
with  rat  plasma  translated  well  to  in  vivo  settings  with  an  increase  in  peptide  circulation  
half-­life  and  exposure  (T1/2  =  4.2  h  and  AUC  =  17.2  mg*h/dL)  compared  to  22A  (T1/2  =  2.1  
h  and  AUC  =  5.5  mg*h/dL)  (Table  3-­4).  We  expected  that  these  significant  PK  differences  
between  two  peptides  would  translate  into  increased  cholesterol  mobilization  by  sHDL  in  
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vivo.  Additionally,  we  anticipated  that   levels  of  esterified  cholesterol  would  be  different  
between   two   formulations   in   vivo   based   on   clear   differences   in   LCAT-­catalyzed  
esterification   between   22A-­sHDL   and   22A-­P-­sHDL   in   vitro.   However,   we   saw   no  
differences  in  cholesterol  mobilization  and  esterification  profiles  between  22A-­sHDL  and  
22A-­P-­sHDL  in  vivo  as  quantified  by  enzymatic  assay  of  rat  serum  samples  (Figure  3-­4c,  
3-­4d,  Table  3-­4).  Finally,   if  sHDL  particle  stayed   intact  upon   in  vivo  administration,  we  
would  expect  to  see  longer  circulation  half-­life  for  total  phospholipids  with  22A-­P-­sHDL  
relative  to  22A-­sHDL.  To  test  this  hypothesis,  we  determined  phospholipid  concentrations  
in  plasma  pre-­  and  post-­sHDL  administration  by  an  enzymatic  assay.  We  observed  no  
differences  in  phospholipid  PK  parameters  between  22A-­sHDL  and  22A-­P-­sHDL  except  
for  T1/2   in  which  22A-­P-­sHDL  (1.3  h)  showed  significantly  decreased  T1/2  compared   to  
22A-­sHDL   (1.8  h)   (Figure  3-­4b,  Table  3-­4).  Altogether,   these   results   suggest   that   the  
apparent  differences  in  22A-­P  and  22A  stabilities  in  plasma  and  LCAT  activation  abilities  
had  not  resulted  in  measurable  differences  in  cholesterol  mobilization  and  esterification  
in  vivo.    
  
Lipid  composition  of  sHDL  impacts  cholesterol  mobilization  in  vivo  
To  investigate  the  contribution  of  phospholipid  composition  of  sHDL  on  cholesterol  
mobilization  and  esterification  profiles  in  vivo,  we  administered  22A-­POPC,  22A-­DMPC,  
22A-­DPPC,  and  22A-­DSPC  sHDL  to  healthy  Sprague  Dawley  rats.  Based  on  cholesterol  
efflux  from  RAW  264.7  cells  and  LCAT-­catalyzed  esterification  results   in  vitro  we  were  
expecting  to  see  higher  cholesterol  mobilization  and  esterification  for  POPC  and  DMPC-­
based  sHDL  in  vivo.  However,  the  results  of  in  vivo  administration  of  50  mg/kg  of  sHDL  
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were  reversed  with  22A-­DSPC  showed  significantly  higher  free  cholesterol  mobilization  
to   the   plasma   compartment   represented   by   the   area   under   the   effect   curve   (AUEC)  
AUEC22A-­DSPC   =   540   mg*h/dL   compared   to   three   other   sHDL   formulations   with   lower  
AUEC22A-­POPC   =   80  mg*h/dL,  AUEC22A-­DMPC  =   130  mg*h/dL,   and  AUEC22A-­DPPC   =   220  
mg*h/dL  (Figure  3-­5,  Table  3-­5).  Although  the  Cmax  of  plasma  EC  was  higher  for  DMPC-­
based  sHDL,  DSPC-­based  sHDL  administration  resulted  in  higher  EC  concentration  at  
later  time  points  and  3.5-­fold  greater  AUEC  values  relative  to  DMPC-­based  sHDL  (Figure  
3-­5d,  Table  3-­5).  The  differences  between  in  vitro  and  in  vivo  results  could  be  attributed  
to  differences  in  lipid  Tm  affecting  the  in  vivo  circulation  time.  Our  in  vivo  data  supports  
this  hypothesis  where  phospholipids  with  higher  transition  temperatures  such  as  DSPC  
(Tm   =   55°C)   showed   greater   half-­life   and   slower   clearance   than   other   phospholipids  
(Figure   3-­5b).   Interestingly,   the   22A   peptide   kinetics   such   as   plasma   half-­life   after  
administration  of  sHDL  in  rats  did  not  follow  phospholipid  kinetics  similar  to  the  differences  
in  PK  parameters  between  lipid  and  peptide  obtained  with  22A-­  and  22A-­P-­sHDL.  The  
half-­life  of  22A  after  22A-­DSPC  infusion  was  nearly  identical  to  22A-­DMPC,  22A-­POPC,  
and  22A-­DPPC   formulations   (3.3  h,  3.0  h,  3.3  h,  and  3.3  h,   respectively)   (Table  3-­5).  
Taken  together,  these  results  suggest  that  the  ability  of  sHDL  to  mobilize  cholesterol  is  
strongly  dependent  on  phospholipid  composition  and  pharmacokinetics.    
  
Remodeling  of  endogenous  HDL  in  human  plasma    
To   assess   how   different   compositions   of   sHDL   facilitate   the   remodeling   of  
endogenous  lipoproteins,  all  sHDL  particles  were  incubated  with  human  plasma  for  1  hour  
at  1  mg/mL  peptide  concentration.  The  HDL  sub-­fractions  were  separated  by  size  using  
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1D   native   PAGE   electrophoresis   and   visualized   by   Western   Blot   using   anti-­ApoA-­I  
antibody  (Figure  3-­6).  We  have  confirmed  that  anti-­ApoA-­I  antibody  does  not  recognize  
22A,  21A  or  22A-­P,  thus,  we  examined  the  impact  of  sHDL  incubation  on  the  remodeling  
of  endogenous  ApoA-­I  containing  proteins.  Compared  to  human  plasma  control  incubated  
with  PBS,  incubation  of  plasma  with  22A-­sHDL,  21A-­sHDL,  and  22A-­P-­sHDL  resulted  in  
the  remodeling  of  endogenous  HDL  indicated  by  a  diminished  signal  for  the  large  a-­HDL  
and  increased  levels  of  lipid-­poor  ApoA-­I.  The  effect  of  the  phospholipid  composition  of  
sHDL  on  endogenous  HDL  remodeling  was  more  prominent.  Incubation  of  plasma  with  
22A-­POPC   resulted   in   a   shift   of   HDL   size   from   large   a-­HDL   to   smaller   pre-­β   HDL.  
Incubation  with  22A-­DMPC  showed   the   formation  of  even  smaller  pre-­β  HDL  particles  
with  a  band  of  lipid-­free  ApoA-­I.  In  contrast,  plasma  incubation  with  22A-­DSPC  displayed  
very  limited  HDL  remodeling,  likely  due  to  the  rigidity  of  the  DSPC  lipid  membrane  and  
thus  reduced  the  insertion  of  endogenous  ApoA-­I.  The  22A-­DPPC  incubation  with  plasma  
resulted  in  some  reduction  of  a-­HDL  levels  and  formation  of  a  predominant  band  of  lipid-­
free   ApoA-­I.   Overall,   the   extent   of   HDL   remodeling   was   significantly   affected   by   the  
phospholipid  composition  of  sHDL.  The  sHDL  prepared  with  high  Tm  phospholipids  (22A-­
DPPC  and  22A-­DSPC)  exhibited  higher  plasma  stability  and  less  remodeling.  
  
  Discussion     
Our  previous  studies  have  shown  that  upon  intravenous  administration  of  sHDL,  
22A  peptide  becomes  rapidly  hydrolyzed  into  21A  due  to  loss  of  terminal  lysine  [159].  The  
addition   of   C-­terminal   proline   after   the   labile   lysine   in   22A   afforded   a   resistant   to  
proteolysis  peptide  as  shown  by  incubation  of  22A-­P  with  rat  plasma.  The  new  peptide  
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was  successfully  formulated  into  sHDL  and  dosed  into  rats.  We  expected  to  see  longer  
circulation   time   and   corresponding   greater   in   vivo   cholesterol  mobilization   for   22A-­P-­
sHDL.  As  predicted  in  vitro,  the  half-­life  of  22A-­P  in  animals  was  extended  from  2.1  to  4.2  
hours  and  AUC  for  22A-­P  is  nearly  3-­fold  higher.  However,  the  longer  circulation  time  of  
22A-­P   in  vivo  did  not   translate   into  a  higher  cholesterol  mobilization  profile  by  22A-­P-­
sHDL  compared  to  22A-­sHDL.  Furthermore,  the  AUC  of  the  phospholipid  component  of  
22A-­P-­sHDL  and  22A-­sHDL  were  also  not  affected  by  the  extension  of  the  peptide  half-­
life.  When  sHDL  particles  prepared  with  the  same  peptide  22A  and  different  phospholipids  
(POPC,  DMPC,  DPPC,   or  DSPC)  were   administered   to   rats   the   peptide   half-­life  was  
similar  for  all   four  formulations  (3.2  ±  0.1  h).  However,  the  phospholipid  half-­life  varied  
dramatically  with  DSPC  circulating  for  6.0  h  compared  to  1.0  -­  3.3  h  for  other  lipids.  The  
trend  of  phospholipid  circulation   time   for  each  sHDL   formulation   in  animal  serum  was  
similar   to   that   of   cholesterol  mobilization   (22A-­DSPC>   22A-­DPPC,   22A-­DMPC>   22A-­
POPC).  Moreover,  these  findings  are  further  supported  by  our  HDL  remodeling  results,  
showing  only  limited  interaction  of  22A-­DSPC  with  endogenous  HDL,  which  could  extend  
circulation  half-­life.  The  limited  interaction  between  sHDL  and  endogenous  lipoproteins  is  
likely  due  to  the  difficulty  of  protein  insertion  in  the  gel  membrane  of  DSPC  (Tm  of  55  °C,  
above  physiological  temperature)  as  was  observed  in  vitro  for  22A-­DSPC  interaction  with  
LCAT.   Altogether,   the   data   suggest   that   the   pharmacokinetics   of   peptide   and   lipid  
components   in   sHDL  are  not   interdependent  and  original   infused  sHDL  particles  may  
dissociate  or  become  remodeled  upon  administration  in  vivo.  In  addition,  the  phospholipid  
rather   than  peptide   component   in   sHDL  has  a  major   impact  on   the  ability   to  mobilize  
cholesterol   in   vivo.   However,   it   is   important   to   note   that   the   peptide   sequence  
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modifications   performed   by   us   were   rather   minor.   It   has   been   shown   that   different  
sequences  of  ApoA-­I  mimetic  peptides  have  measurable  differences  in  cholesterol  efflux  
in  vitro  and  variable  in  vivo  performance  [162,  176,  177,  179].    
Several  other  groups  reported  on  the  discordance  between  the  PK  of  protein  and  
phospholipid  components  of  HDL  in  vivo.  Xu  et  al.  investigated  the  fate  of  ApoA-­I  protein  
and   phospholipid   after   in   vivo   administration   of   HDL   in   an   attempt   to   interrogate   the  
validity   of   the   reverse   cholesterol   transport   pathway   [197]   (Xu   et   al.,   2017).   The  
investigators   used   ABCA1-­derived   ApoA-­I-­HDL   with   radiolabeled   components   and  
reported  that  phospholipids  and  ApoA-­I  enter  different  pathways  for  clearance  in  mice.  
The   authors   suggested   that   after   the   administration   of   radiolabeled   ApoA-­I-­HDL,  
phospholipids  were  rapidly  cleared  by  the  liver  and  also  transferred  to  LDL  while  ApoA-­I  
fused   with   endogenous   HDL   and   circulated   longer.   CSL-­112,   the   ApoA-­I-­soybean  
phosphatidylcholine   sHDL   product   undergoing   phase   III   clinical   trial,   is   believed   to  
undergo   remodeling   in   human  plasma  with   the  generation   of   lipid-­poor  ApoA-­I   that   is  
important  for  cholesterol  efflux  [198].  Another  sHDL  product  in  clinical  development,  CER-­
001,   composed   from   ApoA-­I   and   primarily   sphingomyelin,   have   shown   differences,  
specifically  longer  half-­life  for  phospholipid  (~46  h)  relatively  to  ApoA-­I  (~10  h)  [22,  158].  
We  also  found  that  incorporation  of  polyethylene  glycol-­modified  lipids  in  ApoA-­I  peptide-­
based  sHDL  extended  circulation  time  for  lipids  and  prolonged  the  duration  of  mobilized  
cholesterol  circulation  but  had  not  altered  ApoA-­I  peptide  PK  [199].  Therefore,  peptide  
and  lipid  components  of  sHDL  may  both  contribute  to  cholesterol  mobilization,  however  
not  as  intact  nanoparticles,  but  rather  as  separate  entities  via  different  mechanisms.  
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The  phospholipid  composition  also  impacted  the  ease  of  sHDL  preparation,  purity,  
and  size  of  the  resulting  nanoparticles  and  their  stability   in  vitro  and   in  vivo.  The  sHDL  
prepared   with   DSPC,   DPPC,   and   DMPC   showed   relatively   similar   narrow   size  
distributions   and  high  purities  while   sHDL  prepared  with  POPC  appeared   to   be  more  
heterogeneous  with  larger  average  particle  sizes  and  a  presence  of  liposomal  impurities.  
This   relative  difficulty  of   forming  pure  POPC-­based  sHDL  particles  has  been   reported  
previously  and  was  attributed  to  the  fluidity  and  instability  of  the  POPC  membrane  at  room  
temperature,  which  was  well  above  the  phospholipid’s  Tm  [165].  The  sHDL  prepared  with  
saturated   lipids   appeared   to   be   more   homogeneous   and   pure   but   required   heating  
particles  above   lipid  Tm  during  preparation   to   facilitate  ApoA-­I  peptide-­lipid  binding.   In  
addition,  the  presence  of  unsaturated  double  bonds  in  lipids  such  as  POPC  could  result  
in  phospholipid  oxidation,  although  this  phenomenon  was  not  investigated  in  this  study.    
Interestingly,  we  also  observed  a  discordance  between  in  vitro  and  in  vivo  results  
for  sHDL  prepared  with  different  phospholipids  and  peptides.  The  in  vitro  trends  for  higher  
cholesterol  efflux  and  superior  ability  to  activate  LCAT  for  22A-­POPC  and  22A-­DMPC  did  
not   translate   into   higher   cholesterol   mobilization   and   esterification   in   vivo.   The   free  
cholesterol  mobilization  and  circulation  time  appear  to  be  closely  following  the  circulation  
time  of  phospholipids,  with  the  longer  circulating  saturated  DSPC  exhibiting  higher  Cmax  
for  FC  mobilization  and  AUEC.  Thus,  the  ease  of  cholesterol  incorporation  in  unsaturated  
22A-­POPC  becomes  of  limited  significance  in  vivo  due  to  rapid  elimination  of  POPC.  The  
esterification   seems   to   follow   the   same   trend,   as   faster   LCAT-­catalyzed   lipolysis   and  
sterol  esterification  did  not  translate  to  greater  Cmax  and  AUEC  for  EC  in  vivo.  However,  
it  is  important  to  point  out  that  the  actual  rate  of  EC  formation  and  LCAT  activation  in  vivo  
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was   not   directly   measured   in   this   study   and   will   require   additional   experiments   as  
described  by  Turner  et  al.  (Turner  et  al.,  2012).  The  stability  of  22A-­P  is  greatly  improved  
in   vivo   relative   to   22A,   however   phospholipid   PK   appeared   to   be   unchanged   and  
cholesterol  mobilization  follows  phospholipid  PK.  One  of  the  explanations  for  this  may  be  
that  both  22A  and  22A-­P  are  capable  of   forming  sHDL   in  vitro  and  maintaining  sHDL  
stability   in  vivo,  as  the  structures  of  all  three  peptides  used  by  us  are  very  similar.  It   is  
also   important   to  point   out   that  other  groups  had  seen  discordance  between  showing  
some  structure-­activity  relationship  for  ApoA-­I  peptides  in  vitro  and  seeing  no  statistical  
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Table  3-­1  Biophysical  characterization  of  peptides.  aHelical  wheel  plots  were  generated  
using  the  online  tool  called  Helixator  where  hydrophobic  amino  acids  were  highlighted  in  blue.  
bHydrophobic  moments  were  calculated  by  the  3D  Hydrophobic  Moment  Vector  Calculator.  
cHelix  stability  (∆Ghel),  transfer  energy  from  water  to  membrane  (∆Gtran),  and  tilt  angle  in  
membranes  were  predicted  by  FMAP  server  for  22A,  21A,  and  22A-­P  peptide  sequences;;  
dHelical  content  of  lipid-­free  and  lipid-­bound  peptides  was  determined  by  circular  dichroism;;  
ePeptide  stability  in  rat  plasma  was  determined  by  LC-­MS  shown  as  percent  remaining  peptide  































!Ghel'(kcal/mol)c' 119.8! 119.4! 119.8!
!Gtran'(kcal/mol)c' 114.7! 113.4! 114.7!










stability'(%)e' 48.4!±!10.6! 96.8!±!5.4! 89.3!±!12.5!
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Figure  4-­1  Size  distribution  and  purity  of  sHDL  prepared  with  various  peptide  (A,  B)  and  
phospholipid  (C,  D)  compositions.  The  size  was  determined  by  dynamic  light  scattering  (DLS)  (A,  
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Table  4-­2  Characterization  of  sHDL  particles  prepared  with  different  peptides  and  phospholipids.  
aParticle  size  of  sHDL  measured  by  DLS;;  bRetention  time  of  sHDL  particle  measured  bby  GPC;;  
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Figure  4-­2  Effect  of  peptides  and  sHDL  on  cholesterol  efflux.  Free  peptides  (22A,  21A,  
22A-­P)  were  used  to  efflux  cholesterol  from  BHK  cells  stably  transfected  with  ABCA1  
transporter  (a)  and  sHDL  (22A-­DMPC,  21A-­DMPC,  22A-­P-­DMPC  and  22A-­POPC,  22A-­DMPC,  
22A-­DPPC,  22A-­DSPC)  were  utilized  to  efflux  cholesterol  from  RAW  264.7  macrophage  cells  
(b,  c)  at  0.01,  0.03,  and  0.1  mg/mL  for  18  hrs.  The  contribution  of  ABCA1  transporter  was  
determined  by  subtracting  efflux  values  of  Mock-­transfected  cell  line  from  ABCA1-­transfected  
cell  line  (n=3,  mean  ±  SEM).  Statistical  differences  were  compared  to  22A  peptide  or  22A-­
DMPC  with  one-­way  ANOVA  analysis  with  Dunnett’s  post-­hoc  test.  P  <  0.05  was  considered  
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Figure  4-­3  Effect  of  peptide  and  phospholipid  composition  in  sHDL  on  LCAT  lipolysis  
and  esterification  rates.  (a,  b)  The  rate  of  sHDL  lipolysis  was  determined  by  incubating  sHDL  
(0.1  mg/mL)  prepared  with  variable  peptide  composition  (22A-­DMPC,  21A-­DMPC,  22A-­P-­
DMPC)  or  variable  phospholipid  composition  (22A-­POPC,  22A-­DMPC,  22A-­DPPC,  22A-­DSPC)  
with  human  rhLCAT  (15  µg/mL)  at  37  °C  for  0,  5,  15,  30,  60,  90,  and  120  min.  The  
concentration  of  phospholipid  at  each  time  point  was  determined  by  LC-­MS  and  the  rate  of  
lipolysis  calculated  from  the  slope  of  the  concentration  of  the  starting  material  versus  time.  
LCAT  esterification  activity  was  measured  for  sHDL  containing  fluorescent  cholesterol  analog,  
dehydroergosterol  (DHE)  (c,  d).  The  initial  reaction  rates  (V0)  are  plotted  as  a  function  of  DHE  
concentration  and  the  data  were  fitted  into  the  Michaelis-­Menten  kinetic  equation  to  calculate  
Vmax  and  Km  (n=3,  mean  ±  SEM).  Statistical  differences  were  compared  to  22A  peptide  or  22A-­
DMPC  with  one-­way  ANOVA  analysis  with  Dunnett’s  post-­hoc  test.  P  <  0.05  was  considered  
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Table  4-­3  Michaelis-­Menten  paramenters  of  sHDL  particles  prepared  with  different  












































Figure  4-­4  Pharmacokinetic  analysis  of  22A  and  22A-­P  peptides  (a)  or  total  
phospholipids  (b)  in  rat  serum.  Pharmacodynamic  assessment  of  free  cholesterol  (c)  and  
esterified  cholesterol  (d)  mobilization  in  rat  serum.  Healthy  male  Sprague-­Dawley  rats  were  
given  a  single  tail  vein  injection  of  50  mg/kg  (based  on  peptide)  of  22A-­POPC-­DPPC  or  22A-­P-­
POPC-­DPPC  and  blood  samples  were  collected  at  pre-­dose  and  0.25,  0.5,  1,  2,  4,  8,  and  24  h  
after  sHDL  administration.  Serum  concentrations  of  peptides  were  determined  by  LC-­MS  while  
concentrations  of  phospholipids,  free  cholesterol,  and  esterified  cholesterol  were  measured  
enzymatically  (n=3).  Statistical  difference  was  compared  with  two-­tailed  Student’s  t-­test.  P  <  
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Table  4-­4  Pharmacokinetic  and  pharmacodynamic  parameters  (%CV)  of  peptide,  total  
phospholipids  (PL),  free  cholesterol  (FC),  and  esterified  cholesterol  (EC)  after  50  mg/kg  doses  
of  22A-­sHDL  and  22A-­P-­sHDL  treatments.  Data  were  shown  as  mean  with  CV%.  *P<0.05,  **P  <  
0.01,  ***P  <  0.001.  AUC:  the  area  under  the  curve.  K:  elimination  rate  constant.  T1/2:  the  half-­life  
of  elimination.  CL:  total  clearance.  Vd:  volume  of  distribution.  Tmax,E:  time  at  which  the  Emax  is  
observed.  Emax:  the  maximum  plasma  concentration  of  different  cholesterol  species.  AUEC:  the  
area  under  the  effect  curve.  
	  
   Parameters  
Groups  
22A-­sHDL   22A-­P-­sHDL  
Peptide  
AUC  (mg*h/dL)   5.5  (22.0)   17.2  (10.6)***  
K  (h-­1)   0.3  (25.8)   0.2  (12.0)  
T  ½  (h)   2.1  (22.4)   4.2  (10.8)**  
CL  (dL/h)   2.3  (21.8)   0.7  (10.9)**  
Vd  (dL)   6.9  (7.7)   4.4  (6.2)**  
PL  
AUC  (mg*h/dL)   424.4  (15.7)   371.8  (23.5)  
K  (h-­1)   0.4  (23.8)   0.5  (16.0)  
T  ½  (h)   1.8  (18.8)   1.3  (11.4)*  
CL  (dL/h)   0.1  (7.7)   0.1  (7.0)  
Vd  (dL)   0.1  (21.4)   0.1  (2.1)  
FC  
Tmax,E  (h)   0.5  (0.0)   0.8  (33.3)  
Emax  (mg/dL)   46.7  (5.8)   44.4  (13.0)  
AUEC  (mg*h/dL)   158.0  (19.1)   175.3  (28.5)  
EC  
Tmax,E  (h)   0.42  (24.5)   0.4  (33.3)  
Emax  (mg/dL)   51.3  (31.8)   42.2  (37.3)  




   130  
  
Figure  4-­5  Pharmacokinetic  analysis  of  22A  (a)  and  total  phospholipids  (b)  in  rat  serum.  
Pharmacodynamic  assessment  of  free  cholesterol  (c)  and  esterified  cholesterol  (d)  mobilization  
in  rat  serum.  Healthy  male  Sprague-­Dawley  rats  were  given  a  single  tail  vein  injection  of  50  
mg/kg  (based  on  peptide)  of  22A-­POPC,  22A-­DMPC,  22A-­DPPC,  or  22A-­DSPC  and  blood  
samples  were  collected  at  pre-­dose  and  0.25,  0.5,  1,  2,  4,  8,  and  24  h  after  sHDL  
administration.  Serum  concentrations  of  peptides  were  determined  by  LC-­MS  while  
concentrations  of  phospholipids,  free  cholesterol,  and  esterified  cholesterol  were  measured  
enzymatically  (n=3).  Statistical  differences  for  22A-­phospholipid  were  compared  to  22A-­DMPC  
with  one-­way  ANOVA  analysis  with  Dunnett’s  post-­hoc  test.  P  <  0.05  was  considered  
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Table  4-­5  Pharmacokinetic  and  pharmacodynamic  parameters  (%CV)  of  22A  peptide,  
total  phospholipids  (PL),  free  cholesterol  (FC),  and  esterified  cholesterol  (EC)  after  50  mg/kg  
doses  of  22A-­POPC,  22A-­DMPC,  22A-­DPPC,  and  22A-­DSPC  sHDL  treatments.  Data  were  
shown  as  mean  with  CV%.  *P<0.05,  **P  <  0.01,  ***P  <  0.001.  AUC:  the  area  under  the  curve.  K:  
elimination  rate  constant.  T1/2:  the  half-­life  of  elimination.  CL:  total  clearance.  Vd:  volume  of  
distribution.  Tmax,E:  time  at  which  the  Emax  is  observed.  Emax:  the  maximum  plasma  concentration  
of  different  cholesterol  species.  AUEC:  the  area  under  the  effect  curve.  
  
	  
   Parameters  
Groups  
22A-­POPC   22A-­DMPC   22A-­DPPC   22A-­DSPC  
Peptide  
AUC  (mg*h/dL)   3.6  (8.6)**   6.6  (10.0)   4.6  (15.2)*   6.9  (17.7)  
K  (h-­1)   0.2  (6.0)   0.2  (1.7)   0.2  (2.4)   0.2  (4.0)  
T  ½  (h)   3.3  (6.2)   3.0  (1.8)   3.3  (2.4)   3.3  (4.2)  
CL  (dL/h)   5.6  (11.8)**   3.2  (13.9)   4.6  (17.4)   2.9  (25.2)  
Vd  (dL)   27.1  (16.7)**   14.0  (15.5)   21.9  (19.0)   13.7  (29.1)  
PL  
AUC  (mg*h/dL)   371.6  (29.0)   703.2  (23.2)   934.9  (22.8)   2396  (21.1)***  
K  (h-­1)   0.7  (10.6)***   0.2  (4.4)   0.3  (16.8)   0.0  (12.6)**  
T  ½  (h)   1.0  (9.8)***   3.3  (4.4)   2.2  (18.6)*   6.0  (12.4)***  
CL  (dL/h)   0.1  (22.2)   0.1  (23.3)   0.0  (27.7)***   0.0  (27.3)***  
Vd  (dL)   0.2  (29.8)   0.3  (23.3)   0.2  (45.9)   0.1  (16.0)*  
FC  
Tmax,E  (h)   0.7  (35.4)   0.4  (28.3)   0.7  (35.4)   1.3  (35.4)*  
Emax  (mg/dL)   25.8  (36.8)   37.6  (19.8)   44.8  (5.1)   51.5  (15.3)  
AUEC  (mg*h/dL)   79.4  (33.9)   126.5  (10.0)   215.0  (20.9)   536.4  (19.1)***  
EC  
Tmax,E  (h)   0.5  (70.7)   0.8  (28.3)   0.9  (84.3)   6.7  (28.3)**  
Emax  (mg/dL)   7.7  (65.2)   28.2  (30.3)   24.9  (13.7)   20.6  (24.7)  
AUEC  (mg*h/dL)   84.8  (65.3)   93.3  (41.9)   98.9  (31.6)   334.7  (18.0)**  
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Figure  4-­6  Effect  of  sHDL  incubation  with  human  plasma  on  endogenous  HDL  
remodeling.  Various  compositions  of  sHDL  were  incubated  in  human  plasma  at  1  mg/mL  for  1  h  
at  37°C.  Lipoproteins  were  separated  by  1-­D  native  page  electrophoresis  and  visualized  by  
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Chapter  5:  Conclusions  and  Future  Direction  
The  work  presented  in  this  thesis  describes  innovative  approaches  to  ameliorate  
lipid   storage   in   the  Niemann-­Pick   family   of   diseases   by   harnessing   the   activity   of   the  
body’s  endogenous  cholesterol  and  sphingomyelin  scavenging  system,  which   includes  
ApoA-­I  and  HDL.    
Synthetic HDL (sHDL) has been previously tested in patients with atherosclerosis 
to reduce cholesterol accumulations in the hardened arteries. In Chapter 2, applying the 
same strategy to Niemann-Pick disease type C (NPC), we prepared sHDLs made from 
ApoA-I mimetic peptide 5A complexed with phospholipids such as SM, POPC, or DMPC 
at various ratios. The mimetic peptide 5A was selected based on its specific interaction 
with the ATP-binding cassette transporter A1 (ABCA1), which played a pivotal role in 
mediating cellular efflux of cholesterol and phospholipids to lipid-free ApoA-I and small 
HDL. Different sHDL formulations and 5A alone were tested in several NPC primary 
patient fibroblast cell lines, and it was found that 5A-SM was capable of reducing 
accumulated cholesterol while lipid-free 5A peptide was not a good cholesterol acceptor. 
Additionally, we observed dose and time-dependent reductions in cholesterol from 
endolysosomal compartments after the treatment with 5A-SM. While   the   rescue   of  
cholesterol  storage  from  mutant  fibroblasts  required  expression  of  ABCA1,  fluorescently  
labeled   sHDLs   readily   entered   cells   by   macropinocytosis.   The   lipid   and   peptide  
constituents   of   the   nanoparticles   remained   tightly   associated   within   cells,   with   some  
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trafficking   to   LAMP1   and   filipin-­stained   vesicles. The   particles   showed   evidence   of  
cholesterol  target  engagement  and  rescue  of  disease  phenotypes  when  administered  to  
NPC   mice   via   intraperitoneal   injection.   The   amelioration   of   only   peripheral,   but   not  
neurological  phenotypes  in  NPC  mice  was  observed.  Thus,  future  studies  will  be  focused  
on  direct   brain   (intracranial)   administration   route  of   sHDL   to  determine   its  potential   to  
prevent  the  loss  of  Purkinje  neurons  and  rescue  of  motor  phenotype.        
Chapter   3  was   focused  on  exploring  ApoA-­I  mimetics   for   the   treatment   of   acid  
sphingomyelinase  deficiency  in  Niemann-­Pick  disease  type  A  (NPA)  and  B  (NPB).  NPA/B  
patients  had  marked  decrease  in  plasma  HDL-­cholesterol  levels.  Several  groups  showed  
that   small   pre-­b   HDL   in   patients   with   acid   sphingomyelinase   deficiency   was   highly  
enriched  in  sphingomyelin.  Interestingly,  the  expression  of  the  ABCA1  gene  as  well  as  
sphingomyelin  efflux  to   lipid-­free  ApoA-­I  protein   in  fibroblast  cells  of  NPB  patients  was  
normal.  Taken  together,  these  results  suggested  that  lipid-­free  ApoA-­I  mimetic  peptides  
or  lipid-­poor  sHDL  may  be  capable  of  binding  sphingomyelin  similar  to  native  ApoA-­I  and  
nascent  HDL.  Here,  we  identified  one  ApoA-­I  mimetic  peptide  (22A)  and  22A-­sHDL  (22A-­
DMPC   and   22A-­DPPC),   which   significantly   reduced   the   amount   of   accumulated  
sphingomyelin   in  Niemann-­Pick   type  A  cells.  We  showed  that  peptide  and  sHDL  were  
non-­toxic   in   vitro   and   required   the   ABCA1   to   efflux   some   stored   sphingomyelin.  
Furthermore,   we   administered   22A   and   22A-­DMPC   into   wild   type   adult   mice   via  
intravenous  route.  It  was  found  that  22A  at  300  mg/kg  rapidly  mobilized  sphingomyelin  
into  circulation  while  sHDL  was  not  effective  at   the  dose   tested   (75  mg/kg).  Together,  
these  studies  provide   the  proof-­of-­concept  data   to  support   the   therapeutic  potential  of  
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ApoA-­I  mimetics  for  the  Niemann-­Pick  Disease  type  A.  Future  studies  of  22A  safety  and  
efficacy  will  be  explored  in  the  mouse  model  of  NPA  disease.  
In   Chapter   4,   we   examined   the   contribution   of   ApoA-­I   mimetic   peptide   and  
phospholipid   type   in   sHDL   on   the   ability   of   sHDL   to   mobilize   cholesterol   in   vivo.  
Conventionally,   the   composition   of   ApoA-­I   mimetics   was   developed   in   vitro   using   a  
radioactive  cholesterol  efflux  assay  to  predict   its  relative  efficacy   in  vivo.  Then,  ApoA-­I  
peptides   were   complexed   with   phospholipids   to   produce   sHDL.   The   choice   for  
phospholipids   was   mostly   random   and   also   not   supported   by   in   vivo   studies.   In   this  
chapter,   we   systematically   changed   either   ApoA-­I   peptide   (22A,   21A,   22A-­P)   or  
phospholipid  (DMPC,  POPC,  DPPC,  DSPC)  composition  in  sHDL  and  studied  the  ability  
of  different  sHDL  formulations  to  efflux  cholesterol  in  vitro  and  in  vivo.  We  observed  the  
discordance   between   in   vitro   and   in   vivo   results   for   sHDL   prepared   with   different  
phospholipids  and  peptides.  The  in  vitro  trends  for  higher  cholesterol  efflux  for  22A-­POPC  
and   22A-­DMPC   did   not   translate   into   higher   cholesterol   mobilization   in   vivo.   The  
cholesterol  mobilization  and  circulation  time  appeared  to  be  closely  following  circulation  
time  of  phospholipids.  The  stability  of  22A-­P  was  greatly  improved  in  vivo  relative  to  22A,  
however   phospholipid   pharmacokinetics   appeared   to   be   unchanged   and   cholesterol  
mobilization   followed   phospholipid.   This   data   suggested   that   the   pharmacokinetics   of  
peptide  and  lipid  components  in  sHDL  were  not  interdependent  and  original  infused  sHDL  
particles  may  dissociate  or  become  remodeled  upon  administration   in  vivo.  In  addition,  
the  phospholipid,  rather  than  peptide  component  in  sHDL  had  a  major  impact  on  the  ability  
to   mobilize   cholesterol   in   vivo.   Further   examination   is   needed   to   determine   if   higher  
   136  
cholesterol  mobilization  for  sHDL  composed  of  saturated  lipids  will  lead  to  a  greater  anti-­
atherosclerosis  effect  in  a  murine  model  of  the  disease  is  needed.  
Although   sHDL   particles   presented   in   this   dissertation   mimic   endogenous  
lipoproteins,   they   have   a   short   circulation   half-­life   and  may   not   cross   the   blood-­brain  
barrier.  In  vivo  stability  of  non-­lipidated  ApoA-­I  mimetic  peptides  is  even  less  promising.  
Future  research  should  be  focused  on  extending  the  half-­life  of  ApoA-­I  peptides  and  sHDL  
with  the  goal  of  decreasing  the  dose  required  to  achieve  efficacy  and  thus  reducing  the  
risk  of  toxic  side  effects.  One  way  to  increase  the  circulation  time  of  ApoA-­I  peptides  is  to  
protect  the  vulnerable  sites  from  in  vivo  proteolysis  using  unnatural  or  less  labile  amino  
acids  or  conjugation  of  peptides  to  poly  (ethylene  glycol),  PEG.  In  terms  of  sHDL,  few  
strategies  have  been  already  explored  including  PEGylation  or  addition  of  phospholipids  
with   higher   transition   temperatures   (e.g.,   di-­steroyl-­phosphatidylcholine,   DSPC)   [199].  
The  more  complicated  issue  is  a  low  brain  uptake  of  sHDL  particles,  especially  important  
for  Niemann-­Pick  type  C  and  A  patients.  In  the  brain,  HDL  is  composed  primarily  from  
ApoE  protein.  Studies  from  other  investigators  revealed  several  successful  approaches  
to  improve  brain  targeting  of  sHDL  by  utilizing  ApoE  rather  than  ApoA-­I  mimetic  peptide  
sequences   or   by   incorporating   brain   endothelium   targeting   peptides   [201-­203].   The  
surface  of  sHDL  could  be  modified  by  covalently  attaching  ligands  targeting  vascular  cell  
adhesion  molecule,  integrin,  LDL  receptor-­related  protein,  and  LDL  receptor.    
The  work  presented  in  this  dissertation  serves  as  the  foundation  for  future  research  
in  the  area  of  Niemann-­Pick  disease  and  HDL  field.  
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